[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"ASO, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":409},{"warningLetters":4,"total":408},[5,31,53,74,93,117,138,157,173,193,214,234,252,271,293,309,329,348,366,389],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1196,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-10-29T13:20:00Z\">10\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-01T04:00:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpaso-real-produce-llc-691665-10012024\">Paso Real Produce LLC\u003C\u002Fa>","Division of Southwest Imports","Foreign Supplier Verification Program (FSVP)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Salvador Pulido Novoa\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FPresident \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Paso Real Produce LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1301 W. Capote Central Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pharr\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78577\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:salvador@pasorealproduce.com\"> salvador@pasorealproduce.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: &nbsp;CMS # 691665\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Pulido, &nbsp;\u003C\u002Fp>\n\n\u003Cp>On August 9-14, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Paso Real Produce, LLC located at 1301 W. Capote Central Ave., Pharr, TX 78577. &nbsp;We also conducted inspections on September 10, 2021 and April 4-5, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. &nbsp;You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-ruleforeign-supplier-verification-programs-fsvp-importers-food-humans-and-animals. &nbsp;\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of this significant violation, you are not in compliance with section 805 of the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We have not received your response to the Form 483a issued on August 14, 2024.\u003C\u002Fp>\n\n\u003Cp>Your significant violation of the FSVP regulation are as follows: &nbsp;\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, your firm did not develop an FSVP for any of the foods you import, including each of the following: &nbsp;\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Avocados imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Limes imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Limes imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Limes imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This is a repeat observation from the previous inspections conducted on September 10, 2021 and April 4-5, 2023 &nbsp;\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. &nbsp;It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L. &nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the foods you import which appear to be in violation of section 805. We may place these foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)). &nbsp;\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. &nbsp;Your response should address the specific things you are doing to correct any violations. &nbsp;You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. &nbsp;If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Rosa Linda Santos, Compliance Officer, Division of Southwest Imports, 1201 Main Street, Suite 7200, Dallas, TX, 75202. &nbsp;If you have any questions regarding this letter, or wish to provide your response via email, you may contact Rosa Linda Santos at rosa.santos@fda.hhs.gov. &nbsp; Please reference CMS #691665 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTodd Cato\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Southwest Imports &nbsp;\u003Cbr>\n1201 Main Street, Suite 7200\u003Cbr>\nDallas, TX 75202&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc: Paso Real Produce LLC &nbsp; &nbsp; &nbsp; &nbsp;\u003Cbr>\n1301 W. Capote Central Ave. &nbsp; &nbsp; &nbsp;\u003Cbr>\nPharr, TX 78577\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Salvador Pulido Novoa\n\nRecipient Title\n\nOwner\u002FPresident\n\nPaso Real Produce LLC\n\n1301 W. Capote Central Ave.\n\nPharr, TX 78577\n\nUnited States\n\nsalvador@pasorealproduce.com\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nOctober 1, 2024\n\nWARNING LETTER\n\nRe: CMS # 691665\n\nDear Mr. Pulido,\n\nOn August 9-14, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Paso Real Produce, LLC located at 1301 W. Capote Central Ave., Pharr, TX 78577. We also conducted inspections on September 10, 2021 and April 4-5, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-ruleforeign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of this significant violation, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\n\nWe have not received your response to the Form 483a issued on August 14, 2024.\n\nYour significant violation of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, your firm did not develop an FSVP for any of the foods you import, including each of the following:\n\nAvocados imported from (b)(4) located in (b)(4)\n\nLimes imported from (b)(4) located in (b)(4)\n\nLimes imported from (b)(4) located in (b)(4)\n\nLimes imported from (b)(4) located in (b)(4)\n\nThis is a repeat observation from the previous inspections conducted on September 10, 2021 and April 4-5, 2023\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the foods you import which appear to be in violation of section 805. We may place these foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to the Food and Drug Administration, Attention: Rosa Linda Santos, Compliance Officer, Division of Southwest Imports, 1201 Main Street, Suite 7200, Dallas, TX, 75202. If you have any questions regarding this letter, or wish to provide your response via email, you may contact Rosa Linda Santos at rosa.santos@fda.hhs.gov. Please reference CMS #691665 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nProgram Division Director\n\nDivision of Southwest Imports\n\n1201 Main Street, Suite 7200\n\nDallas, TX 75202\n\nCc: Paso Real Produce LLC\n\n1301 W. Capote Central Ave.\n\nPharr, TX 78577","Paso Real Produce LLC","paso-real-produce-llc-691665-10012024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpaso-real-produce-llc-691665-10012024","2026-10-26T08:09:40.292767+00:00","Warning Letter","Issued","2024-10-29","691665","Food & Beverages","Mr. Salvador Pulido Novoa","2026-08-19T21:55:14.304+00:00","Via Express Delivery","2024-10-01",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},297,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-29T05:00:00Z\">01\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdiasol-inc-719460-01292026\">Diasol, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Monica F. Abeles\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and President  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Diasol, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>310 S. 43rd Ave., Ste. B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85009\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@diasol.com\"> (b)(6)@diasol.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS #719460\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>January 29, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Abeles:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Phoenix, AZ from July 21, 2025, through August 19, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures disinfectants used to disinfect dialysate delivery systems and water purification systems used in hemodialysis (i.e. Diasol Bicarb, Diasol Concentrate, Diasol Additives, and CirtiSol Concentrate) for treatment of patients with renal failures or toxemic conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cu>Unapproved Device Violation\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Our inspection revealed that your solutions of Citric Acid in 50% and 20% concentrations indicated for use in the cleaning, decalcification, and heat disinfection of hemodialysis machines are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). While you do have a clearance under section 510(k), K020231, for a Citric Acid product intended for use with sorbent regenerated dialysis to allow physicians to customize the dialysate to meet patients’ needs, that product is not intended for use in the disinfection of hemodialysis machines. Accordingly, you were required to submit a premarket notification (510(k)) for your solutions of Citric Acid in 50% and 20% concentrations indicated for use in the cleaning, decalcification, and heat disinfection of hemodialysis machines (see 21 CFR 807.81(a)(3)(ii)).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\u003C\u002Fp>\u003Cp>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received your email responses dated September 10, 2025, October 8, 2025, and November 21, 2025, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm on August 19, 2025. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for finished device acceptance, as required by 21 CFR § 820.80(d).\u003C\u002Fp>\u003Cp>Specifically, according to your procedure for Final Acceptance, SOP 80.001, Rev. 03, your firm did not adequately implement final testing activities. For example:\u003C\u002Fp>\u003Cp>A. Your firm claims compliance to following \u003Cstrong>(b)(4)\u003C\u002Fstrong> (currently \u003Cstrong>(b)(4)\u003C\u002Fstrong>). The standard requires all electrolytes identified on the label must be within \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the labeled value, except sodium, which must be within \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, whichever is greater. However, the acceptability range in your DMR and Device History Records (DHRs) does not meet this requirement. For example:\u003C\u002Fp>\u003Cp>i. The acceptable range for formulations with 1K Potassium is \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL per the standard; however, your firm’s specified range for 1K Potassium is established at \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL, as documented in your DMR and DHRs. Nine (9) DHRs reviewed from March 2024 to July 2025 for dialysate acid concentrate products labeled as having \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL of Potassium showed that they were released with Potassium concentration results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL, which exceeds the acceptable range in \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL.\u003C\u002Fp>\u003Cp>ii. According to \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard, the minimum acceptable level of Calcium should be \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL; however, your firm’s acceptance criteria for formulations requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL of Calcium, set between \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL as documented in your DMR and DHRs. Out of 23 Device History Records (DHRs) reviewed from March 2024 to July 2025 for acid concentrate labeled as \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL of Calcium, 15 DHRs were released with Calcium results at \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL, which is below the allowed range established by the \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard.\u003C\u002Fp>\u003Cp>B. Your firm’s In-Process and Final Batch Testing Procedure, WI 80.004, Rev. 3 and the procedure for Final Acceptance, SOP 80.001, Rev. 3, requires that Dextrose (Glucose) is tested on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> container for each batch in accordance with the specifications in your Device History Records (DHRs). Your firm did not implement these procedures or its process for releasing finished products. Your firm released 4 out of 34 DHRs without Dextrose (Glucose) test results. Your firm began distributing three batches (Batch #’s 3170, 3168, and 3166) of the Diasol Acid Concentrates without Dextrose results on 7\u002F14\u002F2025; and one batch (Batch #DCS16) of the Dry Citrisol product without Dextrose result on 08\u002F05\u002F2025.\u003C\u002Fp>\u003Cp>Your response is inadequate. We understand that you entered into an agreement with \u003Cstrong>(b)(4)\u003C\u002Fstrong> to perform testing side-by-side with other labs such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine the test result error for specific flagged batches, or to determine if it is your firm’s production error, with the electrolyte ranges not meeting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard. Your firm should also recognize that your specification ranges are not compliant, instead of solely concentrating on determining if the laboratory testing method (\u003Cstrong>(b)(4)\u003C\u002Fstrong> method) is accurate. You should demonstrate that your specifications meet the relevant \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard your firm has selected to follow and FDA requirements for their intended use. The lab-to-lab comparison studies should be reviewed in combination after updating your Device Master Records (DMRs) to comply with \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard. Your firm should confirm which specific analytical methods the labs use to ensure adherence to the standard.\u003C\u002Fp>\u003Cp>Please provide documented evidence that your firm is committed to updating your DMRs to comply with the applicable standards. You should be specific in your Final Acceptance Procedure and DMR\u002FDHRs that the electrolyte ranges are compliant. Your firm should not use the current non-compliant electrolyte ranges pending additional testing. Changing laboratories may not address the main problem that your specifications do not meet the required \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard. All electrolyte ranges should reflect the requirements of the standard you have chosen to follow. Finally, all results for the batches noted in the FDA 483 for observation 1A, should be reviewed to conform with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard.\u003C\u002Fp>\u003Cp>Furthermore, regarding observation 1B, we understand that you are performing glucose testing on retained samples from the affected lots and your procedures (WI 80.004 and SOP 80.001) have been updated to include QA review and signoff for glucose testing prior to release. Also, you have planned to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> audits of DHRs and batch release documentation and conduct CAPA effectiveness review. Please provide evidence of these corrective actions. Your firm should provide justification demonstrating how weight verification substitutes for chemical testing requirements for glucose content or perform the required chemical testing. Without such written justification, your response is inadequate. Furthermore, you may need to reassess the risk analysis if you find that this testing substitution was inadequate for glucose content.\u003C\u002Fp>\u003Cp>2. Failure to adequately validate a process whose results cannot be fully verified by subsequent inspection and test according to established procedures, as required by 21 CFR § 820.75(a). Specifically,\u003C\u002Fp>\u003Cp>A. Your firm conducted a cleaning validation for the re-usable \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums under Drum Cleaning Validation (Protocol #75.007, dated 09\u002F04\u002F2019). The reusable \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums are cleaned with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to filling them with a new batch of acid concentrate after they are returned from your customers and stored in your warehouse for an undetermined amount of time. The cleaning validation and re-validation of the drums are inadequate. For example,\u003C\u002Fp>\u003Cp>i. The study did not demonstrate there are no chemical residues from the earlier batches to prevent cross contamination. These drums are used to package and distribute Diasol and Citrisol acid concentrates that are made with differing raw materials such as acetic acid and citric acid. Also, the study does not evaluate that the reusable drums can be re-used indefinitely considering the processes, reuse, storage and solvents used in these drums.\u003C\u002Fp>\u003Cp>ii. The Validation Report generated on 10\u002F07\u002F2019 was not accompanied by the raw data for drums \u003Cstrong>(b)(4)\u003C\u002Fstrong> to support the conclusion presented, and the data could not be provided upon investigator’s request.\u003C\u002Fp>\u003Cp>iii. Data for re-validation dated 10\u002F09\u002F2020 using \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums showed conductivity and pH tests failed on all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums after wash. There was no documented deviation or evidence of an investigation of these failures.\u003C\u002Fp>\u003Cp>iv. Re-validation data of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums dated 07\u002F19\u002F2021 did not include total plate count results for microbiological testing on 4 of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums after wash.\u003C\u002Fp>\u003Cp>Also, your firm’s Work Instruction, Drum Washing, WI 70.003, Rev. 2, requires re-validation of the washing method \u003Cstrong>(b)(4)\u003C\u002Fstrong> but no revalidation has been conducted since 2023.\u003C\u002Fp>\u003Cp>B. Your firm utilizes both a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> mixing tank to mix dialysate acid concentrates. The validation protocols and reports (#75.005 and #75.006) for the mixing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks are inadequate. For example,\u003C\u002Fp>\u003Cp>i. The mixer speed is one of the six key parameters for homogeneity of the finished product, according to your mixing validation but neither the protocol nor the report specifies the mixing speed of the tank mixers.\u003C\u002Fp>\u003Cp>ii. Temperature is stated to affect mixing time in the batch production work instruction (WI 70.007, Batch Assembly, Rev. 2), and all lots produced for both validations show \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, there is no specified acceptable temperature range or assessment of the duration of mixing affects the quality of your product.\u003C\u002Fp>\u003Cp>iii. Sample sizes are not justified in multiple testing areas for your products while mixing. There is no rationale for the sample size and the method of collecting \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the mixing tanks to determine homogeneity of the batch during this mixing validation. Currently, your firm collects three production samples from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to test the composition of the dialysate concentrate. However, the glucose level is \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This practice of using \u003Cstrong>(b)(4)\u003C\u002Fstrong> production samples was not included in your mixing process validation to demonstrate your batch is uniform across all filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>iv. The reports state that longer mixing times does not affect the batch, but your firm did not provide adequate scientific rationale with supporting evidence for the maximum mixing time, or how you reached this conclusion.\u003C\u002Fp>\u003Cp>Additionally, the mixing validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank confirmed the mixing process with a mixer and a recirculation pump; however, the mixer in the firm’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> mixing tank has not been operational since around 2022, and since then, the batches have only been mixed using the recirculation pump system, but this new mixing process has not been validated.\u003C\u002Fp>\u003Cp>C. The \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was installed in your facility in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to produce water for dialysate concentrate was not adequately validated. For example, your firm could not show that components were installed as per the piping and instrumentation diagram; that controls and alarms were configured correctly, and that critical process parameters and their operating ranges were properly established and controlled. Your firm could not provide a schematic showing how the components were installed and how the specifications for the operating parameters were determined.\u003C\u002Fp>\u003Cp>D. Your firm conducts total viable counts to monitor the microbiological quality of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water used to prepare dialysate concentrates, following the Microbiological Testing Procedure, WI 80.002, Rev. 5 using \u003Cstrong>(b)(4)\u003C\u002Fstrong> plate technique on \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates incubated at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, in practice your firm has incubated \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> at temperatures up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This test method has not been validated to confirm its effectiveness in recovering microorganisms from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. We understand you developed a new drum cleaning validation protocol and report (SOP No. 75.007, Rev. 2).\u003C\u002Fp>\u003Cp>You also agreed to implement related procedures, perform retrospective review and CAPA for failed pH\u002Fconductivity tests and missing microbial data, conduct re-validation of cleaning process using newly installed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, retrain employees on cleaning procedures, and schedule \u003Cstrong>(b)(4)\u003C\u002Fstrong> audits to ensure compliance with cleaning validation procedures. Please ensure that you have addressed any cross-contamination risks between Diasol and Dryasol (Acetic Acid), and Citrisol (Citric Acid) products for using reusable drums. Your firm claims that life span of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums is between \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but cleaning validation should still evaluate the effect on containers when deterioration is anticipated. There is no raw\u002Fhistorical data for drums \u003Cstrong>(b)(4)\u003C\u002Fstrong> to support the validation report generated on 10\u002F7\u002F2019, but your firm plans to implement SOPs for retention and traceability of raw validation data.\u003C\u002Fp>\u003Cp>Regarding observation 2B, your CAPA plan involves carrying out new mixing validation runs for each tank using the mixer and recirculating pump separately. Your firm is planning to conduct in-process and final acceptance testing on samples and assessing homogeneity by taking samples and conducting analytical tests (pH, conductivity, and concentration). Also, you’ve stated you plan to retrain QA and validation personnel on the revised documentation. Please ensure that you have documented the actual mixer speeds used when conducting the validation studies which appears to be the main issue with the process parameters (omitting the mixer speed in your previous validation report). The mixer speed is a critical parameter that directly impacts the homogeneity and consistency of dialysate acid concentrates. Your firm claims that temperature variation has minimal impact on your mixing process and that you have little control over \u003Cstrong>(b)(4)\u003C\u002Fstrong> water temperature \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A lack of control over the water temperature does not eliminate validation requirements. Your firm should include acceptable ranges prior to executing your validation because temperature is a critical parameter among pH, conductivity, specific gravity, and mixing time. The adequacy of this response cannot be determined at this time.\u003C\u002Fp>\u003Cp>Regarding observation 2C, your firm committed to ensuring that all water purification systems meet expectations for validation, documentation, and control. Your response stated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> installation and setup followed the manufacturer’s guidelines and that all \u003Cstrong>(b)(4)\u003C\u002Fstrong> parameters and \u003Cstrong>(b)(4)\u003C\u002Fstrong> log were configured according to the manufacturer’s instruction for starting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Your firm claims that these requirements and the drawing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> components are adequate. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturers guidelines do not substitute for formal validation protocols (IQ\u002FOQ\u002FPQ). You should demonstrate that the validation requirements are met, ensuring that the water system is suitable for your use and complies with the specifications, in addition to installation adhering to the manufacturer’s guidelines. Also, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system has been in use since \u003Cstrong>(b)(4)\u003C\u002Fstrong> without proper validation which represents \u003Cstrong>(b)(4)\u003C\u002Fstrong> years of unvalidated operations. The adequacy of this response cannot be determined at this time since corrective actions are in progress.\u003C\u002Fp>\u003Cp>Regarding observation 2D, your firm’s CAPA plan is for all microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> water to revert to the validated method outlined in your Microbial Testing (WI 80.002. Rev. 5) procedure. You stated a formal study will be conducted to assess the impact of the modified method, and that the validation will follow USP 61, USP 62, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> guidelines. Also, your procedure will be revised if the modified method is successful and is validated. Your firm said that your incubators with temperature spike occurred because an air conditioner in the facility broke down causing the temperature to rise, and the QC operator did not know how to lower the temperature. The environmental explanations do not justify using unvalidated methods and you should have stopped testing until the conditions were corrected. Your firm claims that temperature spike was resolved “2 days later” and your firm purchased “\u003Cstrong>(b)(4)\u003C\u002Fstrong> new incubators” and will assess plates for impact. Your firm has not addressed why you continued to use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates that were held outside labeled conditions or did not provide validation for the modified conditions. The adequacy of this response cannot be determined at this time as corrective actions are in progress.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish process control procedures that describe any process controls necessary to ensure conformance to specifications, as required by 21 CFR § 820.70(a). Specifically,\u003C\u002Fp>\u003Cp>A. Your firm has not adequately implemented its procedure for Microbiological Testing, WI 80.002, Rev. 5. The microbiological sampling and testing of \u003Cstrong>(b)(4) \u003C\u002Fstrong>water, which is used to prepare the acid concentrate products, has not been adequately implemented due to the following conditions: For example,\u003C\u002Fp>\u003Cp>i. The exact location of the sampling port location for collecting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water and the identity of the person collecting samples are not documented. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> water sample is taken from one of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling ports.\u003C\u002Fp>\u003Cp>ii. The sampling port used on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system does not represent actual point-of-use conditions where the water will be utilized in manufacturing.\u003C\u002Fp>\u003Cp>iii. Samples are collected using non-sterile containers, introducing potential contamination that could affect test results.\u003C\u002Fp>\u003Cp>iv. Samples are plated using non-sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringes that expired in June 2016.\u003C\u002Fp>\u003Cp>v. The incubator temperature for incubating the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates to measure the total microbial count of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water sample should be maintained between \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On 07\u002F21\u002F2025 and 07\u002F24\u002F2025, the thermometer showed temperatures of 41°C and 42°C on 07\u002F23\u002F2025, respectively.\u003C\u002Fp>\u003Cp>vi. \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates from \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples are read on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, exceeding the required incubation at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>vii. The Laboratory Record-Culture Reading sheets do not include the start and end times for incubation, which makes it impossible to confirm that the minimum requirement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been met.\u003C\u002Fp>\u003Cp>viii. The Laboratory Record-\u003Cstrong>(b)(4)\u003C\u002Fstrong> sheets reviewed for endotoxin tests lack the start and end times for incubation, which does not show compliance with the necessary incubation periods.\u003C\u002Fp>\u003Cp>B. The monitoring and disinfection of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not being conducted appropriately per the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Instructions for use and Maintenance, WI 70.001, Rev. 2 For example, your procedure requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring of specific parameters including pressures, flow rates, water quality measurements (TDS, pH, conductivity, hardness), and system performance metrics, whereas:\u003C\u002Fp>\u003Cp>i. The temperature, conductivity, pH, prefilter outlet pressure, and reject % of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system currently used to manufacture the acid concentrate products is not being adequately monitored \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for 2024 and 2025 found the pH and conductivity of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water has not been measured \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the temperature is not a monitored parameter, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> has not been documented as the gauge is broken, and the feed conductivity and Reject % has not been monitored since the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system panel has not worked since on or about 06\u002F21\u002F2022.\u003C\u002Fp>\u003Cp>ii. The disinfection process fails to include the complete \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. The pipes carrying \u003Cstrong>(b)(4)\u003C\u002Fstrong> water to mixing tanks and washing areas are not included in disinfection procedures, creating potential microbial contamination pathways that could compromise product quality.\u003C\u002Fp>\u003Cp>C. The temperature of the warehouse where finished product and raw materials are stored is not monitored adequately per your procedure, Facility Maintenance - Cleaning and Pest Control, WI 71.002, Rev. 2. For example,\u003C\u002Fp>\u003Cp>i. WI 71.002 specifies air conditioning settings of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (summer) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (winter), but the Temperature Log (WI Form 71.002) allows an \"Acceptable Range\" of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There is no documented rationale, or testing to support storage of finished products at temperatures up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Also, the USP grade raw material labels require that Potassium Chloride is kept in “dry and room temperature” storage conditions; Calcium Chloride require “cold, dry” storage conditions; and Citric Acid requires “dry, cool” storage conditions.\u003C\u002Fp>\u003Cp>ii. Warehouse humidity is not measured despite raw materials requiring dry storage conditions.\u003C\u002Fp>\u003Cp>iii. Per SOP 72.001, Rev. 1, calibrated thermometers are required for monitoring warehouse temperatures; however, uncalibrated thermometers are used in where raw materials are stored and dispensed in the warehouse without proper temperature control.\u003C\u002Fp>\u003Cp>iv. Temperature is only measured at one location outside the mixing area, but the facility is approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> square feet and has multiple designated storage areas for raw materials and finished products. The different storage areas have independent HVAC systems but lack individual monitoring.\u003C\u002Fp>\u003Cp>On 7\u002F29\u002F25, the investigators observed the thermometer in the warehouse showed 90°F, while the mixing room near the drum filling areas reached 98°F. The temperature in the warehouse, where the finished products are stored prior to loading trucks, is not monitored. It was also observed the bay door was open on most days during the inspection, with outside temperatures reaching over 100°F.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Regarding observation 3A, we acknowledge that your firm initiated a CAPA plan to address microbiological testing procedures and \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system standardization. These include revision of Microbiological Testing procedure (WI 80.002, Rev. 5) to require proper documentation of sampling ports, and implementation of standardized \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system protocols. Your firm agreed to update your sampling location by transition from using the \"farthest point\" to identifying true point-of-use locations for \u003Cstrong>(b)(4)\u003C\u002Fstrong> water sampling. Your firm should demonstrate the requirements to validate new sampling locations to ensure they are truly representative of actual use points. You should also establish specifications that clean \u003Cstrong>(b)(4)\u003C\u002Fstrong> should be used when adding \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples to \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates and ensure that sterile equipment is mandatory for contamination control principles and the use of expired syringes should not be allowed. Despite your equipment upgrades and procedural improvements, we recommend that while the immediate technical issues may be resolved, the root cause of the monitoring and detection failures has not been adequately addressed.\u003C\u002Fp>\u003Cp>Regarding observation 3B, your firm has committed to repairing the broken pressure gauge and restoring \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system panel functionality. You stated that you have hired a third-party to conduct a comprehensive system audit to identify additional potential failures, along with employee retraining on updated SOPs and implementation of a preventive maintenance schedule. Please explain the 3-year delay in addressing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> panel failure that has existed since 2022. There is no proper justification why \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system was not maintained, identified, or corrected during the equipment failure period. Also, we understand that you have taken corrective actions to address disinfection protocols for your entire \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Please revise your \u003Cstrong>(b)(4)\u003C\u002Fstrong>-004 to include a full system disinfection procedure, covering all piping, valves, and endpoints. Finally, you indicated that training will be provided to employees on updated procedures and implement a verification checklist to ensure all components are disinfected. Your response cannot be adequately determined without a follow-up inspection to verify the repairs you completed at your facility.\u003C\u002Fp>\u003Cp>Regarding observation 3C, your firm has implemented corrections to address the temperature in the warehouse where finished product and raw materials are stored. Please provide adequate evidence demonstrating proper relocation of temperature-sensitive materials to cooler conditions per USP requirements and any evaluation of the products left over that had been stored there. There is lack of justification for storage of temperature-sensitive raw materials requiring \"cold, dry\" or \"cool, dry\" conditions. The adequacy of this response cannot be determined at this time. Please provide supporting documents and detail the actions taken to resolve the improper storage of your products and raw materials, as well as documentation demonstrating actions you have taken to address the temperature and humidity issues.\u003C\u002Fp>\u003Cp>4. Failure to appropriately design, construct, and install equipment used in the manufacturing process to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR § 820.70(g). Specifically,\u003C\u002Fp>\u003Cp>The following conditions of your production equipment were observed throughout the inspection. For example,\u003C\u002Fp>\u003Cp>A. \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used to manufacture the Diasol products, and Citrisol Acid Concentrates, and Citric Acid. The inspection found deficiencies including:\u003C\u002Fp>\u003Cp>i. Water leaking from \u003Cstrong>(b)(4)\u003C\u002Fstrong> housing and hoses, creating potential contamination risks.\u003Cbr>ii. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system control panel is inoperable eliminating the ability to monitor critical water quality parameters (conductivity, reject percentage)\u003Cbr>iii. 12-inch dead leg in water piping to mixing tanks and drum washing area can harbor microbial growth.\u003Cbr>iv. Missing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> pressure gauge needle, bent and inoperable pump feed pressure gauge, and uncalibrated gauges and flowmeters throughout the system.\u003C\u002Fp>\u003Cp>B. The mixing and drum filling area deficiencies include:\u003C\u002Fp>\u003Cp>i. Leaking pipefitting at base of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank in the filling line for dialysate acid concentrates.\u003Cbr>ii. Inoperable motor for \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank mixing blades, forcing reliance solely on recirculating pump for mixing.\u003Cbr>iii. Drum filling hose observed touching the floor during operations.\u003Cbr>iv. Both electrical control panels are inoperable including flow meter displays for both \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks.\u003C\u002Fp>\u003Cp>C. It was observed that the conditions of the equipment in the drum washing area raised contamination concerns. The drums are cleaned with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> before they are used, and the caps are cleaned by placing them in a bucket filled with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water before use. For example:\u003C\u002Fp>\u003Cp>i. Hoses and \u003Cstrong>(b)(4)\u003C\u002Fstrong> hose are stored inside water-filled bucket creating potential for microbial growth and cross-contamination.\u003Cbr>ii. Washing hoses observed touching the floor are compromising cleanliness of equipment used for container preparation.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your firm acknowledged several equipment deficiencies related to improper design, maintenance, and installation that hindered effective cleaning, adjustment, and operation. You stated for observation 4A and 4B that all leaking components are being replaced with \u003Cstrong>(b)(4)\u003C\u002Fstrong> housing, hoses inspected, and replacement parts requested from your supplier.\u003C\u002Fp>\u003Cp>The damaged gauges have been replaced with new units and a 12-inch dead leg will be removed and piping reconfigured to eliminate stagnant water zones. In addition, your firm plans to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> PM checks, and employees will receive retraining on equipment inspection and reporting protocols. Your procedures will be revised to include \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system monitoring and maintenance procedures. Your firm indicated there is difficulty locating replacement boards for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> panel and plans to continue \u003Cstrong>(b)(4)\u003C\u002Fstrong> readings.\u003C\u002Fp>\u003Cp>However, you have not addressed a timeline for obtaining replacement \u003Cstrong>(b)(4)\u003C\u002Fstrong> panel board versus indefinite \u003Cstrong>(b)(4)\u003C\u002Fstrong> operation. It is unclear what is your current method for monitoring conductivity and reject percentage if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system remains operational. We cannot verify the calibration status of your newly installed gauges and flowmeters at your facility. Please provide supporting documents to verify that the actions mentioned above have been implemented, along with the timeline, the method used to monitor the water quality parameters, and the calibration status of your new measuring equipment.\u003C\u002Fp>\u003Cp>Additionally, your responses indicate that equipment issues and corrective actions will also address pipe fitting at the base of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank which was replaced and pressure tested. The hose holders were installed to prevent floor contact, and SOPs were updated to include hose sanitation protocols. Your firm stated the mixing motor requires replacement and validation, but currently mixing is performed using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing of each batch to ensure homogeneity. The electrical systems are under repair requiring \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling operations. Some of the concerns we have with your corrective actions is that you have no plan to repair or replace critical monitoring equipment, claiming it's unnecessary. There is no specific timeline given for replacing critical equipment such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank motor. Additionally, we have concerns about the temporary \u003Cstrong>(b)(4)\u003C\u002Fstrong> mixing method, including how \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing guarantees batch homogeneity without proper validation protocols. The adequacy of your response cannot be determined at this time. Please address our concerns stated above and provide supporting documentations to verify the adequacy of your corrective actions.\u003C\u002Fp>\u003Cp>Regarding observation 4C, your firm stated that all hoses were removed from water buckets to eliminate improper storage. The wall-mounted hose hangers were installed with drip trays beneath to prevent water pooling. Sanitation procedures were revised to include instructions prohibiting hose submersion, with visual aids and diagrams for proper storage. You state employee training will be conducted, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitation checks will now include hose storage verification. Per your firm’s Work Instruction #70.003, \u003Cstrong>(b)(4)\u003C\u002Fstrong> water buckets they are now designated solely for soaking drum caps (maximum \u003Cstrong>(b)(4)\u003C\u002Fstrong>), with water changed every \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm claims hoses were removed from water buckets but then describes continued use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> water buckets for drum cap soaking for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your corrective actions focus on hose hangers but fails to adequately address the fundamental contamination risks associated with improper hose storage. No detailed assessment was provided regarding duration of improper hose storage, potential impact on product quality, products already released using this practice, and your current actions to effectively eliminate contamination risks.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Please address our concerns stated above and provide supporting documentations to verify the adequacy of your corrective actions.\u003C\u002Fp>\u003Cp>5. Failure to suitably design buildings to perform necessary operations, as required by 21 CFR § 820.70(f).\u003C\u002Fp>\u003Cp>Specifically, the following conditions were observed at your facility.\u003C\u002Fp>\u003Cp>A. The floors in mixing, gallon filling, and washing areas show erosion and pitting that creates areas where water can accumulate.\u003C\u002Fp>\u003Cp>B. The washing area wall where drums are cleaned shows multiple problems including moisture damage, structural deterioration, and apparent mold growth on tiles.\u003C\u002Fp>\u003Cp>C. Two doors were improperly secured - the wash area exterior door was not fully closed and the warehouse bay door (where finished product is stored) remained open during operations.\u003C\u002Fp>\u003Cp>Your response for observation 5A and 5B is inadequate. Your firm proposed corrective and preventative actions to address the inadequate conditions of your facility. However, we are concerned that your firm plans to use the same chemical-resistant epoxy polyurethane solution that has already failed multiple times since 2019. There is no mention of concrete repair or proposed surface preparation before recoating. The salt erosion from your products may continue damaging the concrete substrate of your facility and purchased repair products have not been evaluated to determine adherence to existing damaged concrete. There are no established procedures for addressing the black mold-like substance or underlying moisture problems and no proposed ventilation improvements or containment systems to prevent future damage.\u003C\u002Fp>\u003Cp>In addition, please evaluate the impact of open doors at your facility on environmental controls, specifically how door breaches affect temperature, humidity, and contamination control in the manufacturing environment. This may have broader implications on your firm’s manufacturing processes and product quality. The adequacy of your response for observation 5C cannot be determined at this time.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a). Specifically,\u003C\u002Fp>\u003Cp>Your firm did not adequately implement procedures for Nonconforming Product, SOP 90.001, Rev. 5, and Final Acceptance, SOP 80.001, Rev. 3. For example:\u003C\u002Fp>\u003Cp>A. You did not initiate Product Nonconforming Reports (PNCRs) when chemical laboratory out-of-specification (OOS) test results failed to meet specifications during final acceptance testing or investigate the root causes of these failures. For example,\u003C\u002Fp>\u003Cp>i. Diasol acid concentrate Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) failed specifications for both Dextrose (92 mg\u002FdL compared to allowable range \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FdL) and Calcium (2.30 mEq\u002FL compared to allowable range \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL) tested on 6\u002F28\u002F2025.\u003C\u002Fp>\u003Cp>ii. Citrisol acid concentrate Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) failed Dextrose specification (92 mg\u002FdL compared to allowable range \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FdL) on 6\u002F28\u002F25.\u003C\u002Fp>\u003Cp>iii. Diasol acid concentrate Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) failed Magnesium specification (1.15 mEq\u002FL compared to allowable range \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL) on 5\u002F27\u002F25.\u003C\u002Fp>\u003Cp>In all cases, your firm said new samples were submitted for re-testing and re-tests eventually passed. However, your original failed results were excluded from the DHR and no PNCRs were initiated to investigate the causes of the failures. Furthermore, the investigation revealed 22 samples requiring re-testing due to OOS results between April 1, 2025, and July 25, 2025, with no corresponding PNCRs documented.\u003C\u002Fp>\u003Cp>B. Your firm’s procedure for Microbiological Testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples, WI 80.002, Rev. 5 establishes an action level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> colonies (\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002FmL) and a limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> colonies (equivalent to \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002FmL) and requires nonconformance report initiation when the action levels are exceeded. For example:\u003C\u002Fp>\u003Cp>i. On 6\u002F18\u002F25, microbiological test showed 6 CFU\u002F0.1mL (exceeding the 5 CFU action level) for Diasol acid concentrate batch #3153 (Lot #PHV06191). However, the batch was produced before microbiological results were obtained and before the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system disinfection. There was no Product Nonconformity Report initiated to determine the need to investigate the cause of the failure.\u003C\u002Fp>\u003Cp>ii. On 4\u002F28\u002F25, microbiological test showed that action level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002F0.1mL was exceeded where the original test results were not documented. The sample was inappropriately re-tested multiple times using frozen\u002Fthawed samples on 04\u002F28\u002F2025 and 05\u002F02\u002F2025. The three batches (\u003Cstrong>(b)(4)\u003C\u002Fstrong> - Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> before obtaining the action level test results and before the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system disinfection. There was no Product Nonconformity Report initiated to determine the need to investigate the cause of the failure.\u003C\u002Fp>\u003Cp>C. The firm’s procedure for \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing is done by testing each completed batch for endotoxins using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> test \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> water is tested for endotoxins \u003Cstrong>(b)(4)\u003C\u002Fstrong> a week. Your firm did not document invalid test results appropriately obtained on 07\u002F10\u002F2025 with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, package \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Exp. Date 08\u002F30\u002F2027), to determine whether investigation of the invalid result was necessary. The same lot of the unevaluated \u003Cstrong>(b)(4)\u003C\u002Fstrong> that led to invalid results has been used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> product batches and \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples.\u003C\u002Fp>\u003Cp>D. Nonconformance report investigations, disposition, and corrective actions were inadequate for the following nonconformity product reports:\u003C\u002Fp>\u003Cp>i. Product Nonconformity Report #105 was initiated on 6\u002F20\u002F24 for Acetic Acid Glacial (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) contaminated with bleach affecting multiple batches of the dialysate acid concentrates. The investigation failed to document how bleach contamination occurred. Your firm received \u003Cstrong>(b)(4)\u003C\u002Fstrong> totes but only investigated \u003Cstrong>(b)(4)\u003C\u002Fstrong> tote and \u003Cstrong>(b)(4)\u003C\u002Fstrong> additional batches were manufactured using remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> totes without verifying they were contamination-free. The preventative actions lacked implementation details for improved raw material controls.\u003C\u002Fp>\u003Cp>ii. Product Nonconformity Report #99 was initiated on 2\u002F12\u002F24 for calcium concentration 8% below acceptable range for Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The investigation was incomplete such that it failed to address concurrent low glucose and sodium chloride concentrations identified in the same laboratory reports. There was inadequate root cause analysis for multiple component failures.\u003C\u002Fp>\u003Cp>iii. Product Nonconformity Report #102 was initiated on 6\u002F30\u002F25 for low calcium test results for Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>). The report identified a procedural issue with drum \u003Cstrong>(b)(4)\u003C\u002Fstrong> when adding \u003Cstrong>(b)(4)\u003C\u002Fstrong> chemicals to \u003Cstrong>(b)(4)\u003C\u002Fstrong> drums. You found that \u003Cstrong>(b)(4)\u003C\u002Fstrong> with multiple raw materials at once causes displacement and affects test results. Your firm failed to update the associated procedure (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, WI 70.008, Rev. 1) to prevent recurrence, and inadequate corrective action was implemented.\u003C\u002Fp>\u003Cp>iv. Product Nonconformity Report #104 was initiated on 7\u002F3\u002F25 for Batches (#3170 – Lot #PHV07031, #3168 – Lot #PHV07021, and #3166 – Lot #PHV07011) missing dextrose test results. There is insufficient evidence to support investigation conclusion that contract laboratory equipment was out of service. PNR#104 indicated that the contract lab did not test the samples because the equipment was out of service. The investigators confirmed this claim, but your firm provided incorrect information. Later, your firm admitted you did not reach out to the contract laboratory to find out why the dextrose testing was not performed for the three batches. Your firm released batches without required glucose testing based on unsupported patient safety claims. The investigation lacked risk analysis to justify release without complete testing data.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Regarding observation 6A, your firm’s immediate actions are to address the proper handling of OOS test results for the batches by initiating PNCRs or investigate root causes of failures during final acceptance testing. You stated your NCR procedures will be updated, along with managing of DHR documentation, and OOS handling protocols will be implemented. Despite your firm’s historical promises of conducting retrospective PNCRs, there is no evidence of completion, and no corrective actions have been initiated for batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which also had OOS results requiring documentation and root cause assessment.\u003C\u002Fp>\u003Cp>Regarding observation 6B, your firm indicated that a positive microbial result was attributed to cross-contamination by a new QC employee whose sleeve touched the sample during testing. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system was disinfected on 6\u002F18, and the water used for batch #3153 reportedly passed quality acceptance after disinfection. Your firm claims no production occurred between 6\u002F16-6\u002F19, however batch #3153 was produced on 6\u002F19 using water from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system that had not been properly disinfected. Your CAPA plan is to establish deviation documentations, conduct retrospective reviews of batches, perform microbial re-testing of retained \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples, and update procedures to include excursion handling and sample integrity. Your firm claimed that results were \"false positive\" due to employee error without providing adequate scientific justification. However, there is a contradiction in the timeline: your firm stated no production occurred between 6\u002F16-6\u002F19, yet batch #3153 was produced on 6\u002F19 using water from the compromised system. Your response is inadequate.\u003C\u002Fp>\u003Cp>Regarding observation 6C, your firm investigated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and determined excessive heat caused the test failures of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit. \u003Cstrong>(b)(4)\u003C\u002Fstrong> recommended storing \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits at \u003Cstrong>(b)(4)\u003C\u002Fstrong> in refrigerated conditions. Two boxes of compromised test kits were destroyed after producing nonconforming results. You stated that you retested samples using test kits that passed acceptability criteria. Your firm’s CAPA plan is to have \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits stored in refrigerated conditions, review procedure to include flowchart for handling invalid \u003Cstrong>(b)(4)\u003C\u002Fstrong> results, conduct mandatory deviation entry, and sample quarantine procedures. Your firm claims only 2 boxes were affected but the FDA findings indicate 40 batches, and 20 samples may be impacted. We have taken into consideration that you evaluated all the impacted products when you initiated your voluntary recall. The adequacy of this response cannot be determined at this time. We will review your response updates along with your procedures and CAPA to ensure the storage and evaluation of materials outside of proper storage conditions are properly addressed.\u003C\u002Fp>\u003Cp>Regarding observation 6D, the following PNCR’s were reviewed and corrective actions implemented for: 1) PNCR #105: corrective action was taken to perform analytical testing of retained samples, implementation of chlorine strip testing for acetic acid totes, staff training on contamination protocols, revised PNCR templates, and enhanced supplier qualification processes. However, there is still no clear explanation of detection method for bleach contamination, 2) PNCR #99: corrective action is to have the batch rework to restore specifications, expanded PNCR documentation, QA staff training on deviation protocols, and revise SOPs requiring investigation of all OOS parameters. Your firm acknowledged that glucose and sodium issues were not investigated but provides no evidence this has been corrected, 3) PNCR #102: corrective action is taken to update your work instructions (WI 70.009 and 70.008) with clear restrictions against simultaneous \u003Cstrong>(b)(4)\u003C\u002Fstrong> of multiple chemicals, implementation of step-by-step \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedures, and provide personnel training, and 4) PNCR #104: your corrective action is to conduct retrospective risk assessment, enhanced verification protocols, revise SOPs requiring all critical test results before release, and implementation of batch disposition checklists. However, your firm justifies releasing batches without required testing based on \"emergency\" needs of your customers. The adequacy of your response for observation 6D cannot be determined at this time as corrective actions are in progress.\u003C\u002Fp>\u003Cp>Our overall concerns with this observation and the corrective actions taken is your summary reveals systemic issues including delayed reporting, incomplete investigations, inadequate documentation, and patterns of releasing products without full quality data verification. Please ensure these corrective actions have been adequately verified and implemented and provide supporting documentation when they are available.\u003C\u002Fp>\u003Cp>7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a). Specifically,\u003C\u002Fp>\u003Cp>Your firm has not adequately followed your complaint handling procedure, Complaint File, SOP 198.001, Rev. 2, as you failed to document and determine the need to investigate “order replacements” related to complaints about product, packaging, and labeling issues. For example, the following complaints were not properly investigated:\u003C\u002Fp>\u003Cp>A. Reviewed a complaint on 5\u002F20\u002F24 about product G100225-10DEX100 (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) causing unstable conductivity in dialysis machines preventing patient treatment.\u003C\u002Fp>\u003Cp>B. Eight complaints between March 2024 and July 2025 were reviewed for damaged cases of gallons and bags.\u003C\u002Fp>\u003Cp>C. One complaint in June 2024 was reviewed about missing gallon labels on Citric Acid 50% products.\u003C\u002Fp>\u003Cp>D. Two complaints in 2025 involving cracked drums that caused product leakage.\u003C\u002Fp>\u003Cp>E. One March 2024 return logged for damaged case and bag.\u003C\u002Fp>\u003Cp>Your firm also failed to evaluate any of these complaints to determine whether they constituted medical device reportable events.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your firm proposed corrective and preventative actions to address “product replacements” related to complaints about product, packaging, and labeling issues that are documented into your complaint tracking system. However, your firm continues to classify “product replacements” due to damage, labeling, or performance issues as “requests” rather than complaints requiring formal documentation and evaluation. While your firm updated your SOP to include replacements as complaints, you simultaneously maintain that transit damage replacements are not complaints. Your firm states that none of the complaints are reportable without demonstrating proper application of MDR evaluation criteria. Despite mentioning implementation of an MDR screening process, your firm has not demonstrated understanding of proper MDR criteria for assessing individual complaints. \u003Cem>Please refer to 21 CFR Part 820.198(a)(3) for further guidance to evaluate whether the complaint represents an event which is required to be reported to FDA under Part 803, Medical Device Reporting.\u003C\u002Fem>\u003C\u002Fp>\u003Cp>8. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR § 820.100(a). Specifically,\u003C\u002Fp>\u003Cp>Your firm failed to adequately implement your Corrective and Preventive Action (CAPA) procedure, SOP 100.001, Rev. 1 with multiple systemic issues identified across four specific CAPAs. For example,\u003C\u002Fp>\u003Cp>A. CAPA #24 was initiated on 2\u002F16\u002F24 and closed on 8\u002F8\u002F24 to address Diasol Acid Concentrate mix ratio issue which was not adequately investigated and failed to expand scope when a second complaint occurred on 5\u002F9\u002F24 involving \u003Cstrong>(b)(4)\u003C\u002Fstrong> gallons of concentrate with unstable conductivity readings. Your firm failed to adequately investigate why batch exceeded production yield (NPR No. 98) before lot release. Your firm did not document additional testing, product removal, and rework activities performed on returned product.\u003C\u002Fp>\u003Cp>B. CAPA #25 was initiated on 2\u002F16\u002F24 and closed on 8\u002F8\u002F24 to address nonconformances associated with labeling controls. The CAPA was ineffective as new mislabeling complaint occurred on 6\u002F11\u002F24 during the effectiveness verification phase. The original CAPA addressed mislabeled Diasol acid concentrate (Complaint #03, 7\u002F27\u002F22) but was closed as effective on 8\u002F8\u002F24 despite ongoing issues. The new complaint involved unlabeled Citric Acid 50%-gallon containers.\u003C\u002Fp>\u003Cp>C. CAPA #26 was initiated in May 2024 and appended CAPA 26A initiated on 12\u002F10\u002F24 to address facility and equipment deterioration identified in internal audit for plant equipment cleaning and maintenance, salt deposits that damage equipment and floors, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> water that damages pressure worker motor. No corrective actions have been completed or documented.\u003C\u002Fp>\u003Cp>D. CAPA #27 was initiated on 4\u002F10\u002F24 to correct a previous 483 observation for inadequate response with unclear scope, insufficient root cause analysis, and inadequate corrective actions. The CAPA has been open since 4\u002F10\u002F24 and repeat deficiencies were found during the current inspection.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your firm acknowledged the CAPA deficiencies and committed to taking corrective actions to ensure Part 820.100 is followed. However, CAPA #24 has no evidence the expanded investigation was completed, and no documentation was provided regarding evaluation of the additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> gallons that failed conductivity. There is no assurance that a link has been established to NCR #98 for excess yield issues. CAPA #25 was addressed with promised corrective actions and CAPA #30 was generated for additional actions, but neither provide evidence of addressing the root causes. Your firm has not demonstrated that cross-product labeling risks are controlled, and implementation verification is delayed until March 2026. CAPA #26 is a repeat observation spanning 7 years (2018-2025) with no actual corrections and response consists only of additional promises without actual progress. Finally, corrections to CAPA #27 and its root cause analysis is inadequate and there is no evidence that repeat deficiencies have been addressed.\u003C\u002Fp>\u003Cp>9. Failure to establish design history file, as required by 21 CFR § 820.30(j). Specifically,\u003C\u002Fp>\u003Cp>Your firm did not adequately implement your Design Control procedure, SOP 30.001, Rev.1, for maintaining adequate design documentation. For example,\u003C\u002Fp>\u003Cp>A. Lack of Design History File (DHF) for Citric Acid (50% and 20% concentrations) used for cleaning, decalcification, and disinfecting hemodialysis machines, despite manufacturing and distributing \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches since 2022.\u003C\u002Fp>\u003Cp>B. Inadequate Design History Files (DHFs) for Dryasol and Citrisol such that it references design inputs for \"Diasol acid concentrate,\" but no DHF exists for this referenced device. The electrolyte concentration specifications claim compliance with \u003Cstrong>(b)(4) \u003C\u002Fstrong>standards, but the actual acceptability ranges for Potassium and Calcium do not meet the standard requirements. Also, the DHFs fail to include or reference the location of required design verification and validation studies for these Class 2 medical devices.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your firm acknowledges poor implementation due to considering legacy formulations “low risk” and inadequate training on applying design controls to accessory products. Your firm stated you suspended sales as of September 1, 2025, and are determining if a 510(k) is needed, but this doesn't address years of non-compliance or demonstrate proper regulatory understanding. Your firm stated that your DHFs reference non-existent Diasol acid concentrate design inputs and the Electrolyte specifications for potassium and calcium do not meet \u003Cstrong>(b)(4)\u003C\u002Fstrong> standards. There is no design verification and validation documentation provided. Your firm plans to create the missing DHFs and update specifications but claims Diasol was marketed in 1985 prior to design file implementation, which does not exempt it from current requirements.\u003C\u002Fp>\u003Cp>10. Failure to adequately establish procedures for design change, as required by 21 CFR § 820.30(i). Specifically,\u003C\u002Fp>\u003Cp>Your firm did not implement your procedure, Design Control, SOP 30.001, Rev.1, by failing to adequately document, evaluate, and validate design change made to the Diasol Acid Concentrate device before implementation. For example:\u003C\u002Fp>\u003Cp>Your firm used Calcium Chloride Anhydrous instead of the required USP grade Calcium Chloride Dihydrate in \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing batches (August 19-21, 2024), totaling \u003Cstrong>(b)(4)\u003C\u002Fstrong> gallons of products. This substitution caused elevated calcium concentrations in batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>), requiring a Product Nonconformity Report (#100) on 8\u002F22\u002F2024 and subsequent rework to correct the calcium levels. Your firm failed to conduct required risk assessments regarding patient safety impacts and did not perform validation studies to evaluate potential effects on users, product stability, or long-term device performance.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your firm’s corrective action includes issuance of PNR#100 and rework of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> affected batches. You quarantined and removed the remaining substituted raw material from inventory. You created retrospective design change documentation and updated your SOP design control procedure to clarify that raw material substitutions constitute design changes. You stated that you haven’t conducted training for QA, R&amp;D, and procurement teams, and implemented mandatory design change checklist and \u003Cstrong>(b)(4)\u003C\u002Fstrong> compliance audits. You plan to conduct formal risk assessments for all design changes, including raw material substitutions, and mandate validation or verification studies prior to implementing any design changes. However, your firm has not provided a comprehensive risk assessment for this incident to evaluate potential ramifications of ingredient substitution. There is no demonstration that proper validation studies were conducted to establish equivalency of the substituted material.\u003C\u002Fp>\u003Cp>11. Failure to adequately establish procedures for design verification, as required by 21 CFR § 820.30(f). Specifically,\u003C\u002Fp>\u003Cp>Your firm has not adequately implemented your procedure for Design Controls, SOP 30.001, Rev. 1, section 4.6 Design Verification, regarding inadequate design verification for stability studies supporting product shelf-life claims. For example:\u003C\u002Fp>\u003Cp>A. The 3-year shelf-life stability study of your Diasol and Citrisol acid concentrates \u003Cem>(Stability Study Protocol and Stability Study Report, both numbered #110.001, signed 05\u002F09\u002F2019)\u003C\u002Fem> lacks any supporting laboratory data and fails to demonstrate that tested products used the same container closure system as finished products. There is no scientific rationale provided for sample selection, including testing a Diasol formulation with different magnesium concentration (\u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL vs. current \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq\u002FL) and selecting \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Citrisol acid concentrations. There is missing evidence that required pH and Conductivity testing was performed at all specified time points per the stability protocol requirements in \u003Cem>WI 80.004 In-process and Final Batch Testing\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>B. No stability study exists to support the assigned 3-year shelf-life for the Dry Citrisol Acid Concentrate. The product’s expiration date exceeded the expiration date of at least one packaged raw material powder used in two different lots (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>), which are set for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Meanwhile, the citric acid powder (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) in both products will expire on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your firm stated you have a long manufacturing history, producing concentrates since 1998 (with predecessor \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing since 1985). However, your stability study performed in 2019 used an outdated formulation (\u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq Mg) while current products contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq Mg. Your firm claims the \u003Cstrong>(b)(4)\u003C\u002Fstrong> mEq magnesium difference will not impact stability of the acid concentrate solution. The initial batch testing included proper pH and conductivity documentation, and subsequent tests have handwritten pH and conductivity records. You said you will perform verification on all lab samples to ensure correct dilution. However, your firm failed to provide missing laboratory data and there is no documented justification showing the older formulation is representative of current products. There is no demonstration that the magnesium difference does not affect stability conclusions and despite mentioning handwritten records and verification procedures, actual testing data remains missing. Your firm failed to demonstrate compliance with your protocol or address systematic documentation gaps. Additionally, your responses indicated that additional time is required to respond to this part of the observation.\u003C\u002Fp>\u003Cp>12. Failure to adequately establish requirements that must be met by contractors and consultants, as required by 21 CFR § 820.50(a). Specifically,\u003C\u002Fp>\u003Cp>Your firm failed to adequately implement your supplier evaluation procedure, SOP 50.001, Rev. 2 in two main areas:\u003C\u002Fp>\u003Cp>A. Your firm lacks documented evaluation of your contract laboratory that performs chemical analysis of dialysis acid concentrate products. No documented evidence exists that the laboratory uses validated analytical test methods per \u003Cstrong>(b)(4)\u003C\u002Fstrong> standards. The laboratory's \u003Cstrong>(b)(4)\u003C\u002Fstrong> method is inadequately justified for testing potassium, magnesium, glucose, and calcium levels, as the standard only indicates \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sodium analysis. Despite four information requests, your contract laboratory failed to provide complete details about their analyzers and test methodologies, leaving your firm unaware of actual testing procedures.\u003C\u002Fp>\u003Cp>B. Your firm lacks documented evaluation demonstrating that your quality audit consultant is competent to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> audits.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. The response requested additional time to respond to this item and mentions you are planning to update your supplier qualifications. Review of these responses found no documented evaluation exists for the contract laboratory performing chemical analysis. No evidence was provided demonstrating the laboratory uses validated analytical test methods per \u003Cstrong>(b)(4)\u003C\u002Fstrong> standards and the laboratory's \u003Cstrong>(b)(4)\u003C\u002Fstrong> method is only validated for sodium analysis, not for potassium, magnesium, glucose, and calcium as required. Your firm has not provided evidence that you have taken immediate steps to obtain proper documentation or verify the analytical methods from your contract laboratory.\u003C\u002Fp>\u003Cp>Regarding observation 12B, your firm stated that you contracted \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your last two internal audits. Your firm plans to hire a certified auditor for 2025 and establish qualification criteria based on experience and certification. A CAPA table was provided, but no corrective actions have been implemented yet—all items are scheduled for future completion. Your firm’s planned corrective actions include conducting formal competency assessments, reviewing qualifications and certifications, creating consultant evaluation forms, updating QMS procedures, and staff training. Your firm has not provided evidence that you have taken any immediate action to address the ongoing use of potentially unqualified suppliers and consultants. The adequacy of this response cannot be determined.\u003C\u002Fp>\u003Cp>13. Failure to perform risk analysis, as required by 21 CFR § 820.30(g). For example,\u003C\u002Fp>\u003Cp>A. Your firm does not have a documented risk analysis for your Diasol liquid acid concentrate.\u003C\u002Fp>\u003Cp>B. The existing risk analysis for your Dryasol acid concentrate fails to evaluate potential harms to patients and users for hazards already identified in your firm’s risk analysis document (DHF 30.003, rev. 1). The analysis does not include risk estimations for known and foreseeable hazards associated with dialysate concentrates, including electrolyte imbalance, lack of dextrose, pyrogen reactions, microbial infections, particulate emboli, and toxicity from chemical contaminants.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your firm’s stated that you initiated a risk analysis for your Diasol liquid acid concentrate by following \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard. Your preventative actions include risk analysis for all products and staff training, and CAPA #2025-04-DLC is scheduled to be completed by 12\u002F08\u002F25. A review of your firm’s corrections observed that products continue to be manufactured and distributed without documented risk analysis. You should ensure critical elements such as detailed hazard identification, quantitative risk estimation (severity x probability), specific risk control measures, and residual risk evaluation. The 4+ month timeline to correct the observation appears to be excessive.\u003C\u002Fp>\u003Cp>Regarding observation 13B, your firm updated your risk analysis procedure to include patient risk assessment. Immediate action is to initiate internal review of DHF 30.003, Rev. 3 by a cross-functional team to include all known and foreseeable hazards and incorporate clinical harms and severity ratings. Your preventative action is to update risk management SOPs to require clinical review and train design and regulatory affairs teams on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and FDA guidance. However, your firm submitted DHF 30.002 for Citrisol instead of the required Dryasol analysis. The adequacy of this response cannot be determined.\u003C\u002Fp>\u003Cp>\u003Cu>Medical Device Reporting Violation(s)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s dialysate concentrates are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to report to us the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included in your firm’s internal email communication dated May 20, 2024, reasonably suggests that your firm’s Diasol liquid acid concentrate malfunctioned during use. Specifically, the device caused unstable conductivity in the dialysis machine, preventing the dialysis treatment from being performed. As a result, the device failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). This device, classified as a hemodialysis system and accessories under 21 CFR 876.5820 (product code KPO), is considered life-supporting or life-sustaining. A malfunction is reportable if it involves a device that is considered to be life-supporting or life-sustaining and thus is essential to maintaining human life, as is the case here, or if it results in the failure of the device to perform its essential function—here, dialysis—thereby compromising the device’s therapeutic effectiveness, which could cause or contribute to a death or serious injury. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63578, 63585 (Dec. 11, 1995), Comment 12, for more information. Accordingly, because this device malfunctioned and the device or a similar device you market would be likely to cause or contribute to a death or serious injury if the malfunction were to recur, the adverse event represents a reportable malfunction under 21 CFR 803.3. During the inspection, your firm acknowledged that no MDR had been submitted for this event.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated September 8, 2025, cannot be determined at this time. In its response, your firm states that it plans to revise its MDR procedure, conduct staff training, and perform a retrospective review to submit MDRs for each identified MDR Reportable complaint. FDA has not yet received an electronic version of Form 3500A for the above reference event. In addition, no supporting documentation of corrective actions was provided, as these remain in progress.\u003C\u002Fp>\u003Cp>Your firm’s responses dated October 7, 2025, and November 10, 2025, did not provide evidence or documentation to address the noted violation.\u003C\u002Fp>\u003Cp>In addition, the inspection revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm presented its procedural documents titled “Complaint File”, SOP 198.001, Rev. 2, dated 04\u002F25\u002F2024 and “Medical Device Reporting (MDR) Procedure”, SOP 198.002, Rev. 2, dated 04\u002F25\u002F2024. After collectively reviewing them as your firm’s MDR procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>a) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, and “malfunction”, and the definition found in 21 CFR 803.20(c)(1) for the term “reasonably suggests”, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>b) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\u003Cbr>i. Instructions for how to obtain and submit information that corresponds generally to the format of Form FDA 3500A.\u003Cbr>ii. Instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive.\u003Cbr>iii. How your firm will ensure that all information required in 21 CFR Part 803, subpart E, that is reasonably known to you is submitted for each event. Specifically, which types of information corresponding generally to the format of Form FDA 3500A will need to be submitted, to include the information in your possession at the time you filed your initial report and if you later obtain any required information that was not available at the time you filed your initial report.\u003C\u002Fp>\u003Cp>In addition, based on FDA’s records, as of October 8, 2025, your firm has not completed its load test and guidance compliance submission for electronic Medical Device Reporting (eMDR). We recommend your firm follow the instructions located at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program under “Low Volume Enrollment Process” to obtain its WebTrader production account.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated September 8, 2025, cannot be determined at this time. In its response, your firm stated that it plans to update its MDR procedure by November 8, 2025, conduct staff training, and establish an electronic submission account. However, no supporting evidence was provided, as these corrective actions are still ongoing.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated October 7, 2025, and concluded that it is not adequate. Your response states that corrective actions are still in progress and included a copy of its revised MDR procedure titled “Medical Device Reporting (MDR) Procedure”, SOP 198.002, Rev. 2, dated 09\u002F09\u002F2025. Upon review of the revision, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>The revision does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the revision still omits the definition of “malfunction” in 21 CFR 803.3, and “reasonably suggests” in 21 CFR 803.20(c)(1). The absence of these definitions may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>The revision does not include the requirement for submitting supplemental or follow up reports within 30 calendar days of the day that you receive information required under 21 CFR Part 803 that you did not provide because it was not known or was not available when you submitted the initial report, as required under 21 CFR 803.56.\u003C\u002Fp>\u003Cp>In addition, your firm has not yet completed its load test and guidance compliance submission for eMDR. We recommend that your firm follow the instructions provided above to obtain a WebTrader production account for electronic submissions.\u003C\u002Fp>\u003Cp>Your firm’s response dated November 10, 2025, did not provide evidence or documentation to address the noted violation.\u003C\u002Fp>\u003Cp>\u003Cu>Unique Device Identifier (UDI) and GUDID Violation(s)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>\u003Cem>Misbranding under Section 502(c) for Failure to Have Compliant Labeling\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The inspection also revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of the Act to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of Citrisol Powder 45125-10, CitriSol 100225-10, Diasol 100225-10, Citric Acid 50%, Diasol 10000-25, and Dryasol 45225-10 devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for Citrisol Powder 45125-10, CitriSol 100225-10, Diasol 100225-10, Citric Acid 50%, Diasol 10000-25, and Dryasol 45225-10 devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses Automatic Identification and Data Capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>\u003Cem>Misbranding under Section 502(t)(2) for Failure to Submit Required Information\u003C\u002Fem>\u003C\u002Fp>\u003Cp>In addition, Citrisol Powder 45125-10, Citric Acid 50%, and Dryasol 45225-10 devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Our inspection revealed that your firm designs the finished product label for your Citrisol Powder 45125-10, Citric Acid 50%, and Dryasol 45225-10 devices and final product labeling reflects your firm’s name, and address. Diasol, Inc is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>Our office requests that Diasol, Inc. immediately cease any activities that result in the misbranding or adulteration of your devices, such as the commercial distribution of your devices for the uses described above.\u003C\u002Fp>\u003Cp>A follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of 21 CFR Part 820. You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\u003Cul>\u003Cli>Initial certifications by consultant and establishment – July 31, 2026.\u003C\u002Fli>\u003Cli>Subsequent certifications – September 1, 2027, and September 1, 2028.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps you have taken to address the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective action cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 3 Acting Assistant Director, Jeffrey Wooley, at CDRHEnforcement@fda.hhs.gov . Please include in the subject line, “CMS Case 719460” when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Charles J. Chacko, via email at charles.chacko@fda.hhs.gov\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and to bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMonica F. Abeles\n\nRecipient Title\n\nOwner and President\n\nDiasol, Inc.\n\n310 S. 43rd Ave., Ste. B\n\nPhoenix, AZ 85009\n\nUnited States\n\n(b)(6)@diasol.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #719460\nJanuary 29, 2026\nDear Ms. Abeles:\nDuring an inspection of your firm located in Phoenix, AZ from July 21, 2025, through August 19, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures disinfectants used to disinfect dialysate delivery systems and water purification systems used in hemodialysis (i.e. Diasol Bicarb, Diasol Concentrate, Diasol Additives, and CirtiSol Concentrate) for treatment of patients with renal failures or toxemic conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\nUnapproved Device Violation\nOur inspection revealed that your solutions of Citric Acid in 50% and 20% concentrations indicated for use in the cleaning, decalcification, and heat disinfection of hemodialysis machines are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). While you do have a clearance under section 510(k), K020231, for a Citric Acid product intended for use with sorbent regenerated dialysis to allow physicians to customize the dialysate to meet patients’ needs, that product is not intended for use in the disinfection of hemodialysis machines. Accordingly, you were required to submit a premarket notification (510(k)) for your solutions of Citric Acid in 50% and 20% concentrations indicated for use in the cleaning, decalcification, and heat disinfection of hemodialysis machines (see 21 CFR 807.81(a)(3)(ii)).\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received your email responses dated September 10, 2025, October 8, 2025, and November 21, 2025, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm on August 19, 2025. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for finished device acceptance, as required by 21 CFR § 820.80(d).\nSpecifically, according to your procedure for Final Acceptance, SOP 80.001, Rev. 03, your firm did not adequately implement final testing activities. For example:\nA. Your firm claims compliance to following (b)(4) (currently (b)(4)). The standard requires all electrolytes identified on the label must be within (b)(4) of the labeled value, except sodium, which must be within (b)(4), or (b)(4), whichever is greater. However, the acceptability range in your DMR and Device History Records (DHRs) does not meet this requirement. For example:\ni. The acceptable range for formulations with 1K Potassium is (b)(4) mEq\u002FL per the standard; however, your firm’s specified range for 1K Potassium is established at (b)(4) mEq\u002FL, as documented in your DMR and DHRs. Nine (9) DHRs reviewed from March 2024 to July 2025 for dialysate acid concentrate products labeled as having (b)(4) mEq\u002FL of Potassium showed that they were released with Potassium concentration results of (b)(4) mEq\u002FL, which exceeds the acceptable range in (b)(4) standard of (b)(4) mEq\u002FL.\nii. According to (b)(4) standard, the minimum acceptable level of Calcium should be (b)(4) mEq\u002FL; however, your firm’s acceptance criteria for formulations requires (b)(4) mEq\u002FL of Calcium, set between (b)(4) mEq\u002FL as documented in your DMR and DHRs. Out of 23 Device History Records (DHRs) reviewed from March 2024 to July 2025 for acid concentrate labeled as (b)(4) mEq\u002FL of Calcium, 15 DHRs were released with Calcium results at (b)(4) mEq\u002FL, which is below the allowed range established by the (b)(4) standard.\nB. Your firm’s In-Process and Final Batch Testing Procedure, WI 80.004, Rev. 3 and the procedure for Final Acceptance, SOP 80.001, Rev. 3, requires that Dextrose (Glucose) is tested on the (b)(4) container for each batch in accordance with the specifications in your Device History Records (DHRs). Your firm did not implement these procedures or its process for releasing finished products. Your firm released 4 out of 34 DHRs without Dextrose (Glucose) test results. Your firm began distributing three batches (Batch #’s 3170, 3168, and 3166) of the Diasol Acid Concentrates without Dextrose results on 7\u002F14\u002F2025; and one batch (Batch #DCS16) of the Dry Citrisol product without Dextrose result on 08\u002F05\u002F2025.\nYour response is inadequate. We understand that you entered into an agreement with (b)(4) to perform testing side-by-side with other labs such as (b)(4) and (b)(4) to determine the test result error for specific flagged batches, or to determine if it is your firm’s production error, with the electrolyte ranges not meeting the (b)(4) standard. Your firm should also recognize that your specification ranges are not compliant, instead of solely concentrating on determining if the laboratory testing method ((b)(4) method) is accurate. You should demonstrate that your specifications meet the relevant (b)(4) standard your firm has selected to follow and FDA requirements for their intended use. The lab-to-lab comparison studies should be reviewed in combination after updating your Device Master Records (DMRs) to comply with (b)(4) standard. Your firm should confirm which specific analytical methods the labs use to ensure adherence to the standard.\nPlease provide documented evidence that your firm is committed to updating your DMRs to comply with the applicable standards. You should be specific in your Final Acceptance Procedure and DMR\u002FDHRs that the electrolyte ranges are compliant. Your firm should not use the current non-compliant electrolyte ranges pending additional testing. Changing laboratories may not address the main problem that your specifications do not meet the required (b)(4) standard. All electrolyte ranges should reflect the requirements of the standard you have chosen to follow. Finally, all results for the batches noted in the FDA 483 for observation 1A, should be reviewed to conform with the (b)(4) standard.\nFurthermore, regarding observation 1B, we understand that you are performing glucose testing on retained samples from the affected lots and your procedures (WI 80.004 and SOP 80.001) have been updated to include QA review and signoff for glucose testing prior to release. Also, you have planned to conduct (b)(4) audits of DHRs and batch release documentation and conduct CAPA effectiveness review. Please provide evidence of these corrective actions. Your firm should provide justification demonstrating how weight verification substitutes for chemical testing requirements for glucose content or perform the required chemical testing. Without such written justification, your response is inadequate. Furthermore, you may need to reassess the risk analysis if you find that this testing substitution was inadequate for glucose content.\n2. Failure to adequately validate a process whose results cannot be fully verified by subsequent inspection and test according to established procedures, as required by 21 CFR § 820.75(a). Specifically,\nA. Your firm conducted a cleaning validation for the re-usable (b)(4) drums under Drum Cleaning Validation (Protocol #75.007, dated 09\u002F04\u002F2019). The reusable (b)(4) drums are cleaned with (b)(4) water using a (b)(4) prior to filling them with a new batch of acid concentrate after they are returned from your customers and stored in your warehouse for an undetermined amount of time. The cleaning validation and re-validation of the drums are inadequate. For example,\ni. The study did not demonstrate there are no chemical residues from the earlier batches to prevent cross contamination. These drums are used to package and distribute Diasol and Citrisol acid concentrates that are made with differing raw materials such as acetic acid and citric acid. Also, the study does not evaluate that the reusable drums can be re-used indefinitely considering the processes, reuse, storage and solvents used in these drums.\nii. The Validation Report generated on 10\u002F07\u002F2019 was not accompanied by the raw data for drums (b)(4) to support the conclusion presented, and the data could not be provided upon investigator’s request.\niii. Data for re-validation dated 10\u002F09\u002F2020 using (b)(4) drums showed conductivity and pH tests failed on all (b)(4) drums after wash. There was no documented deviation or evidence of an investigation of these failures.\niv. Re-validation data of (b)(4) drums dated 07\u002F19\u002F2021 did not include total plate count results for microbiological testing on 4 of the (b)(4) drums after wash.\nAlso, your firm’s Work Instruction, Drum Washing, WI 70.003, Rev. 2, requires re-validation of the washing method (b)(4) but no revalidation has been conducted since 2023.\nB. Your firm utilizes both a (b)(4) and a (b)(4) mixing tank to mix dialysate acid concentrates. The validation protocols and reports (#75.005 and #75.006) for the mixing process for (b)(4) tanks are inadequate. For example,\ni. The mixer speed is one of the six key parameters for homogeneity of the finished product, according to your mixing validation but neither the protocol nor the report specifies the mixing speed of the tank mixers.\nii. Temperature is stated to affect mixing time in the batch production work instruction (WI 70.007, Batch Assembly, Rev. 2), and all lots produced for both validations show (b)(4); however, there is no specified acceptable temperature range or assessment of the duration of mixing affects the quality of your product.\niii. Sample sizes are not justified in multiple testing areas for your products while mixing. There is no rationale for the sample size and the method of collecting (b)(4) from the (b)(4) of the mixing tanks to determine homogeneity of the batch during this mixing validation. Currently, your firm collects three production samples from the (b)(4), and (b)(4) to test the composition of the dialysate concentrate. However, the glucose level is (b)(4). This practice of using (b)(4) production samples was not included in your mixing process validation to demonstrate your batch is uniform across all filled (b)(4).\niv. The reports state that longer mixing times does not affect the batch, but your firm did not provide adequate scientific rationale with supporting evidence for the maximum mixing time, or how you reached this conclusion.\nAdditionally, the mixing validation for the (b)(4) tank confirmed the mixing process with a mixer and a recirculation pump; however, the mixer in the firm’s (b)(4) mixing tank has not been operational since around 2022, and since then, the batches have only been mixed using the recirculation pump system, but this new mixing process has not been validated.\nC. The (b)(4), which was installed in your facility in (b)(4) to produce water for dialysate concentrate was not adequately validated. For example, your firm could not show that components were installed as per the piping and instrumentation diagram; that controls and alarms were configured correctly, and that critical process parameters and their operating ranges were properly established and controlled. Your firm could not provide a schematic showing how the components were installed and how the specifications for the operating parameters were determined.\nD. Your firm conducts total viable counts to monitor the microbiological quality of the (b)(4) water used to prepare dialysate concentrates, following the Microbiological Testing Procedure, WI 80.002, Rev. 5 using (b)(4) plate technique on (b)(4) plates incubated at (b)(4) for (b)(4). However, in practice your firm has incubated (b)(4) plates for up to (b)(4) at temperatures up to (b)(4). This test method has not been validated to confirm its effectiveness in recovering microorganisms from the (b)(4) water samples.\nThe adequacy of your response cannot be determined at this time. We understand you developed a new drum cleaning validation protocol and report (SOP No. 75.007, Rev. 2).\nYou also agreed to implement related procedures, perform retrospective review and CAPA for failed pH\u002Fconductivity tests and missing microbial data, conduct re-validation of cleaning process using newly installed (b)(4), retrain employees on cleaning procedures, and schedule (b)(4) audits to ensure compliance with cleaning validation procedures. Please ensure that you have addressed any cross-contamination risks between Diasol and Dryasol (Acetic Acid), and Citrisol (Citric Acid) products for using reusable drums. Your firm claims that life span of the (b)(4) drums is between (b)(4), but cleaning validation should still evaluate the effect on containers when deterioration is anticipated. There is no raw\u002Fhistorical data for drums (b)(4) to support the validation report generated on 10\u002F7\u002F2019, but your firm plans to implement SOPs for retention and traceability of raw validation data.\nRegarding observation 2B, your CAPA plan involves carrying out new mixing validation runs for each tank using the mixer and recirculating pump separately. Your firm is planning to conduct in-process and final acceptance testing on samples and assessing homogeneity by taking samples and conducting analytical tests (pH, conductivity, and concentration). Also, you’ve stated you plan to retrain QA and validation personnel on the revised documentation. Please ensure that you have documented the actual mixer speeds used when conducting the validation studies which appears to be the main issue with the process parameters (omitting the mixer speed in your previous validation report). The mixer speed is a critical parameter that directly impacts the homogeneity and consistency of dialysate acid concentrates. Your firm claims that temperature variation has minimal impact on your mixing process and that you have little control over (b)(4) water temperature (b)(4). A lack of control over the water temperature does not eliminate validation requirements. Your firm should include acceptable ranges prior to executing your validation because temperature is a critical parameter among pH, conductivity, specific gravity, and mixing time. The adequacy of this response cannot be determined at this time.\nRegarding observation 2C, your firm committed to ensuring that all water purification systems meet expectations for validation, documentation, and control. Your response stated that the (b)(4) installation and setup followed the manufacturer’s guidelines and that all (b)(4) parameters and (b)(4) log were configured according to the manufacturer’s instruction for starting the (b)(4) water system. Your firm claims that these requirements and the drawing of (b)(4) components are adequate. The (b)(4) manufacturers guidelines do not substitute for formal validation protocols (IQ\u002FOQ\u002FPQ). You should demonstrate that the validation requirements are met, ensuring that the water system is suitable for your use and complies with the specifications, in addition to installation adhering to the manufacturer’s guidelines. Also, your (b)(4) water system has been in use since (b)(4) without proper validation which represents (b)(4) years of unvalidated operations. The adequacy of this response cannot be determined at this time since corrective actions are in progress.\nRegarding observation 2D, your firm’s CAPA plan is for all microbial testing of (b)(4) water to revert to the validated method outlined in your Microbial Testing (WI 80.002. Rev. 5) procedure. You stated a formal study will be conducted to assess the impact of the modified method, and that the validation will follow USP 61, USP 62, and (b)(4) guidelines. Also, your procedure will be revised if the modified method is successful and is validated. Your firm said that your incubators with temperature spike occurred because an air conditioner in the facility broke down causing the temperature to rise, and the QC operator did not know how to lower the temperature. The environmental explanations do not justify using unvalidated methods and you should have stopped testing until the conditions were corrected. Your firm claims that temperature spike was resolved “2 days later” and your firm purchased “(b)(4) new incubators” and will assess plates for impact. Your firm has not addressed why you continued to use the (b)(4) plates that were held outside labeled conditions or did not provide validation for the modified conditions. The adequacy of this response cannot be determined at this time as corrective actions are in progress.\n3. Failure to adequately establish process control procedures that describe any process controls necessary to ensure conformance to specifications, as required by 21 CFR § 820.70(a). Specifically,\nA. Your firm has not adequately implemented its procedure for Microbiological Testing, WI 80.002, Rev. 5. The microbiological sampling and testing of (b)(4) water, which is used to prepare the acid concentrate products, has not been adequately implemented due to the following conditions: For example,\ni. The exact location of the sampling port location for collecting the (b)(4) water and the identity of the person collecting samples are not documented. The (b)(4) water sample is taken from one of (b)(4) sampling ports.\nii. The sampling port used on the (b)(4) water system does not represent actual point-of-use conditions where the water will be utilized in manufacturing.\niii. Samples are collected using non-sterile containers, introducing potential contamination that could affect test results.\niv. Samples are plated using non-sterile (b)(4) syringes that expired in June 2016.\nv. The incubator temperature for incubating the (b)(4) plates to measure the total microbial count of the (b)(4) water sample should be maintained between (b)(4). On 07\u002F21\u002F2025 and 07\u002F24\u002F2025, the thermometer showed temperatures of 41°C and 42°C on 07\u002F23\u002F2025, respectively.\nvi. (b)(4) plates from (b)(4) samples are read on the (b)(4), exceeding the required incubation at (b)(4) for (b)(4).\nvii. The Laboratory Record-Culture Reading sheets do not include the start and end times for incubation, which makes it impossible to confirm that the minimum requirement of (b)(4) has been met.\nviii. The Laboratory Record-(b)(4) sheets reviewed for endotoxin tests lack the start and end times for incubation, which does not show compliance with the necessary incubation periods.\nB. The monitoring and disinfection of the (b)(4) is not being conducted appropriately per the (b)(4) and (b)(4) Instructions for use and Maintenance, WI 70.001, Rev. 2 For example, your procedure requires (b)(4) monitoring of specific parameters including pressures, flow rates, water quality measurements (TDS, pH, conductivity, hardness), and system performance metrics, whereas:\ni. The temperature, conductivity, pH, prefilter outlet pressure, and reject % of the (b)(4) water system currently used to manufacture the acid concentrate products is not being adequately monitored (b)(4). A review of the (b)(4) for 2024 and 2025 found the pH and conductivity of the (b)(4) water has not been measured (b)(4), the temperature is not a monitored parameter, the (b)(4) has not been documented as the gauge is broken, and the feed conductivity and Reject % has not been monitored since the (b)(4) water system panel has not worked since on or about 06\u002F21\u002F2022.\nii. The disinfection process fails to include the complete (b)(4) water system. The pipes carrying (b)(4) water to mixing tanks and washing areas are not included in disinfection procedures, creating potential microbial contamination pathways that could compromise product quality.\nC. The temperature of the warehouse where finished product and raw materials are stored is not monitored adequately per your procedure, Facility Maintenance - Cleaning and Pest Control, WI 71.002, Rev. 2. For example,\ni. WI 71.002 specifies air conditioning settings of (b)(4) (summer) and (b)(4) (winter), but the Temperature Log (WI Form 71.002) allows an \"Acceptable Range\" of (b)(4). There is no documented rationale, or testing to support storage of finished products at temperatures up to (b)(4). Also, the USP grade raw material labels require that Potassium Chloride is kept in “dry and room temperature” storage conditions; Calcium Chloride require “cold, dry” storage conditions; and Citric Acid requires “dry, cool” storage conditions.\nii. Warehouse humidity is not measured despite raw materials requiring dry storage conditions.\niii. Per SOP 72.001, Rev. 1, calibrated thermometers are required for monitoring warehouse temperatures; however, uncalibrated thermometers are used in where raw materials are stored and dispensed in the warehouse without proper temperature control.\niv. Temperature is only measured at one location outside the mixing area, but the facility is approximately (b)(4) square feet and has multiple designated storage areas for raw materials and finished products. The different storage areas have independent HVAC systems but lack individual monitoring.\nOn 7\u002F29\u002F25, the investigators observed the thermometer in the warehouse showed 90°F, while the mixing room near the drum filling areas reached 98°F. The temperature in the warehouse, where the finished products are stored prior to loading trucks, is not monitored. It was also observed the bay door was open on most days during the inspection, with outside temperatures reaching over 100°F.\nThe adequacy of your response cannot be determined at this time. Regarding observation 3A, we acknowledge that your firm initiated a CAPA plan to address microbiological testing procedures and (b)(4) water system standardization. These include revision of Microbiological Testing procedure (WI 80.002, Rev. 5) to require proper documentation of sampling ports, and implementation of standardized (b)(4) water system protocols. Your firm agreed to update your sampling location by transition from using the \"farthest point\" to identifying true point-of-use locations for (b)(4) water sampling. Your firm should demonstrate the requirements to validate new sampling locations to ensure they are truly representative of actual use points. You should also establish specifications that clean (b)(4) should be used when adding (b)(4) water samples to (b)(4) plates and ensure that sterile equipment is mandatory for contamination control principles and the use of expired syringes should not be allowed. Despite your equipment upgrades and procedural improvements, we recommend that while the immediate technical issues may be resolved, the root cause of the monitoring and detection failures has not been adequately addressed.\nRegarding observation 3B, your firm has committed to repairing the broken pressure gauge and restoring (b)(4) water system panel functionality. You stated that you have hired a third-party to conduct a comprehensive system audit to identify additional potential failures, along with employee retraining on updated SOPs and implementation of a preventive maintenance schedule. Please explain the 3-year delay in addressing the (b)(4) panel failure that has existed since 2022. There is no proper justification why (b)(4) monitoring of the (b)(4) water system was not maintained, identified, or corrected during the equipment failure period. Also, we understand that you have taken corrective actions to address disinfection protocols for your entire (b)(4) water system. Please revise your (b)(4)-004 to include a full system disinfection procedure, covering all piping, valves, and endpoints. Finally, you indicated that training will be provided to employees on updated procedures and implement a verification checklist to ensure all components are disinfected. Your response cannot be adequately determined without a follow-up inspection to verify the repairs you completed at your facility.\nRegarding observation 3C, your firm has implemented corrections to address the temperature in the warehouse where finished product and raw materials are stored. Please provide adequate evidence demonstrating proper relocation of temperature-sensitive materials to cooler conditions per USP requirements and any evaluation of the products left over that had been stored there. There is lack of justification for storage of temperature-sensitive raw materials requiring \"cold, dry\" or \"cool, dry\" conditions. The adequacy of this response cannot be determined at this time. Please provide supporting documents and detail the actions taken to resolve the improper storage of your products and raw materials, as well as documentation demonstrating actions you have taken to address the temperature and humidity issues.\n4. Failure to appropriately design, construct, and install equipment used in the manufacturing process to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR § 820.70(g). Specifically,\nThe following conditions of your production equipment were observed throughout the inspection. For example,\nA. (b)(4) water system (b)(4) is used to manufacture the Diasol products, and Citrisol Acid Concentrates, and Citric Acid. The inspection found deficiencies including:\ni. Water leaking from (b)(4) housing and hoses, creating potential contamination risks.\nii. The (b)(4) water system control panel is inoperable eliminating the ability to monitor critical water quality parameters (conductivity, reject percentage)\niii. 12-inch dead leg in water piping to mixing tanks and drum washing area can harbor microbial growth.\niv. Missing the (b)(4) pressure gauge needle, bent and inoperable pump feed pressure gauge, and uncalibrated gauges and flowmeters throughout the system.\nB. The mixing and drum filling area deficiencies include:\ni. Leaking pipefitting at base of (b)(4) tank in the filling line for dialysate acid concentrates.\nii. Inoperable motor for (b)(4) tank mixing blades, forcing reliance solely on recirculating pump for mixing.\niii. Drum filling hose observed touching the floor during operations.\niv. Both electrical control panels are inoperable including flow meter displays for both (b)(4) and (b)(4) tanks.\nC. It was observed that the conditions of the equipment in the drum washing area raised contamination concerns. The drums are cleaned with (b)(4) water using a (b)(4) before they are used, and the caps are cleaned by placing them in a bucket filled with (b)(4) water before use. For example:\ni. Hoses and (b)(4) hose are stored inside water-filled bucket creating potential for microbial growth and cross-contamination.\nii. Washing hoses observed touching the floor are compromising cleanliness of equipment used for container preparation.\nThe adequacy of your response cannot be determined at this time. Your firm acknowledged several equipment deficiencies related to improper design, maintenance, and installation that hindered effective cleaning, adjustment, and operation. You stated for observation 4A and 4B that all leaking components are being replaced with (b)(4) housing, hoses inspected, and replacement parts requested from your supplier.\nThe damaged gauges have been replaced with new units and a 12-inch dead leg will be removed and piping reconfigured to eliminate stagnant water zones. In addition, your firm plans to conduct (b)(4) PM checks, and employees will receive retraining on equipment inspection and reporting protocols. Your procedures will be revised to include (b)(4) water system monitoring and maintenance procedures. Your firm indicated there is difficulty locating replacement boards for the (b)(4) panel and plans to continue (b)(4) readings.\nHowever, you have not addressed a timeline for obtaining replacement (b)(4) panel board versus indefinite (b)(4) operation. It is unclear what is your current method for monitoring conductivity and reject percentage if the (b)(4) water system remains operational. We cannot verify the calibration status of your newly installed gauges and flowmeters at your facility. Please provide supporting documents to verify that the actions mentioned above have been implemented, along with the timeline, the method used to monitor the water quality parameters, and the calibration status of your new measuring equipment.\nAdditionally, your responses indicate that equipment issues and corrective actions will also address pipe fitting at the base of the (b)(4) tank which was replaced and pressure tested. The hose holders were installed to prevent floor contact, and SOPs were updated to include hose sanitation protocols. Your firm stated the mixing motor requires replacement and validation, but currently mixing is performed using a (b)(4) with (b)(4) testing of each batch to ensure homogeneity. The electrical systems are under repair requiring (b)(4) filling operations. Some of the concerns we have with your corrective actions is that you have no plan to repair or replace critical monitoring equipment, claiming it's unnecessary. There is no specific timeline given for replacing critical equipment such as the (b)(4) tank motor. Additionally, we have concerns about the temporary (b)(4) mixing method, including how (b)(4) testing guarantees batch homogeneity without proper validation protocols. The adequacy of your response cannot be determined at this time. Please address our concerns stated above and provide supporting documentations to verify the adequacy of your corrective actions.\nRegarding observation 4C, your firm stated that all hoses were removed from water buckets to eliminate improper storage. The wall-mounted hose hangers were installed with drip trays beneath to prevent water pooling. Sanitation procedures were revised to include instructions prohibiting hose submersion, with visual aids and diagrams for proper storage. You state employee training will be conducted, and (b)(4) sanitation checks will now include hose storage verification. Per your firm’s Work Instruction #70.003, (b)(4) water buckets they are now designated solely for soaking drum caps (maximum (b)(4)), with water changed every (b)(4). Your firm claims hoses were removed from water buckets but then describes continued use of (b)(4) water buckets for drum cap soaking for up to (b)(4). Your corrective actions focus on hose hangers but fails to adequately address the fundamental contamination risks associated with improper hose storage. No detailed assessment was provided regarding duration of improper hose storage, potential impact on product quality, products already released using this practice, and your current actions to effectively eliminate contamination risks.\nThe adequacy of your response cannot be determined at this time. Please address our concerns stated above and provide supporting documentations to verify the adequacy of your corrective actions.\n5. Failure to suitably design buildings to perform necessary operations, as required by 21 CFR § 820.70(f).\nSpecifically, the following conditions were observed at your facility.\nA. The floors in mixing, gallon filling, and washing areas show erosion and pitting that creates areas where water can accumulate.\nB. The washing area wall where drums are cleaned shows multiple problems including moisture damage, structural deterioration, and apparent mold growth on tiles.\nC. Two doors were improperly secured - the wash area exterior door was not fully closed and the warehouse bay door (where finished product is stored) remained open during operations.\nYour response for observation 5A and 5B is inadequate. Your firm proposed corrective and preventative actions to address the inadequate conditions of your facility. However, we are concerned that your firm plans to use the same chemical-resistant epoxy polyurethane solution that has already failed multiple times since 2019. There is no mention of concrete repair or proposed surface preparation before recoating. The salt erosion from your products may continue damaging the concrete substrate of your facility and purchased repair products have not been evaluated to determine adherence to existing damaged concrete. There are no established procedures for addressing the black mold-like substance or underlying moisture problems and no proposed ventilation improvements or containment systems to prevent future damage.\nIn addition, please evaluate the impact of open doors at your facility on environmental controls, specifically how door breaches affect temperature, humidity, and contamination control in the manufacturing environment. This may have broader implications on your firm’s manufacturing processes and product quality. The adequacy of your response for observation 5C cannot be determined at this time.\n6. Failure to adequately establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a). Specifically,\nYour firm did not adequately implement procedures for Nonconforming Product, SOP 90.001, Rev. 5, and Final Acceptance, SOP 80.001, Rev. 3. For example:\nA. You did not initiate Product Nonconforming Reports (PNCRs) when chemical laboratory out-of-specification (OOS) test results failed to meet specifications during final acceptance testing or investigate the root causes of these failures. For example,\ni. Diasol acid concentrate Batch (b)(4) (Lot (b)(4)) failed specifications for both Dextrose (92 mg\u002FdL compared to allowable range (b)(4) mg\u002FdL) and Calcium (2.30 mEq\u002FL compared to allowable range (b)(4) mEq\u002FL) tested on 6\u002F28\u002F2025.\nii. Citrisol acid concentrate Batch (b)(4) (Lot (b)(4)) failed Dextrose specification (92 mg\u002FdL compared to allowable range (b)(4) mg\u002FdL) on 6\u002F28\u002F25.\niii. Diasol acid concentrate Batch (b)(4) (Lot (b)(4)) failed Magnesium specification (1.15 mEq\u002FL compared to allowable range (b)(4) mEq\u002FL) on 5\u002F27\u002F25.\nIn all cases, your firm said new samples were submitted for re-testing and re-tests eventually passed. However, your original failed results were excluded from the DHR and no PNCRs were initiated to investigate the causes of the failures. Furthermore, the investigation revealed 22 samples requiring re-testing due to OOS results between April 1, 2025, and July 25, 2025, with no corresponding PNCRs documented.\nB. Your firm’s procedure for Microbiological Testing on (b)(4) water samples, WI 80.002, Rev. 5 establishes an action level of (b)(4) colonies ((b)(4) CFU\u002FmL) and a limit of (b)(4) colonies (equivalent to (b)(4) CFU\u002FmL) and requires nonconformance report initiation when the action levels are exceeded. For example:\ni. On 6\u002F18\u002F25, microbiological test showed 6 CFU\u002F0.1mL (exceeding the 5 CFU action level) for Diasol acid concentrate batch #3153 (Lot #PHV06191). However, the batch was produced before microbiological results were obtained and before the (b)(4) system disinfection. There was no Product Nonconformity Report initiated to determine the need to investigate the cause of the failure.\nii. On 4\u002F28\u002F25, microbiological test showed that action level of (b)(4) CFU\u002F0.1mL was exceeded where the original test results were not documented. The sample was inappropriately re-tested multiple times using frozen\u002Fthawed samples on 04\u002F28\u002F2025 and 05\u002F02\u002F2025. The three batches ((b)(4) - Lot (b)(4), (b)(4) - Lot (b)(4), and (b)(4) – Lot (b)(4)) were manufactured on (b)(4) and (b)(4) before obtaining the action level test results and before the (b)(4) system disinfection. There was no Product Nonconformity Report initiated to determine the need to investigate the cause of the failure.\nC. The firm’s procedure for (b)(4) testing is done by testing each completed batch for endotoxins using the (b)(4) test (b)(4) and (b)(4) water is tested for endotoxins (b)(4) a week. Your firm did not document invalid test results appropriately obtained on 07\u002F10\u002F2025 with (b)(4), package (b)(4) (Exp. Date 08\u002F30\u002F2027), to determine whether investigation of the invalid result was necessary. The same lot of the unevaluated (b)(4) that led to invalid results has been used for (b)(4) product batches and (b)(4) water samples.\nD. Nonconformance report investigations, disposition, and corrective actions were inadequate for the following nonconformity product reports:\ni. Product Nonconformity Report #105 was initiated on 6\u002F20\u002F24 for Acetic Acid Glacial (Lot (b)(4)) contaminated with bleach affecting multiple batches of the dialysate acid concentrates. The investigation failed to document how bleach contamination occurred. Your firm received (b)(4) totes but only investigated (b)(4) tote and (b)(4) additional batches were manufactured using remaining (b)(4) totes without verifying they were contamination-free. The preventative actions lacked implementation details for improved raw material controls.\nii. Product Nonconformity Report #99 was initiated on 2\u002F12\u002F24 for calcium concentration 8% below acceptable range for Batch (b)(4). The investigation was incomplete such that it failed to address concurrent low glucose and sodium chloride concentrations identified in the same laboratory reports. There was inadequate root cause analysis for multiple component failures.\niii. Product Nonconformity Report #102 was initiated on 6\u002F30\u002F25 for low calcium test results for Batch (b)(4) (Lot (b)(4)). The report identified a procedural issue with drum (b)(4) when adding (b)(4) chemicals to (b)(4) drums. You found that (b)(4) with multiple raw materials at once causes displacement and affects test results. Your firm failed to update the associated procedure ((b)(4), WI 70.008, Rev. 1) to prevent recurrence, and inadequate corrective action was implemented.\niv. Product Nonconformity Report #104 was initiated on 7\u002F3\u002F25 for Batches (#3170 – Lot #PHV07031, #3168 – Lot #PHV07021, and #3166 – Lot #PHV07011) missing dextrose test results. There is insufficient evidence to support investigation conclusion that contract laboratory equipment was out of service. PNR#104 indicated that the contract lab did not test the samples because the equipment was out of service. The investigators confirmed this claim, but your firm provided incorrect information. Later, your firm admitted you did not reach out to the contract laboratory to find out why the dextrose testing was not performed for the three batches. Your firm released batches without required glucose testing based on unsupported patient safety claims. The investigation lacked risk analysis to justify release without complete testing data.\nThe adequacy of your response cannot be determined at this time. Regarding observation 6A, your firm’s immediate actions are to address the proper handling of OOS test results for the batches by initiating PNCRs or investigate root causes of failures during final acceptance testing. You stated your NCR procedures will be updated, along with managing of DHR documentation, and OOS handling protocols will be implemented. Despite your firm’s historical promises of conducting retrospective PNCRs, there is no evidence of completion, and no corrective actions have been initiated for batches (b)(4) and (b)(4), which also had OOS results requiring documentation and root cause assessment.\nRegarding observation 6B, your firm indicated that a positive microbial result was attributed to cross-contamination by a new QC employee whose sleeve touched the sample during testing. The (b)(4) water system was disinfected on 6\u002F18, and the water used for batch #3153 reportedly passed quality acceptance after disinfection. Your firm claims no production occurred between 6\u002F16-6\u002F19, however batch #3153 was produced on 6\u002F19 using water from the (b)(4) water system that had not been properly disinfected. Your CAPA plan is to establish deviation documentations, conduct retrospective reviews of batches, perform microbial re-testing of retained (b)(4) water samples, and update procedures to include excursion handling and sample integrity. Your firm claimed that results were \"false positive\" due to employee error without providing adequate scientific justification. However, there is a contradiction in the timeline: your firm stated no production occurred between 6\u002F16-6\u002F19, yet batch #3153 was produced on 6\u002F19 using water from the compromised system. Your response is inadequate.\nRegarding observation 6C, your firm investigated with (b)(4) and determined excessive heat caused the test failures of the (b)(4) kit. (b)(4) recommended storing (b)(4) test kits at (b)(4) in refrigerated conditions. Two boxes of compromised test kits were destroyed after producing nonconforming results. You stated that you retested samples using test kits that passed acceptability criteria. Your firm’s CAPA plan is to have (b)(4) test kits stored in refrigerated conditions, review procedure to include flowchart for handling invalid (b)(4) results, conduct mandatory deviation entry, and sample quarantine procedures. Your firm claims only 2 boxes were affected but the FDA findings indicate 40 batches, and 20 samples may be impacted. We have taken into consideration that you evaluated all the impacted products when you initiated your voluntary recall. The adequacy of this response cannot be determined at this time. We will review your response updates along with your procedures and CAPA to ensure the storage and evaluation of materials outside of proper storage conditions are properly addressed.\nRegarding observation 6D, the following PNCR’s were reviewed and corrective actions implemented for: 1) PNCR #105: corrective action was taken to perform analytical testing of retained samples, implementation of chlorine strip testing for acetic acid totes, staff training on contamination protocols, revised PNCR templates, and enhanced supplier qualification processes. However, there is still no clear explanation of detection method for bleach contamination, 2) PNCR #99: corrective action is to have the batch rework to restore specifications, expanded PNCR documentation, QA staff training on deviation protocols, and revise SOPs requiring investigation of all OOS parameters. Your firm acknowledged that glucose and sodium issues were not investigated but provides no evidence this has been corrected, 3) PNCR #102: corrective action is taken to update your work instructions (WI 70.009 and 70.008) with clear restrictions against simultaneous (b)(4) of multiple chemicals, implementation of step-by-step (b)(4) procedures, and provide personnel training, and 4) PNCR #104: your corrective action is to conduct retrospective risk assessment, enhanced verification protocols, revise SOPs requiring all critical test results before release, and implementation of batch disposition checklists. However, your firm justifies releasing batches without required testing based on \"emergency\" needs of your customers. The adequacy of your response for observation 6D cannot be determined at this time as corrective actions are in progress.\nOur overall concerns with this observation and the corrective actions taken is your summary reveals systemic issues including delayed reporting, incomplete investigations, inadequate documentation, and patterns of releasing products without full quality data verification. Please ensure these corrective actions have been adequately verified and implemented and provide supporting documentation when they are available.\n7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a). Specifically,\nYour firm has not adequately followed your complaint handling procedure, Complaint File, SOP 198.001, Rev. 2, as you failed to document and determine the need to investigate “order replacements” related to complaints about product, packaging, and labeling issues. For example, the following complaints were not properly investigated:\nA. Reviewed a complaint on 5\u002F20\u002F24 about product G100225-10DEX100 (Lot (b)(4)) causing unstable conductivity in dialysis machines preventing patient treatment.\nB. Eight complaints between March 2024 and July 2025 were reviewed for damaged cases of gallons and bags.\nC. One complaint in June 2024 was reviewed about missing gallon labels on Citric Acid 50% products.\nD. Two complaints in 2025 involving cracked drums that caused product leakage.\nE. One March 2024 return logged for damaged case and bag.\nYour firm also failed to evaluate any of these complaints to determine whether they constituted medical device reportable events.\nThe adequacy of your response cannot be determined at this time. Your firm proposed corrective and preventative actions to address “product replacements” related to complaints about product, packaging, and labeling issues that are documented into your complaint tracking system. However, your firm continues to classify “product replacements” due to damage, labeling, or performance issues as “requests” rather than complaints requiring formal documentation and evaluation. While your firm updated your SOP to include replacements as complaints, you simultaneously maintain that transit damage replacements are not complaints. Your firm states that none of the complaints are reportable without demonstrating proper application of MDR evaluation criteria. Despite mentioning implementation of an MDR screening process, your firm has not demonstrated understanding of proper MDR criteria for assessing individual complaints. Please refer to 21 CFR Part 820.198(a)(3) for further guidance to evaluate whether the complaint represents an event which is required to be reported to FDA under Part 803, Medical Device Reporting.\n8. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR § 820.100(a). Specifically,\nYour firm failed to adequately implement your Corrective and Preventive Action (CAPA) procedure, SOP 100.001, Rev. 1 with multiple systemic issues identified across four specific CAPAs. For example,\nA. CAPA #24 was initiated on 2\u002F16\u002F24 and closed on 8\u002F8\u002F24 to address Diasol Acid Concentrate mix ratio issue which was not adequately investigated and failed to expand scope when a second complaint occurred on 5\u002F9\u002F24 involving (b)(4) gallons of concentrate with unstable conductivity readings. Your firm failed to adequately investigate why batch exceeded production yield (NPR No. 98) before lot release. Your firm did not document additional testing, product removal, and rework activities performed on returned product.\nB. CAPA #25 was initiated on 2\u002F16\u002F24 and closed on 8\u002F8\u002F24 to address nonconformances associated with labeling controls. The CAPA was ineffective as new mislabeling complaint occurred on 6\u002F11\u002F24 during the effectiveness verification phase. The original CAPA addressed mislabeled Diasol acid concentrate (Complaint #03, 7\u002F27\u002F22) but was closed as effective on 8\u002F8\u002F24 despite ongoing issues. The new complaint involved unlabeled Citric Acid 50%-gallon containers.\nC. CAPA #26 was initiated in May 2024 and appended CAPA 26A initiated on 12\u002F10\u002F24 to address facility and equipment deterioration identified in internal audit for plant equipment cleaning and maintenance, salt deposits that damage equipment and floors, and (b)(4) water that damages pressure worker motor. No corrective actions have been completed or documented.\nD. CAPA #27 was initiated on 4\u002F10\u002F24 to correct a previous 483 observation for inadequate response with unclear scope, insufficient root cause analysis, and inadequate corrective actions. The CAPA has been open since 4\u002F10\u002F24 and repeat deficiencies were found during the current inspection.\nThe adequacy of your response cannot be determined at this time. Your firm acknowledged the CAPA deficiencies and committed to taking corrective actions to ensure Part 820.100 is followed. However, CAPA #24 has no evidence the expanded investigation was completed, and no documentation was provided regarding evaluation of the additional (b)(4) gallons that failed conductivity. There is no assurance that a link has been established to NCR #98 for excess yield issues. CAPA #25 was addressed with promised corrective actions and CAPA #30 was generated for additional actions, but neither provide evidence of addressing the root causes. Your firm has not demonstrated that cross-product labeling risks are controlled, and implementation verification is delayed until March 2026. CAPA #26 is a repeat observation spanning 7 years (2018-2025) with no actual corrections and response consists only of additional promises without actual progress. Finally, corrections to CAPA #27 and its root cause analysis is inadequate and there is no evidence that repeat deficiencies have been addressed.\n9. Failure to establish design history file, as required by 21 CFR § 820.30(j). Specifically,\nYour firm did not adequately implement your Design Control procedure, SOP 30.001, Rev.1, for maintaining adequate design documentation. For example,\nA. Lack of Design History File (DHF) for Citric Acid (50% and 20% concentrations) used for cleaning, decalcification, and disinfecting hemodialysis machines, despite manufacturing and distributing (b)(4) batches since 2022.\nB. Inadequate Design History Files (DHFs) for Dryasol and Citrisol such that it references design inputs for \"Diasol acid concentrate,\" but no DHF exists for this referenced device. The electrolyte concentration specifications claim compliance with (b)(4) standards, but the actual acceptability ranges for Potassium and Calcium do not meet the standard requirements. Also, the DHFs fail to include or reference the location of required design verification and validation studies for these Class 2 medical devices.\nThe adequacy of your response cannot be determined at this time. Your firm acknowledges poor implementation due to considering legacy formulations “low risk” and inadequate training on applying design controls to accessory products. Your firm stated you suspended sales as of September 1, 2025, and are determining if a 510(k) is needed, but this doesn't address years of non-compliance or demonstrate proper regulatory understanding. Your firm stated that your DHFs reference non-existent Diasol acid concentrate design inputs and the Electrolyte specifications for potassium and calcium do not meet (b)(4) standards. There is no design verification and validation documentation provided. Your firm plans to create the missing DHFs and update specifications but claims Diasol was marketed in 1985 prior to design file implementation, which does not exempt it from current requirements.\n10. Failure to adequately establish procedures for design change, as required by 21 CFR § 820.30(i). Specifically,\nYour firm did not implement your procedure, Design Control, SOP 30.001, Rev.1, by failing to adequately document, evaluate, and validate design change made to the Diasol Acid Concentrate device before implementation. For example:\nYour firm used Calcium Chloride Anhydrous instead of the required USP grade Calcium Chloride Dihydrate in (b)(4) manufacturing batches (August 19-21, 2024), totaling (b)(4) gallons of products. This substitution caused elevated calcium concentrations in batches (b)(4) (Lot (b)(4)), (b)(4) (Lot (b)(4)), and (b)(4) (Lot (b)(4)), requiring a Product Nonconformity Report (#100) on 8\u002F22\u002F2024 and subsequent rework to correct the calcium levels. Your firm failed to conduct required risk assessments regarding patient safety impacts and did not perform validation studies to evaluate potential effects on users, product stability, or long-term device performance.\nThe adequacy of your response cannot be determined at this time. Your firm’s corrective action includes issuance of PNR#100 and rework of all (b)(4) affected batches. You quarantined and removed the remaining substituted raw material from inventory. You created retrospective design change documentation and updated your SOP design control procedure to clarify that raw material substitutions constitute design changes. You stated that you haven’t conducted training for QA, R&D, and procurement teams, and implemented mandatory design change checklist and (b)(4) compliance audits. You plan to conduct formal risk assessments for all design changes, including raw material substitutions, and mandate validation or verification studies prior to implementing any design changes. However, your firm has not provided a comprehensive risk assessment for this incident to evaluate potential ramifications of ingredient substitution. There is no demonstration that proper validation studies were conducted to establish equivalency of the substituted material.\n11. Failure to adequately establish procedures for design verification, as required by 21 CFR § 820.30(f). Specifically,\nYour firm has not adequately implemented your procedure for Design Controls, SOP 30.001, Rev. 1, section 4.6 Design Verification, regarding inadequate design verification for stability studies supporting product shelf-life claims. For example:\nA. The 3-year shelf-life stability study of your Diasol and Citrisol acid concentrates (Stability Study Protocol and Stability Study Report, both numbered #110.001, signed 05\u002F09\u002F2019) lacks any supporting laboratory data and fails to demonstrate that tested products used the same container closure system as finished products. There is no scientific rationale provided for sample selection, including testing a Diasol formulation with different magnesium concentration ((b)(4) mEq\u002FL vs. current (b)(4) mEq\u002FL) and selecting (b)(4) lot of (b)(4) Citrisol acid concentrations. There is missing evidence that required pH and Conductivity testing was performed at all specified time points per the stability protocol requirements in WI 80.004 In-process and Final Batch Testing.\nB. No stability study exists to support the assigned 3-year shelf-life for the Dry Citrisol Acid Concentrate. The product’s expiration date exceeded the expiration date of at least one packaged raw material powder used in two different lots ((b)(4) and (b)(4)), which are set for (b)(4), and (b)(4). Meanwhile, the citric acid powder (Lot (b)(4)) in both products will expire on (b)(4).\nYour response is inadequate. Your firm stated you have a long manufacturing history, producing concentrates since 1998 (with predecessor (b)(4) manufacturing since 1985). However, your stability study performed in 2019 used an outdated formulation ((b)(4) mEq Mg) while current products contain (b)(4) mEq Mg. Your firm claims the (b)(4) mEq magnesium difference will not impact stability of the acid concentrate solution. The initial batch testing included proper pH and conductivity documentation, and subsequent tests have handwritten pH and conductivity records. You said you will perform verification on all lab samples to ensure correct dilution. However, your firm failed to provide missing laboratory data and there is no documented justification showing the older formulation is representative of current products. There is no demonstration that the magnesium difference does not affect stability conclusions and despite mentioning handwritten records and verification procedures, actual testing data remains missing. Your firm failed to demonstrate compliance with your protocol or address systematic documentation gaps. Additionally, your responses indicated that additional time is required to respond to this part of the observation.\n12. Failure to adequately establish requirements that must be met by contractors and consultants, as required by 21 CFR § 820.50(a). Specifically,\nYour firm failed to adequately implement your supplier evaluation procedure, SOP 50.001, Rev. 2 in two main areas:\nA. Your firm lacks documented evaluation of your contract laboratory that performs chemical analysis of dialysis acid concentrate products. No documented evidence exists that the laboratory uses validated analytical test methods per (b)(4) standards. The laboratory's (b)(4) method is inadequately justified for testing potassium, magnesium, glucose, and calcium levels, as the standard only indicates (b)(4) for sodium analysis. Despite four information requests, your contract laboratory failed to provide complete details about their analyzers and test methodologies, leaving your firm unaware of actual testing procedures.\nB. Your firm lacks documented evaluation demonstrating that your quality audit consultant is competent to conduct (b)(4) audits.\nThe adequacy of your response cannot be determined at this time. The response requested additional time to respond to this item and mentions you are planning to update your supplier qualifications. Review of these responses found no documented evaluation exists for the contract laboratory performing chemical analysis. No evidence was provided demonstrating the laboratory uses validated analytical test methods per (b)(4) standards and the laboratory's (b)(4) method is only validated for sodium analysis, not for potassium, magnesium, glucose, and calcium as required. Your firm has not provided evidence that you have taken immediate steps to obtain proper documentation or verify the analytical methods from your contract laboratory.\nRegarding observation 12B, your firm stated that you contracted (b)(4) for your last two internal audits. Your firm plans to hire a certified auditor for 2025 and establish qualification criteria based on experience and certification. A CAPA table was provided, but no corrective actions have been implemented yet—all items are scheduled for future completion. Your firm’s planned corrective actions include conducting formal competency assessments, reviewing qualifications and certifications, creating consultant evaluation forms, updating QMS procedures, and staff training. Your firm has not provided evidence that you have taken any immediate action to address the ongoing use of potentially unqualified suppliers and consultants. The adequacy of this response cannot be determined.\n13. Failure to perform risk analysis, as required by 21 CFR § 820.30(g). For example,\nA. Your firm does not have a documented risk analysis for your Diasol liquid acid concentrate.\nB. The existing risk analysis for your Dryasol acid concentrate fails to evaluate potential harms to patients and users for hazards already identified in your firm’s risk analysis document (DHF 30.003, rev. 1). The analysis does not include risk estimations for known and foreseeable hazards associated with dialysate concentrates, including electrolyte imbalance, lack of dextrose, pyrogen reactions, microbial infections, particulate emboli, and toxicity from chemical contaminants.\nThe adequacy of your response cannot be determined at this time. Your firm’s stated that you initiated a risk analysis for your Diasol liquid acid concentrate by following (b)(4) standard. Your preventative actions include risk analysis for all products and staff training, and CAPA #2025-04-DLC is scheduled to be completed by 12\u002F08\u002F25. A review of your firm’s corrections observed that products continue to be manufactured and distributed without documented risk analysis. You should ensure critical elements such as detailed hazard identification, quantitative risk estimation (severity x probability), specific risk control measures, and residual risk evaluation. The 4+ month timeline to correct the observation appears to be excessive.\nRegarding observation 13B, your firm updated your risk analysis procedure to include patient risk assessment. Immediate action is to initiate internal review of DHF 30.003, Rev. 3 by a cross-functional team to include all known and foreseeable hazards and incorporate clinical harms and severity ratings. Your preventative action is to update risk management SOPs to require clinical review and train design and regulatory affairs teams on (b)(4) and FDA guidance. However, your firm submitted DHF 30.002 for Citrisol instead of the required Dryasol analysis. The adequacy of this response cannot be determined.\nMedical Device Reporting Violation(s)\nOur inspection also revealed that your firm’s dialysate concentrates are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i. 21 CFR Part 803 - Medical Device Reporting was promulgated under section 519 of the Act, among other provisions. Significant violations include, but are not limited to, the following:\n1. Failure to report to us the information required by § 803.52 in accordance with the requirements of § 803.12(a), no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included in your firm’s internal email communication dated May 20, 2024, reasonably suggests that your firm’s Diasol liquid acid concentrate malfunctioned during use. Specifically, the device caused unstable conductivity in the dialysis machine, preventing the dialysis treatment from being performed. As a result, the device failed to meet its performance specifications or otherwise perform as intended under 21 CFR 803.3(k). This device, classified as a hemodialysis system and accessories under 21 CFR 876.5820 (product code KPO), is considered life-supporting or life-sustaining. A malfunction is reportable if it involves a device that is considered to be life-supporting or life-sustaining and thus is essential to maintaining human life, as is the case here, or if it results in the failure of the device to perform its essential function—here, dialysis—thereby compromising the device’s therapeutic effectiveness, which could cause or contribute to a death or serious injury. See Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration, 60 Fed. Reg. 63578, 63585 (Dec. 11, 1995), Comment 12, for more information. Accordingly, because this device malfunctioned and the device or a similar device you market would be likely to cause or contribute to a death or serious injury if the malfunction were to recur, the adverse event represents a reportable malfunction under 21 CFR 803.3. During the inspection, your firm acknowledged that no MDR had been submitted for this event.\nThe adequacy of your firm’s response dated September 8, 2025, cannot be determined at this time. In its response, your firm states that it plans to revise its MDR procedure, conduct staff training, and perform a retrospective review to submit MDRs for each identified MDR Reportable complaint. FDA has not yet received an electronic version of Form 3500A for the above reference event. In addition, no supporting documentation of corrective actions was provided, as these remain in progress.\nYour firm’s responses dated October 7, 2025, and November 10, 2025, did not provide evidence or documentation to address the noted violation.\nIn addition, the inspection revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm presented its procedural documents titled “Complaint File”, SOP 198.001, Rev. 2, dated 04\u002F25\u002F2024 and “Medical Device Reporting (MDR) Procedure”, SOP 198.002, Rev. 2, dated 04\u002F25\u002F2024. After collectively reviewing them as your firm’s MDR procedure, the following deficiencies were noted:\na) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, and “malfunction”, and the definition found in 21 CFR 803.20(c)(1) for the term “reasonably suggests”, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\ni. Instructions for how to obtain and submit information that corresponds generally to the format of Form FDA 3500A.\nii. Instructions for how your firm will comply with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive.\niii. How your firm will ensure that all information required in 21 CFR Part 803, subpart E, that is reasonably known to you is submitted for each event. Specifically, which types of information corresponding generally to the format of Form FDA 3500A will need to be submitted, to include the information in your possession at the time you filed your initial report and if you later obtain any required information that was not available at the time you filed your initial report.\nIn addition, based on FDA’s records, as of October 8, 2025, your firm has not completed its load test and guidance compliance submission for electronic Medical Device Reporting (eMDR). We recommend your firm follow the instructions located at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enroll-emdr-program under “Low Volume Enrollment Process” to obtain its WebTrader production account.\nThe adequacy of your firm’s response dated September 8, 2025, cannot be determined at this time. In its response, your firm stated that it plans to update its MDR procedure by November 8, 2025, conduct staff training, and establish an electronic submission account. However, no supporting evidence was provided, as these corrective actions are still ongoing.\nWe reviewed your firm’s response dated October 7, 2025, and concluded that it is not adequate. Your response states that corrective actions are still in progress and included a copy of its revised MDR procedure titled “Medical Device Reporting (MDR) Procedure”, SOP 198.002, Rev. 2, dated 09\u002F09\u002F2025. Upon review of the revision, the following deficiencies were noted:\nThe revision does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. Specifically, the revision still omits the definition of “malfunction” in 21 CFR 803.3, and “reasonably suggests” in 21 CFR 803.20(c)(1). The absence of these definitions may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nThe revision does not include the requirement for submitting supplemental or follow up reports within 30 calendar days of the day that you receive information required under 21 CFR Part 803 that you did not provide because it was not known or was not available when you submitted the initial report, as required under 21 CFR 803.56.\nIn addition, your firm has not yet completed its load test and guidance compliance submission for eMDR. We recommend that your firm follow the instructions provided above to obtain a WebTrader production account for electronic submissions.\nYour firm’s response dated November 10, 2025, did not provide evidence or documentation to address the noted violation.\nUnique Device Identifier (UDI) and GUDID Violation(s)\nMisbranding under Section 502(c) for Failure to Have Compliant Labeling\nThe inspection also revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of the Act to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of Citrisol Powder 45125-10, CitriSol 100225-10, Diasol 100225-10, Citric Acid 50%, Diasol 10000-25, and Dryasol 45225-10 devices do not bear such a UDI.\nSpecifically, the labels for Citrisol Powder 45125-10, CitriSol 100225-10, Diasol 100225-10, Citric Acid 50%, Diasol 10000-25, and Dryasol 45225-10 devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses Automatic Identification and Data Capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\nMisbranding under Section 502(t)(2) for Failure to Submit Required Information\nIn addition, Citrisol Powder 45125-10, Citric Acid 50%, and Dryasol 45225-10 devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Our inspection revealed that your firm designs the finished product label for your Citrisol Powder 45125-10, Citric Acid 50%, and Dryasol 45225-10 devices and final product labeling reflects your firm’s name, and address. Diasol, Inc is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\nOur office requests that Diasol, Inc. immediately cease any activities that result in the misbranding or adulteration of your devices, such as the commercial distribution of your devices for the uses described above.\nA follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of 21 CFR Part 820. You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\nInitial certifications by consultant and establishment – July 31, 2026.\nSubsequent certifications – September 1, 2027, and September 1, 2028.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps you have taken to address the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective action cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 3 Acting Assistant Director, Jeffrey Wooley, at CDRHEnforcement@fda.hhs.gov . Please include in the subject line, “CMS Case 719460” when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Charles J. Chacko, via email at charles.chacko@fda.hhs.gov\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and to bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Diasol, Inc.","diasol-inc-719460-01292026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdiasol-inc-719460-01292026","2026-10-26T08:08:24.411127+00:00","2026-03-03","719460","Medical Devices","Monica F. Abeles","2026-08-19T04:53:45.839+00:00","VIA Electronic Mail","2026-01-29",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":43,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":19,"issuing_office":59,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},11,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2026-07-28T04:00:00Z\">07\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-09T04:00:00Z\">07\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvasocorp-inc-732724-07092026\">VasoCorp, Inc.\u003C\u002Fa>","Human Foods Program","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. William H. Cross III\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>VasoCorp, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>808 Metromont Rd Ste 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hiram\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30141-3056\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 9, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #732724\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Cross:\u003C\u002Fp>\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.vasocorp.com in March 2026 and has determined that you take orders there for the products NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>NeuropAWAY – Nerve Support Formula\u003C\u002Fu>\u003Cbr>“NeuropAWAY Nerve Support Formula is a patented formula that is clinically proven to reduce the overall symptoms of occasional burning, tingling, and numbness by ~76%. NeuropAWAY’s synergistic formula combines Taurine with other key ingredients to improve blood supply to damaged and needy nerves.” “NeuropAWAY Nerve Support 60 Daily Capsules Delivers Key Nutrients to Damaged &amp; Inflamed Nerves.” (www.vasocorp.com)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“Consumption of NeuropAWAY resulted in a signification reduction [Pain] in PI-NRS after 7 days of consumption.” Note: PI-NRS is Pain Intensity Numerical Rating Scale. (https:\u002F\u002Fwww.vasocorp.com\u002Fproducts\u002Fneuropaway-capsules)\u003C\u002Fp>\u003Cp>“VasoCorp was founded by William Cross, a Type 1 diabetic driven by his personal quest for relief from nerve discomfort. After years of dedicated research, William developed the unique formula for our flagship product, NeuropAWAY Nerve Support Formula. . . . You can find NeuropAWAY products in the diabetes section of major pharmacies across the country . . ..” (https:\u002F\u002Fwww.vasocorp.com\u002Fpages\u002Fabout-us)\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>NeuropAWAY pm – Nighttime Nerve Support Formula\u003C\u002Fu>\u003Cbr>“NeuropAWAY targets the cause of neuropathic pains in: head &amp; neck, feet, static nerve, hands, arms, legs…” “NeuropAWAY burning, tingling, &amp; numbness support.” “Supports damaged and needy nerves.” (https:\u002F\u002Fwww.vasocorp.com\u002Fproducts\u002Fneuropaway-pm)\u003C\u002Fli>\u003Cli>\u003Cu>NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula\u003C\u002Fu>\u003Cbr>“R-Alpha Lipoic Acid (ALA) Protect nerves from damage…” \u003Cem>R-Alpha Lipoic Acid is an ingredient in both the NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula products\u003C\u002Fem>. (www.vasocorp.com)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your product NeuropAWAY – Nerve Support Formula is intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, NeuropAWAY – Nerve Support Formula fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #732724 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\u003Cp>Cc:\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. William H. Cross III\n\nRecipient Title\n\nPresident and CEO\n\nVasoCorp, Inc.\n\n808 Metromont Rd Ste 100\n\nHiram, GA 30141-3056\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJuly 9, 2026\nWARNING LETTER\nCMS #732724\n(b)(4)\nDear Mr. Cross:\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.vasocorp.com in March 2026 and has determined that you take orders there for the products NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\nNeuropAWAY – Nerve Support Formula\n“NeuropAWAY Nerve Support Formula is a patented formula that is clinically proven to reduce the overall symptoms of occasional burning, tingling, and numbness by ~76%. NeuropAWAY’s synergistic formula combines Taurine with other key ingredients to improve blood supply to damaged and needy nerves.” “NeuropAWAY Nerve Support 60 Daily Capsules Delivers Key Nutrients to Damaged & Inflamed Nerves.” (www.vasocorp.com)\n“Consumption of NeuropAWAY resulted in a signification reduction [Pain] in PI-NRS after 7 days of consumption.” Note: PI-NRS is Pain Intensity Numerical Rating Scale. (https:\u002F\u002Fwww.vasocorp.com\u002Fproducts\u002Fneuropaway-capsules)\n“VasoCorp was founded by William Cross, a Type 1 diabetic driven by his personal quest for relief from nerve discomfort. After years of dedicated research, William developed the unique formula for our flagship product, NeuropAWAY Nerve Support Formula. . . . You can find NeuropAWAY products in the diabetes section of major pharmacies across the country . . ..” (https:\u002F\u002Fwww.vasocorp.com\u002Fpages\u002Fabout-us)\nNeuropAWAY pm – Nighttime Nerve Support Formula\n“NeuropAWAY targets the cause of neuropathic pains in: head & neck, feet, static nerve, hands, arms, legs…” “NeuropAWAY burning, tingling, & numbness support.” “Supports damaged and needy nerves.” (https:\u002F\u002Fwww.vasocorp.com\u002Fproducts\u002Fneuropaway-pm)\nNeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula\n“R-Alpha Lipoic Acid (ALA) Protect nerves from damage…” R-Alpha Lipoic Acid is an ingredient in both the NeuropAWAY – Nerve Support Formula and NeuropAWAY pm – Nighttime Nerve Support Formula products. (www.vasocorp.com)\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour product NeuropAWAY – Nerve Support Formula is intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, NeuropAWAY – Nerve Support Formula fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #732724 and (b)(4) on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\nCc:\n(b)(4)","VasoCorp, Inc.","vasocorp-inc-732724-07092026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvasocorp-inc-732724-07092026","2026-10-26T08:10:26.67388+00:00","2026-07-28","732724","Dietary Supplements","Mr. William H. Cross III","2026-08-19T04:28:11.089+00:00","Via Email","2026-07-09",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":43,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":59,"recipient_name":90,"body_fetched_at":91,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},455,[77,78,79,59,80,13,13,13],"\u003Ctime datetime=\"2025-11-25T05:00:00Z\">11\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-21T04:00:00Z\">10\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-g-miller-dba-granja-asomante-711894-10212025\">Robert G. Miller dba Granja Asomante \u003C\u002Fa>","PHS Act\u002FShell Egg Regulation\u002FAdulterated \u003Cbr \u002F>\r\n","PHS Act\u002FShell Egg Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Robert G. Miller\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner &amp; President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Robert G. Miller dba Granja Asomante \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Road 569 Km 5.5 Interior\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orocovis\u003C\u002Fspan> \u003Cspan>00720\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puerto Rico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 21, 2025\u003C\u002Fp>\u003Cp>CMS #711894\u003C\u002Fp>\u003Cp>Dear Mr. Miller,\u003C\u002Fp>\u003Cp>On April 15, 2025, through May 1, 2025, the United States Food and Drug Administration (FDA) conducted an inspection of your shell egg farm located at Road 569 Km 5.5 Interior, Orocovis, Puerto Rico, 00720. During the inspection of your farm, FDA investigators observed serious violations of the Prevention of Salmonella Enteritidis (SE) in Shell Eggs During Production, Storage, and Transportation regulation (the Shell Egg regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118) and the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\u003Cp>Failure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the FD&amp;C Act, 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the FD&amp;C Act, the PHS Act and the Shell Egg regulation through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the deviations found at your farm. We received your written response to the FDA-483 on May 20, 2025, describing corrective actions taken. We are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your farm.\u003C\u002Fp>\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\u003Cp>\u003Cu>Shell Egg Regulation (21 CFR Part 118)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>1. You did not have and implement a written SE prevention plan that includes, at minimum, the SE prevention measures required by 21 CFR 118.4. As a shell egg producer with \u003Cstrong>(b)(4)\u003C\u002Fstrong> or more laying hens at your farm, who does not sell all of your eggs directly to consumers and who produces shell eggs for the table market, you are required to have an SE Prevention Plan that includes, at minimum, the SE prevention measures outlined in 21 CFR 118.4 (a) – (e). Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (hereafter refenced as SE plan), created on March 1, 2020, and further revised on August 3, 2023, is inadequate as it does not address all the required SE prevention measures and you are not fully implementing the prevention measures you have addressed, as follows:\u003C\u002Fp>\u003Cp>a. \u003Cu>Pullets\u003C\u002Fu>\u003Cbr>Your written SE plan did not address that chicks would be procured from SE-monitored breeder flocks that meet the National Poultry Improvement Plan's standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard, as required by 21 CFR 118.4(a)(1). Further, you did not ensure the pullet environment was tested for SE when pullets were 14-16 weeks of age, as required by 21 CFR 118.4(a)(2)(i). Specifically, your SE plan indicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your SE Plan stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, however, pullets placed in House #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and House #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, were tested at 17 and 18 weeks, respectively.\u003C\u002Fp>\u003Cp>Your written response stated you have a digital calendar to remind you of when SE samples must be collected, and that the observations related to sampling occurred “because of the logistics of the laboratories.” Your response is unclear as to whether this digital calendar is a corrective action to facilitate coordinating in advance with the laboratory, or whether this calendar existed at the time of the inspection. To the extent it is a corrective action, we will verify the implementation and adequacy of it during the next FDA inspection. Additionally, we note that NPIP offers multiple certification programs. In your revised SE Plan dated May 19, 2025, you state \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however the procedure does not specify that the SE-monitored breeder flocks must meet NPIP’s standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard, as described above.\u003C\u002Fp>\u003Cp>b. \u003Cu>Biosecurity\u003C\u002Fu>\u003Cbr>You did not take steps to ensure that there is no introduction or transfer of SE into or among \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses, as required by 21 CFR 118.4(b). Specifically:\u003C\u002Fp>\u003Cp>1) You did not maintain practices that will protect against cross contamination when persons move between \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses, as required by 21 CFR 118.4(b)(3). Your SE plan \u003Cstrong>(b)(4)\u003C\u002Fstrong> and stated in part, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your plan stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, during the current inspection, we observed that there was no \u003Cstrong>(b)(4)\u003C\u002Fstrong> at the entrance of House #\u003Cstrong>(b)(4)\u003C\u002Fstrong> for staff entering the \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses from the egg collection room. Additionally, staff were observed stepping on the footbaths only for a few seconds when entering the collection room and crossing in between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses instead of immersing in the solution for at least 60 seconds, per the disinfectant’s label instruction.\u003C\u002Fp>\u003Cp>Additionally, your SE plan required \u003Cstrong>(b)(4)\u003C\u002Fstrong> and indicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, from January 5, 2025, through April 13, 2025, you documented \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but there was no indication that the footbaths were refilled with the required disinfectant concentration.\u003C\u002Fp>\u003Cp>Your written response included a revised SE plan, dated May 19, 2025, which states \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response also states \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\u003C\u002Fp>\u003Cp>2) You did not prevent stray poultry, wild birds, cats, and other animals from entering \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses, as required by 21 CFR 118.4(b)(4). Your SE plan \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your SE plan indicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, we observed the following wild birds and evidence of cats within your \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses:\u003C\u002Fp>\u003Cul>\u003Cli>At least seven wild birds flying throughout the hen level of House #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and one wild bird flying inside the hen level of House #\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Apparent cat excrement approximately two feet away from the bottom egg conveyor belt inside House #\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Further, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses were observed to have multiple areas that were open and unsealed allowing for potential ingress points. These areas included gaps at the manure pit level due to damaged metal mesh for House #1, #2, and #5, in addition to damaged front rolling gates at House #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and #\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, House #\u003Cstrong>(b)(4)\u003C\u002Fstrong> was observed to have a large rolling door open.\u003C\u002Fp>\u003Cp>Your written response indicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your revised SE plan, dated May 19, 2025, states \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA has previously communicated concerns with animals and wild birds in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses. We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\u003C\u002Fp>\u003Cp>c. \u003Cu>Rodents, Flies, and Other Pest Control\u003C\u002Fu>\u003Cbr>1) You did not monitor for the presence of rodents by appropriate monitoring methods, and when monitoring indicated unacceptable rodent activity within a \u003Cstrong>(b)(4)\u003C\u002Fstrong> house, use appropriate methods to achieve satisfactory rodent control, as required by 21 CFR 118.4(c)(1). Specifically, your SE plan \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which we consider to be an inappropriate monitoring frequency. This frequency will not allow you to detect rodent \u003Cstrong>(b)(4)\u003C\u002Fstrong> in a timely manner or for you to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as stated in your SE plan, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, your SE plan required \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During review of your contracted pest control company records for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the houses, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear if you took corrective action in response to these findings or if your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by your SE plan.\u003C\u002Fp>\u003Cp>Your written response included a revised SE plan, dated May 19, 2025, indicating \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, based on the example monitoring form you provided, it appears \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\u003C\u002Fp>\u003Cp>2) You did not remove debris within \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses and vegetation and debris outside of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses that may provide harborage for pests, as required by 21 CFR 118.4(c)(3). Specifically, your SE plan \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, we observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>Excessive cat feces adjacent to feed silos for House #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and on the side of House #\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Stagnant water with accumulated debris on the sides of House #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and House #\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Overgrown vegetation covering bait stations located around each \u003Cstrong>(b)(4)\u003C\u002Fstrong> house\u003C\u002Fli>\u003Cli>Spilled chicken feed below the silos used for House #\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Further, we observed that the manure pits for House#\u003Cstrong>(b)(4)\u003C\u002Fstrong>, #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and #\u003Cstrong>(b)(4)\u003C\u002Fstrong> were filled with liquid manure and puddles of water all along the entire length of the pit. We are concerned with the condition of your manure pits, as manure should be kept as dry as possible to make it less attractive to flies (and other insects). Additionally, the debris surrounding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> houses could serve as an attractant or harborage for pests, rodents, and other animals that are known vectors of pathogens.\u003C\u002Fp>\u003Cp>Your written response stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will verify the implementation and adequacy of your corrective actions during the next FDA inspectio\u003Ca>n.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cu>Federal Food, Drug, and Cosmetic Act (FD&amp;C Act)\u003C\u002Fu>\u003Cbr>During the inspection, at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> were observed inside the egg collection room. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> were in direct contact with the portable carts and yellow trays used to transfer shell eggs to the processing site. These conditions are insanitary and render your shell eggs adulterated within the meaning of section 402(a)(4) of the FD&amp;C Act. Your written response indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&amp;C Act, the PHS Act, and the Shell Egg regulation.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Comments\u003C\u002Fstrong>\u003C\u002Fp>\u003Cul>\u003Cli>Your SE plan, created on March 1, 2020, and further revised on August 3, 2023, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, we acknowledge that your procedure indicates \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, it is unclear if you are removing other organic matter from the house prior to disinfection (other than manure and feed) as part of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure. We encourage you to review your current SE plan and subsequent records to ensure this information is included. Further, we remind you that cleaning and disinfection requirements must occur before new laying hens are added to the house, if you have had an environmental test or an egg test that was positive for SE at any point during the life of a flock that was housed in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> house prior to depopulation.\u003C\u002Fli>\u003Cli>Your SE plan, created on March 1, 2020, and further revised on August 3, 2023, addressed \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, there are no cleaning and disinfection measures when moving this shared equipment between houses. We note that your revised SE plan dated May 19, 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however we encourage you to review all shared equipment used on the farm and update your SE plan accordingly.\u003C\u002Fli>\u003Cli>Your SE Plan, created on March 1, 2020, and further revised on August 3, 2023, does not address refrigeration requirements. You stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide any additional information to confirm how the eggs would be held or transported at or below 45F ambient temperature beginning 36 hours after time of lay in the event of a delay in collection operations. Despite your eggs being transferred on a daily basis, we encourage you to update your SE plan to incorporate steps to ensure the eggs are refrigerated (in accordance with the Shell Egg regulation) in the event that eggs are delayed in being sent to a processor.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please note that resources are available on our website at www.fda.gov\u002Feggs that address various aspects of shell egg regulation, including some of the topics addressed in this letter. For example, the December 2011 Guidance for Industry “Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” addresses topics such as rodent monitoring, and the July 2015 Guidance for Industry “Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” provides answers to common questions about the Shell Egg regulation.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply via email to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Lisa Thursam, Compliance Officer, at Lisa.Thursam@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Lisa Thursam, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Lisa Thursam, Compliance Officer, via email at Lisa.Thursam@fda.hhs.gov. Please include CMS reference #711894 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Thomas Kuntz\u003Cbr>Acting Deputy Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Robert G. Miller\n\nRecipient Title\n\nOwner & President\n\nRobert G. Miller dba Granja Asomante\n\nRoad 569 Km 5.5 Interior\n\nOrocovis 00720\n\nPuerto Rico\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nOctober 21, 2025\nCMS #711894\nDear Mr. Miller,\nOn April 15, 2025, through May 1, 2025, the United States Food and Drug Administration (FDA) conducted an inspection of your shell egg farm located at Road 569 Km 5.5 Interior, Orocovis, Puerto Rico, 00720. During the inspection of your farm, FDA investigators observed serious violations of the Prevention of Salmonella Enteritidis (SE) in Shell Eggs During Production, Storage, and Transportation regulation (the Shell Egg regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118) and the Federal Food, Drug, and Cosmetic Act (FD&C Act).\nFailure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the FD&C Act, 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the FD&C Act, the PHS Act and the Shell Egg regulation through links on FDA’s home page at www.fda.gov.\nAt the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the deviations found at your farm. We received your written response to the FDA-483 on May 20, 2025, describing corrective actions taken. We are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your farm.\nYour significant violations are as follows:\nShell Egg Regulation (21 CFR Part 118)\n1. You did not have and implement a written SE prevention plan that includes, at minimum, the SE prevention measures required by 21 CFR 118.4. As a shell egg producer with (b)(4) or more laying hens at your farm, who does not sell all of your eggs directly to consumers and who produces shell eggs for the table market, you are required to have an SE Prevention Plan that includes, at minimum, the SE prevention measures outlined in 21 CFR 118.4 (a) – (e). Your “(b)(4)” (hereafter refenced as SE plan), created on March 1, 2020, and further revised on August 3, 2023, is inadequate as it does not address all the required SE prevention measures and you are not fully implementing the prevention measures you have addressed, as follows:\na. Pullets\nYour written SE plan did not address that chicks would be procured from SE-monitored breeder flocks that meet the National Poultry Improvement Plan's standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard, as required by 21 CFR 118.4(a)(1). Further, you did not ensure the pullet environment was tested for SE when pullets were 14-16 weeks of age, as required by 21 CFR 118.4(a)(2)(i). Specifically, your SE plan indicated (b)(4). Additionally, your SE Plan stated (b)(4), however, pullets placed in House #(b)(4), and House #(b)(4), were tested at 17 and 18 weeks, respectively.\nYour written response stated you have a digital calendar to remind you of when SE samples must be collected, and that the observations related to sampling occurred “because of the logistics of the laboratories.” Your response is unclear as to whether this digital calendar is a corrective action to facilitate coordinating in advance with the laboratory, or whether this calendar existed at the time of the inspection. To the extent it is a corrective action, we will verify the implementation and adequacy of it during the next FDA inspection. Additionally, we note that NPIP offers multiple certification programs. In your revised SE Plan dated May 19, 2025, you state (b)(4); however the procedure does not specify that the SE-monitored breeder flocks must meet NPIP’s standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard, as described above.\nb. Biosecurity\nYou did not take steps to ensure that there is no introduction or transfer of SE into or among (b)(4) houses, as required by 21 CFR 118.4(b). Specifically:\n1) You did not maintain practices that will protect against cross contamination when persons move between (b)(4) houses, as required by 21 CFR 118.4(b)(3). Your SE plan (b)(4) and stated in part, (b)(4). Additionally, your plan stated (b)(4). However, during the current inspection, we observed that there was no (b)(4) at the entrance of House #(b)(4) for staff entering the (b)(4) houses from the egg collection room. Additionally, staff were observed stepping on the footbaths only for a few seconds when entering the collection room and crossing in between the (b)(4) houses instead of immersing in the solution for at least 60 seconds, per the disinfectant’s label instruction.\nAdditionally, your SE plan required (b)(4) and indicated (b)(4). However, from January 5, 2025, through April 13, 2025, you documented (b)(4), but there was no indication that the footbaths were refilled with the required disinfectant concentration.\nYour written response included a revised SE plan, dated May 19, 2025, which states (b)(4). Your response also states (b)(4). We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\n2) You did not prevent stray poultry, wild birds, cats, and other animals from entering (b)(4) houses, as required by 21 CFR 118.4(b)(4). Your SE plan (b)(4). Additionally, your SE plan indicated (b)(4). However, we observed the following wild birds and evidence of cats within your (b)(4) houses:\nAt least seven wild birds flying throughout the hen level of House #(b)(4) and one wild bird flying inside the hen level of House #(b)(4).\nApparent cat excrement approximately two feet away from the bottom egg conveyor belt inside House #(b)(4).\nFurther, your (b)(4) houses were observed to have multiple areas that were open and unsealed allowing for potential ingress points. These areas included gaps at the manure pit level due to damaged metal mesh for House #1, #2, and #5, in addition to damaged front rolling gates at House #(b)(4) and #(b)(4). Further, House #(b)(4) was observed to have a large rolling door open.\nYour written response indicated (b)(4). Your revised SE plan, dated May 19, 2025, states (b)(4). FDA has previously communicated concerns with animals and wild birds in your (b)(4) houses. We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\nc. Rodents, Flies, and Other Pest Control\n1) You did not monitor for the presence of rodents by appropriate monitoring methods, and when monitoring indicated unacceptable rodent activity within a (b)(4) house, use appropriate methods to achieve satisfactory rodent control, as required by 21 CFR 118.4(c)(1). Specifically, your SE plan (b)(4), which we consider to be an inappropriate monitoring frequency. This frequency will not allow you to detect rodent (b)(4) in a timely manner or for you to (b)(4), as stated in your SE plan, (b)(4). Further, your SE plan required (b)(4). During review of your contracted pest control company records for the (b)(4) of the houses, (b)(4). It is unclear if you took corrective action in response to these findings or if your (b)(4), as required by your SE plan.\nYour written response included a revised SE plan, dated May 19, 2025, indicating (b)(4). Additionally, based on the example monitoring form you provided, it appears (b)(4). We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\n2) You did not remove debris within (b)(4) houses and vegetation and debris outside of your (b)(4) houses that may provide harborage for pests, as required by 21 CFR 118.4(c)(3). Specifically, your SE plan (b)(4). However, we observed the following:\nExcessive cat feces adjacent to feed silos for House #(b)(4) and on the side of House #(b)(4)\nStagnant water with accumulated debris on the sides of House #(b)(4) and House #(b)(4)\nOvergrown vegetation covering bait stations located around each (b)(4) house\nSpilled chicken feed below the silos used for House #(b)(4)\nFurther, we observed that the manure pits for House#(b)(4), #(b)(4), #(b)(4), and #(b)(4) were filled with liquid manure and puddles of water all along the entire length of the pit. We are concerned with the condition of your manure pits, as manure should be kept as dry as possible to make it less attractive to flies (and other insects). Additionally, the debris surrounding your (b)(4) houses could serve as an attractant or harborage for pests, rodents, and other animals that are known vectors of pathogens.\nYour written response stated (b)(4). Additionally, you stated (b)(4). We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\nFederal Food, Drug, and Cosmetic Act (FD&C Act)\nDuring the inspection, at least (b)(4) were observed inside the egg collection room. The (b)(4) were in direct contact with the portable carts and yellow trays used to transfer shell eggs to the processing site. These conditions are insanitary and render your shell eggs adulterated within the meaning of section 402(a)(4) of the FD&C Act. Your written response indicated that (b)(4). We will verify the implementation and adequacy of your corrective actions during the next FDA inspection.\nThis letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&C Act, the PHS Act, and the Shell Egg regulation.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\nAdditional Comments\nYour SE plan, created on March 1, 2020, and further revised on August 3, 2023, (b)(4). Additionally, we acknowledge that your procedure indicates (b)(4). However, it is unclear if you are removing other organic matter from the house prior to disinfection (other than manure and feed) as part of your (b)(4) procedure. We encourage you to review your current SE plan and subsequent records to ensure this information is included. Further, we remind you that cleaning and disinfection requirements must occur before new laying hens are added to the house, if you have had an environmental test or an egg test that was positive for SE at any point during the life of a flock that was housed in the (b)(4) house prior to depopulation.\nYour SE plan, created on March 1, 2020, and further revised on August 3, 2023, addressed (b)(4); however, there are no cleaning and disinfection measures when moving this shared equipment between houses. We note that your revised SE plan dated May 19, 2025, (b)(4); however we encourage you to review all shared equipment used on the farm and update your SE plan accordingly.\nYour SE Plan, created on March 1, 2020, and further revised on August 3, 2023, does not address refrigeration requirements. You stated (b)(4). However, you did not provide any additional information to confirm how the eggs would be held or transported at or below 45F ambient temperature beginning 36 hours after time of lay in the event of a delay in collection operations. Despite your eggs being transferred on a daily basis, we encourage you to update your SE plan to incorporate steps to ensure the eggs are refrigerated (in accordance with the Shell Egg regulation) in the event that eggs are delayed in being sent to a processor.\nPlease note that resources are available on our website at www.fda.gov\u002Feggs that address various aspects of shell egg regulation, including some of the topics addressed in this letter. For example, the December 2011 Guidance for Industry “Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” addresses topics such as rodent monitoring, and the July 2015 Guidance for Industry “Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” provides answers to common questions about the Shell Egg regulation.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\nPlease send your reply via email to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Lisa Thursam, Compliance Officer, at Lisa.Thursam@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Lisa Thursam, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Lisa Thursam, Compliance Officer, via email at Lisa.Thursam@fda.hhs.gov. Please include CMS reference #711894 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nThomas Kuntz\nActing Deputy Director\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Robert G. Miller dba Granja Asomante","robert-g-miller-dba-granja-asomante-711894-10212025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frobert-g-miller-dba-granja-asomante-711894-10212025","2026-10-26T08:09:50.39553+00:00","2025-11-25","711894","Mr. Robert G. Miller","2026-08-19T13:26:42.691+00:00","2025-10-21",{"id":94,"raw":95,"subject":100,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":109,"posted_date":110,"marcs_cms_no":111,"product_type":112,"closeout_date":113,"issuing_office":99,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":110,"medical_device_id":19,"response_letter_date":19},3468,[96,97,98,99,100,13,101,13],"\u003Ctime datetime=\"2021-03-12T14:00:00Z\">03\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-12T05:00:00Z\">03\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcloudchasor-llc-613129-03122021\">Cloudchasor LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcloudchasor-llc-613129-06042021\">\u003Ctime datetime=\"2021-06-16T04:00:00Z\">06\u002F16\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Kaufmann\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Cloudchasor LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2505 E 7th St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78702\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear James Kaufmann:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fcloudchasor.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.&nbsp; Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.&nbsp; Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act.&nbsp; These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco.&nbsp; See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)).&nbsp; Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fcloudchasor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Cloudchasor Crumblincookie 60ml and Cloudchasor Habanabanana 60ml.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act.&nbsp; In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 3,300 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations.&nbsp; Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction.&nbsp; However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act.&nbsp; Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them.&nbsp; You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101533, in your response and direct your response via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa> and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at \u003Cspan>(301) 796-9235\u003Ca>\u003C\u002Fa>\u003C\u002Fspan> or via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa>.&nbsp;&nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nVIA UPS and Electronic Mail\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Cloudchasor LLC\u003Cbr>\n403 Fantail Loop Apt B\u003Cbr>\nLakeway, TX 78734-4864\u003C\u002Fp>\n\n\u003Cp>Cloudchasor LLC\u003Cbr>\nJames Kaufmann\u003Cbr>\n2904 Chisholm Trail\u003Cbr>\nAustin, TX 78734\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>WEBSITEWELCOME.COM\u003Cbr>\nabuse@hostgator.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJames Kaufmann\n\nCloudchasor LLC\n\n2505 E 7th St\n\nAustin, TX 78702\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear James Kaufmann:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fcloudchasor.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fcloudchasor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Cloudchasor Crumblincookie 60ml and Cloudchasor Habanabanana 60ml.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 3,300 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101533, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nCloudchasor LLC\n\n403 Fantail Loop Apt B\n\nLakeway, TX 78734-4864\n\nCloudchasor LLC\n\nJames Kaufmann\n\n2904 Chisholm Trail\n\nAustin, TX 78734\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nWEBSITEWELCOME.COM\n\nabuse@hostgator.com","Cloudchasor LLC","cloudchasor-llc-613129-03122021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcloudchasor-llc-613129-03122021","2026-10-26T08:08:16.28841+00:00","Closed Out","2021-03-12","613129","Tobacco","2021-06-16","James Kaufmann","2026-08-20T03:17:12.83+00:00","VIA UPS and Electronic Mail",{"id":118,"raw":119,"subject":124,"body_html":125,"body_text":126,"firm_name":127,"letter_id":128,"created_at":129,"fei_number":19,"letter_url":130,"updated_at":131,"action_type":22,"case_status":23,"posted_date":132,"marcs_cms_no":133,"product_type":134,"closeout_date":19,"issuing_office":123,"recipient_name":19,"body_fetched_at":135,"delivery_method":136,"recipient_title":19,"reference_number":19,"action_taken_date":137,"medical_device_id":19,"response_letter_date":19},648,[120,121,122,123,124,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fasn-labs-716459-09092025\">ASN-LABS\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>ASN-LABS\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1450 Ala Moana Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Honolulu\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96814\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cs@asn-labs.com\"> cs@asn-labs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cbr>September 9, 2025\u003C\u002Fp>\u003Cp>\u003Cbr>ASN-LABS:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fasn-labs.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.\u003Ca id=\"footnoteref1_0zd4dz7\" href=\"#footnote1_0zd4dz7\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 355(a), 352(f)(1), 331(a) and 331(d)]. In addition, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)] resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Ca id=\"footnoteref2_o9rf0rn\" href=\"#footnote2_o9rf0rn\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Ca id=\"footnoteref3_wxyueel\" href=\"#footnote3_wxyueel\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Among the conditions of sections 503A and 503B are restrictions on the bulk drug substances (active pharmaceutical ingredients or APIs) that may be used to compound human drug products. Under section 503A, one of the conditions that must be met for a compounded drug product to qualify for the exemptions is that, if the product is compounded using bulk drug substances, such bulk drug substances (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA [21 U.S.C. § 353a(b)(1)(A)(i)]).\u003C\u002Fp>\u003Cp>Similarly, one of the conditions that must be met for a drug product compounded by an outsourcing facility to qualify for the exemptions under section 503B of the FDCA, is that the outsourcing facility does not compound drug products using bulk drug substances unless the bulk drug substances that are used appear on a list established by the Secretary identifying bulk drug substances for which there is a clinical need (“503B bulks list”), or the compounded drug appears on the drug shortage list in effect under section 506E of the FDCA at the time of compounding, distribution, and dispensing (section 503B(a)(2)(A)(i) of the FDCA [21 U.S.C. § 353b(a)(2)(A)]).\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Sections 503A and 503B\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your compounded retatrutide drug products fail to meet the conditions of sections 503A and 503B. Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.\u003Ca id=\"footnoteref4_ryx1f0r\" href=\"#footnote4_ryx1f0r\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503B, because retatrutide does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list.\u003Ca id=\"footnoteref5_tn8wikb\" href=\"#footnote5_tn8wikb\">\u003Csup>5\u003C\u002Fsup>\u003C\u002Fa>&nbsp;Because your compounded retatrutide drug products have not met all of the conditions of either section 503A or section 503B, they are not eligible for the exemptions in those sections from certain requirements of the FDCA, including FDA approval requirements of section 505 and the requirement under section 502(f)(1) that labeling bear adequate directions for use.\u003C\u002Fp>\u003Cp>Specific violations are described below.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drugs &amp; Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>There are no FDA-approved applications on file for your compounded retatrutide drug product. Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\u003Cp>Furthermore, your compounded retatrutide drug products are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended use. Consequently, their labeling fails to bear adequate directions for their intended use causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Ca id=\"footnoteref6_24dyc5n\" href=\"#footnote6_24dyc5n\">\u003Csup>6\u003C\u002Fsup>\u003C\u002Fa>&nbsp;introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cp>• &nbsp;“The same active ingredient as Wegovy and Ozempic”\u003Cbr>• &nbsp;“Semaglutide is the generic drug in Ozempic (injectable) and Rybelsus (oral) diabetes control medications, and Wegovy (injectable) weight loss medication.”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref7_3z04n7m\" href=\"#footnote7_3z04n7m\">\u003Csup>7\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a), 352(f)(1), 331(a) and 331(d)]. In addition, your claims concerning compounded semaglutide drug products are false or misleading under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)] resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded and unapproved new drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D. Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_0zd4dz7\">\u003Ca href=\"#footnoteref1_0zd4dz7\">1\u003C\u002Fa>The retatrutide, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_o9rf0rn\">\u003Ca href=\"#footnoteref2_o9rf0rn\">2\u003C\u002Fa>We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_wxyueel\">\u003Ca href=\"#footnoteref3_wxyueel\">3\u003C\u002Fa>We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_ryx1f0r\">\u003Ca href=\"#footnoteref4_ryx1f0r\">4\u003C\u002Fa>These substances are also not eligible for the policy applicable to certain bulk drug substances described in the final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA- approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf.\u003C\u002Fli>\n                      \u003Cli id=\"footnote5_tn8wikb\">\u003Ca href=\"#footnoteref5_tn8wikb\">5\u003C\u002Fa>These substances are also not eligible for the policy applicable to certain bulk drug substances described in the final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Revision 1). This guidance describes FDA’s interim regulatory policy for outsourcing facilities registered under section 503B of the FDCA while the 503B bulks list is being developed. Specifically, the guidance sets out conditions under which FDA generally does not intend to take action against an outsourcing facility for compounding a drug product using a bulk drug substance that is not included on the 503B list where the drug product also does not appear on the drug shortage list in effect under section 506E at the time of compounding, distribution, and \ndispensing. These conditions include that the drug product appears on “503B Category 1 – Bulk Drug Substances Under Evaluation”, which includes substances that may be eligible for inclusion on the 503B bulks list, was nominated with adequate support for FDA to evaluate it and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469122.pdf\u003C\u002Fli>\n                      \u003Cli id=\"footnote6_24dyc5n\">\u003Ca href=\"#footnoteref6_24dyc5n\">6\u003C\u002Fa>Your compounded retatrutide drug products are not exempt from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fli>\n                      \u003Cli id=\"footnote7_3z04n7m\">\u003Ca href=\"#footnoteref7_3z04n7m\">7\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nASN-LABS\n\n1450 Ala Moana Blvd\n\nHonolulu, HI 96814\n\nUnited States\n\ncs@asn-labs.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nSeptember 9, 2025\n\nASN-LABS:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fasn-labs.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 355(a), 352(f)(1), 331(a) and 331(d)]. In addition, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)] resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nA. Compounded Drug Products Under the FDCA\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].2\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.3\nAmong the conditions of sections 503A and 503B are restrictions on the bulk drug substances (active pharmaceutical ingredients or APIs) that may be used to compound human drug products. Under section 503A, one of the conditions that must be met for a compounded drug product to qualify for the exemptions is that, if the product is compounded using bulk drug substances, such bulk drug substances (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA [21 U.S.C. § 353a(b)(1)(A)(i)]).\nSimilarly, one of the conditions that must be met for a drug product compounded by an outsourcing facility to qualify for the exemptions under section 503B of the FDCA, is that the outsourcing facility does not compound drug products using bulk drug substances unless the bulk drug substances that are used appear on a list established by the Secretary identifying bulk drug substances for which there is a clinical need (“503B bulks list”), or the compounded drug appears on the drug shortage list in effect under section 506E of the FDCA at the time of compounding, distribution, and dispensing (section 503B(a)(2)(A)(i) of the FDCA [21 U.S.C. § 353b(a)(2)(A)]).\nB. Failure to Meet the Conditions of Sections 503A and 503B\nYour compounded retatrutide drug products fail to meet the conditions of sections 503A and 503B. Drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.4\nDrug products compounded using retatrutide are not eligible for the exemptions provided by section 503B, because retatrutide does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list.5 Because your compounded retatrutide drug products have not met all of the conditions of either section 503A or section 503B, they are not eligible for the exemptions in those sections from certain requirements of the FDCA, including FDA approval requirements of section 505 and the requirement under section 502(f)(1) that labeling bear adequate directions for use.\nSpecific violations are described below.\nC. Violations of the FDCA\nUnapproved New Drugs & Misbranded Drugs\nThere are no FDA-approved applications on file for your compounded retatrutide drug product. Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\nFurthermore, your compounded retatrutide drug products are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended use. Consequently, their labeling fails to bear adequate directions for their intended use causing them to be misbranded under section 502(f)(1) of the FDCA.6 introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA.\nFalse or Misleading Claims\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide products appear on your website:\n• “The same active ingredient as Wegovy and Ozempic”\n• “Semaglutide is the generic drug in Ozempic (injectable) and Rybelsus (oral) diabetes control medications, and Wegovy (injectable) weight loss medication.”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.7\nD. Conclusion\nFor the reasons discussed above, your compounded retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a), 352(f)(1), 331(a) and 331(d)]. In addition, your claims concerning compounded semaglutide drug products are false or misleading under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)] resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded and unapproved new drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nGeorge Tidmarsh, M.D., Ph.D. Director\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The retatrutide, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n3We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n\n4These substances are also not eligible for the policy applicable to certain bulk drug substances described in the final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA- approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf.\n\n5These substances are also not eligible for the policy applicable to certain bulk drug substances described in the final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Revision 1). This guidance describes FDA’s interim regulatory policy for outsourcing facilities registered under section 503B of the FDCA while the 503B bulks list is being developed. Specifically, the guidance sets out conditions under which FDA generally does not intend to take action against an outsourcing facility for compounding a drug product using a bulk drug substance that is not included on the 503B list where the drug product also does not appear on the drug shortage list in effect under section 506E at the time of compounding, distribution, and\ndispensing. These conditions include that the drug product appears on “503B Category 1 – Bulk Drug Substances Under Evaluation”, which includes substances that may be eligible for inclusion on the 503B bulks list, was nominated with adequate support for FDA to evaluate it and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469122.pdf\n\n6Your compounded retatrutide drug products are not exempt from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n7Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","ASN-LABS","asn-labs-716459-09092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fasn-labs-716459-09092025","2026-10-26T08:07:58.368785+00:00","2025-09-16","716459","Drugs","2026-08-19T16:18:57.419+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",{"id":139,"raw":140,"subject":145,"body_html":146,"body_text":147,"firm_name":148,"letter_id":149,"created_at":43,"fei_number":19,"letter_url":150,"updated_at":151,"action_type":22,"case_status":23,"posted_date":152,"marcs_cms_no":153,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":154,"body_fetched_at":155,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":156,"medical_device_id":19,"response_letter_date":19},66,[141,142,143,37,144,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-04T04:00:00Z\">06\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faseptikits-llc-728184-06042026\">AseptiKits, LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device\u003Cbr \u002F>\r\n","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gale H. Thorne Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AseptiKits, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>101 N. 700 W\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>North Salt Lake\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS 728184\u003C\u002Fp>\u003Cp>June 4, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Thorne:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in North Salt Lake, UT from November 11, 2025, through December 3, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets the PALA YourTears models (8,12,14), ALAdrop, SyrilKit, and VitrALA devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection revealed that the PALA YourTears models (8,12,14), ALAdrop, SyrilKit, and VitrALA devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have, for any of these products, an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>You stated in your response that these devices fall under product code NEP and are exempt from premarket notification under 21 CFR 880.5440(b).\u003C\u002Fp>\u003Cp>Under 21 CFR 880.5440(a), an intravascular administration set is a device used to administer fluids from a container to a patient’s vascular system through a needle or catheter inserted into a vein. While under 21 CFR 880.5440(b) some pharmacy compounding systems are exempt from the requirement of premarket notification, in accordance with FDA special controls guidance Pharmacy Compounding Systems - Final Class II Special Controls Guidance Document for Industry and FDA, such exemption “does not encompass the ancillary devices that make up the delivery and container system,” including “fluid transfer sets, metering chambers, I.V. bags, connectors, or other components that provide a fluid contact surface.” (This guidance document is the special control for pharmacy compounding systems within the intravascular administration set classification. 21 CFR 880.5440(b).) Such ancillary devices are classified separately from pharmacy compounding systems.\u003C\u002Fp>\u003Cp>FDA identifies a pharmacy compounding system as an “apparatus, often controlled by software, that is intended to deliver a specified quantity of one or more injections through a designated fluid pathway to achieve in a receiving vessel an injection having a specified concentration or proportion of ingredients different from the initial injections.” \u003Cu>Pharmacy Compounding Systems - Final Class II Special Controls Guidance Document for Industry and FDA\u003C\u002Fu>. Per your marketing website (www.aseptikits.com), the PALA YourTears models (8,12,14) is a closed system bag with filters and syringes intended for sterile preparation of serum. The ALAdrop is a closed system bag with syringe and filter intended for sterile eye drop preparation. The SyrilKit is a kit of 20 syringes with filters intended for sterile solution preparation. The VitrALA is a closed system bag with filters and syringes that is intended to prime and measure drug products. Therefore, the subject devices are syringes, filters and closed system transfer devices (bag). These devices fall under various product codes such as FMF (for syringe) and ONB (for closed system transfer devices).\u003Cbr>These product codes are for class II, non-exempt devices. The products, which contain syringes and containers for the drug, are not pharmacy compounding systems. Accordingly, the subject products are not exempt from premarket notification under 21 CFR § 880.5440(b).\u003C\u002Fp>\u003Cp>In addition, we have reviewed your website, Home | Aseptikits. The website includes references to convenience kits and states “Included class II medical devices are 510(k) approved and assembled into patented convenience kits for medical use.” As noted above, however, the subject products, which are marketed on your website, have not been cleared or approved by FDA for marketing in accordance with FDA’s regulations. Nor is it true that, as your website says, “Kits meet FDA requirements for Convenient[sic] Kits.” Your website includes a statement under “Key Differentiators” that your products “\u003Cem>Meets or exceeds FDA regulations\u003C\u002Fem>.” Because the subject devices lack required authorization, these representations are false and misleading and a device is misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), if its labeling is false or misleading in any particular.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that you immediately cease any activities that result in the misbranding or adulteration of your devices, such as the commercial distribution of your devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jeff Wooley, Acting Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 728184” when replying. If you have any questions about the contents of this letter, please contact: Jeff Wooley at jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGale H. Thorne Jr.\n\nRecipient Title\n\nChief Executive Officer\n\nAseptiKits, LLC\n\n101 N. 700 W\n\nNorth Salt Lake, UT 84054\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 728184\nJune 4, 2026\nDear Mr. Thorne:\nDuring an inspection of your firm located in North Salt Lake, UT from November 11, 2025, through December 3, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets the PALA YourTears models (8,12,14), ALAdrop, SyrilKit, and VitrALA devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violation(s)\nOur inspection revealed that the PALA YourTears models (8,12,14), ALAdrop, SyrilKit, and VitrALA devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have, for any of these products, an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYou stated in your response that these devices fall under product code NEP and are exempt from premarket notification under 21 CFR 880.5440(b).\nUnder 21 CFR 880.5440(a), an intravascular administration set is a device used to administer fluids from a container to a patient’s vascular system through a needle or catheter inserted into a vein. While under 21 CFR 880.5440(b) some pharmacy compounding systems are exempt from the requirement of premarket notification, in accordance with FDA special controls guidance Pharmacy Compounding Systems - Final Class II Special Controls Guidance Document for Industry and FDA, such exemption “does not encompass the ancillary devices that make up the delivery and container system,” including “fluid transfer sets, metering chambers, I.V. bags, connectors, or other components that provide a fluid contact surface.” (This guidance document is the special control for pharmacy compounding systems within the intravascular administration set classification. 21 CFR 880.5440(b).) Such ancillary devices are classified separately from pharmacy compounding systems.\nFDA identifies a pharmacy compounding system as an “apparatus, often controlled by software, that is intended to deliver a specified quantity of one or more injections through a designated fluid pathway to achieve in a receiving vessel an injection having a specified concentration or proportion of ingredients different from the initial injections.” Pharmacy Compounding Systems - Final Class II Special Controls Guidance Document for Industry and FDA. Per your marketing website (www.aseptikits.com), the PALA YourTears models (8,12,14) is a closed system bag with filters and syringes intended for sterile preparation of serum. The ALAdrop is a closed system bag with syringe and filter intended for sterile eye drop preparation. The SyrilKit is a kit of 20 syringes with filters intended for sterile solution preparation. The VitrALA is a closed system bag with filters and syringes that is intended to prime and measure drug products. Therefore, the subject devices are syringes, filters and closed system transfer devices (bag). These devices fall under various product codes such as FMF (for syringe) and ONB (for closed system transfer devices).\nThese product codes are for class II, non-exempt devices. The products, which contain syringes and containers for the drug, are not pharmacy compounding systems. Accordingly, the subject products are not exempt from premarket notification under 21 CFR § 880.5440(b).\nIn addition, we have reviewed your website, Home | Aseptikits. The website includes references to convenience kits and states “Included class II medical devices are 510(k) approved and assembled into patented convenience kits for medical use.” As noted above, however, the subject products, which are marketed on your website, have not been cleared or approved by FDA for marketing in accordance with FDA’s regulations. Nor is it true that, as your website says, “Kits meet FDA requirements for Convenient[sic] Kits.” Your website includes a statement under “Key Differentiators” that your products “Meets or exceeds FDA regulations.” Because the subject devices lack required authorization, these representations are false and misleading and a device is misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), if its labeling is false or misleading in any particular.\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that you immediately cease any activities that result in the misbranding or adulteration of your devices, such as the commercial distribution of your devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jeff Wooley, Acting Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 728184” when replying. If you have any questions about the contents of this letter, please contact: Jeff Wooley at jeffrey.wooley@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCDR Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","AseptiKits, LLC","aseptikits-llc-728184-06042026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faseptikits-llc-728184-06042026","2026-10-26T08:07:58.236111+00:00","2026-06-30","728184","Gale H. Thorne Jr.","2026-08-19T04:32:08.561+00:00","2026-06-04",{"id":158,"raw":159,"subject":12,"body_html":163,"body_text":164,"firm_name":165,"letter_id":166,"created_at":43,"fei_number":19,"letter_url":167,"updated_at":168,"action_type":22,"case_status":23,"posted_date":169,"marcs_cms_no":170,"product_type":26,"closeout_date":19,"issuing_office":162,"recipient_name":171,"body_fetched_at":172,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":88,"medical_device_id":19,"response_letter_date":19},358,[160,77,161,162,12,13,13,13],"\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fasli-foods-inc-719578-11252025\">Asli Foods, Inc \u003C\u002Fa>","Office of Inspections and Investigations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zia Rashid\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Asli Foods, Inc \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8350 Bristol Ct Ste 113\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jessup\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20794-9756\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:aslifoodsinc@gmail.com\"> aslifoodsinc@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 25, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 719578\u003C\u002Fp>\u003Cp>Dear Mr. Zia Rashid:\u003C\u002Fp>\u003Cp>On October 23, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Asli Foods, Inc located at 8350 Bristol Ct Ste 113, Jessup, MD 20794-9756. FDA also conducted an inspection from January 22, 2025, through January 24, 2025. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on October 23, 2025.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003Cbr>&nbsp; You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Prince Chocolate from the foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Herbal Tea from the foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Malka Mix Afghani Seekh Kabab from the foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).&nbsp;\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP records, to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley. Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS# 719578 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nZia Rashid\n\nRecipient Title\n\nPresident\n\nAsli Foods, Inc\n\n8350 Bristol Ct Ste 113\n\nJessup, MD 20794-9756\n\nUnited States\n\naslifoodsinc@gmail.com\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nNovember 25, 2025\nWARNING LETTER\nRE: CMS# 719578\nDear Mr. Zia Rashid:\nOn October 23, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Asli Foods, Inc located at 8350 Bristol Ct Ste 113, Jessup, MD 20794-9756. FDA also conducted an inspection from January 22, 2025, through January 24, 2025. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on October 23, 2025.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import including each of the following foods:\nPrince Chocolate from the foreign supplier (b)(4) located in (b)(4).\n(b)(4) Herbal Tea from the foreign supplier (b)(4) located in (b)(4)\nMalka Mix Afghani Seekh Kabab from the foreign supplier (b)(4) located in (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP records, to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley. Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS# 719578 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Imports","Asli Foods, Inc","asli-foods-inc-719578-11252025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fasli-foods-inc-719578-11252025","2026-10-26T08:07:58.321104+00:00","2026-01-27","719578","Zia Rashid","2026-08-19T07:16:21.733+00:00",{"id":174,"raw":175,"subject":180,"body_html":181,"body_text":182,"firm_name":183,"letter_id":184,"created_at":185,"fei_number":19,"letter_url":186,"updated_at":187,"action_type":22,"case_status":23,"posted_date":188,"marcs_cms_no":189,"product_type":69,"closeout_date":19,"issuing_office":179,"recipient_name":19,"body_fetched_at":190,"delivery_method":191,"recipient_title":19,"reference_number":19,"action_taken_date":192,"medical_device_id":19,"response_letter_date":19},2688,[176,177,178,179,180,13,13,13],"\u003Ctime datetime=\"2022-05-09T16:00:00Z\">05\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-04T04:00:00Z\">05\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fassault-labs-622050-05042022\">Assault Labs\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Dietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Assault Labs\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4000 W. Burbank Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Suite No. 210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Burbank\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91505\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Support@assault-labs.com\"> Support@assault-labs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Sir or Madame:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your product Wild Thing Tropical Tornado flavor, which is labeled as a dietary supplement. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) because the product is an adulterated dietary supplement. You can find the FD&amp;C Act through links on FDA’s website at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-andcosmetic-act-fdc-act and the FDA regulations at https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplement: Unsafe Food Additive\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The label of your product Wild Thing Tropical Tornado flavor declares hordenine HCl and higenamine HCl as dietary ingredients; however, neither one is a dietary ingredient. Under section 201(ff)(1) of the FD&amp;C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Hordenine HCl and higenamine HCl do not qualify as dietary ingredients under section 201(ff)(1) of the FD&amp;C Act because they are not vitamins; minerals; amino acids; herbs or other botanicals; dietary substances for use by man to supplement the diet by increasing the total dietary intake; or concentrates, metabolites, constituents, extracts, or combinations of any dietary ingredients from the preceding categories.\u003C\u002Fp>\n\n\u003Cp>If a substance is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive. Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)]. Adulterated foods cannot be legally imported or marketed in the United States.\u003C\u002Fp>\n\n\u003Cp>Section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements, such as the hordenine HCl and higenamine HCl used in your product, are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. In other words, a non-dietary ingredient added to a dietary supplement must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\u003C\u002Fp>\n\n\u003Cp>Hordenine HCl and higenamine HCl are not generally recognized as safe under their conditions of use in your dietary supplement product. Because hordenine HCl and higenamine HCl do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your Wild Thing Tropical Tornado flavor product is adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act because it contains unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Aaron Dotson, Compliance Officer, via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nAssault Labs\n\n4000 W. Burbank Blvd\n\nSuite No. 210\n\nBurbank, CA 91505\n\nUnited States\n\nSupport@assault-labs.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nDear Sir or Madame:\n\nThis letter concerns your product Wild Thing Tropical Tornado flavor, which is labeled as a dietary supplement. As explained further below, introducing or delivering this product for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the FD&C Act) because the product is an adulterated dietary supplement. You can find the FD&C Act through links on FDA’s website at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-andcosmetic-act-fdc-act and the FDA regulations at https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21.\n\nAdulterated Dietary Supplement: Unsafe Food Additive\n\nThe label of your product Wild Thing Tropical Tornado flavor declares hordenine HCl and higenamine HCl as dietary ingredients; however, neither one is a dietary ingredient. Under section 201(ff)(1) of the FD&C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Hordenine HCl and higenamine HCl do not qualify as dietary ingredients under section 201(ff)(1) of the FD&C Act because they are not vitamins; minerals; amino acids; herbs or other botanicals; dietary substances for use by man to supplement the diet by increasing the total dietary intake; or concentrates, metabolites, constituents, extracts, or combinations of any dietary ingredients from the preceding categories.\n\nIf a substance is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive. Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)]. Adulterated foods cannot be legally imported or marketed in the United States.\n\nSection 201(s) of the FD&C Act [21 U.S.C. § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements, such as the hordenine HCl and higenamine HCl used in your product, are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. In other words, a non-dietary ingredient added to a dietary supplement must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\n\nHordenine HCl and higenamine HCl are not generally recognized as safe under their conditions of use in your dietary supplement product. Because hordenine HCl and higenamine HCl do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your Wild Thing Tropical Tornado flavor product is adulterated under section 402(a)(2)(C)(i) of the FD&C Act because it contains unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Aaron Dotson, Compliance Officer, via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","Assault Labs","assault-labs-622050-05042022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fassault-labs-622050-05042022","2026-10-26T08:07:58.596733+00:00","2022-05-09","622050","2026-08-20T01:55:29.782+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-05-04",{"id":194,"raw":195,"subject":12,"body_html":201,"body_text":202,"firm_name":203,"letter_id":204,"created_at":106,"fei_number":19,"letter_url":205,"updated_at":206,"action_type":22,"case_status":109,"posted_date":207,"marcs_cms_no":208,"product_type":26,"closeout_date":209,"issuing_office":199,"recipient_name":210,"body_fetched_at":211,"delivery_method":212,"recipient_title":19,"reference_number":19,"action_taken_date":213,"medical_device_id":19,"response_letter_date":19},3233,[196,197,198,199,12,13,200,13],"\u003Ctime datetime=\"2021-08-03T13:20:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-20T04:00:00Z\">07\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F2m-associates-inc-614195-07202021\">2m Associates, Inc.\u003C\u002Fa>","Division of Northeast Imports","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F2m-associates-inc-614195-04122022\">\u003Ctime datetime=\"2022-04-19T04:00:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Alpha Bah\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>C.E.O. and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>2m Associates, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>203 W. 140th St, Apt. 4C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10030\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 614195\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: 7\u002F20\u002F2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Bah:\u003C\u002Fp>\n\n\u003Cp>On February 1, 2021 through March 3, 2021, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of 2m Associates Inc. located at 523 Casanova Street, Bronx, NY 10474. We also conducted an initial inspection on April 12, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;broken rice and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>rice imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not have FSVPs for these foods. Because of this significant violation, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>As of the date of this letter, we have not received your response to the Form FDA 483a issued on March 3, 2021.\u003C\u002Fp>\n\n\u003Cp>Your significant violation of the FSVP regulation is as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for each of the following foods:\u003Cbr>\n• \u003Cstrong>(b)(4)\u003C\u002Fstrong> broken rice imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n• \u003Cstrong>(b)(4)\u003C\u002Fstrong> rice imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The above is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of \u003Cstrong>(b)(4)\u003C\u002Fstrong> broken rice and \u003Cstrong>(b)(4)\u003C\u002Fstrong> rice imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We may place the food you import from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing to the FSVP violations within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Linda Ross, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) linda.ross@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ross via email at linda.ross@fda.hhs.gov. Please reference CMS # 614195 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dawne Hines\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Alpha Bah\n\nRecipient Title\n\nC.E.O. and Owner\n\n2m Associates, Inc.\n\n203 W. 140th St, Apt. 4C\n\nNew York, NY 10030\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nCMS # 614195\n\nDate: 7\u002F20\u002F2021\n\nDear Mr. Bah:\n\nOn February 1, 2021 through March 3, 2021, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of 2m Associates Inc. located at 523 Casanova Street, Bronx, NY 10474. We also conducted an initial inspection on April 12, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your (b)(4) broken rice and (b)(4) rice imported from (b)(4), located in (b)(4). Your firm did not have FSVPs for these foods. Because of this significant violation, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\n\nAs of the date of this letter, we have not received your response to the Form FDA 483a issued on March 3, 2021.\n\nYour significant violation of the FSVP regulation is as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for each of the following foods:\n\n• (b)(4) broken rice imported from (b)(4), located in (b)(4).\n\n• (b)(4) rice imported from (b)(4), located in (b)(4).\n\nThe above is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of (b)(4) broken rice and (b)(4) rice imported from (b)(4), located in (b)(4). We may place the food you import from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing to the FSVP violations within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Linda Ross, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) linda.ross@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ross via email at linda.ross@fda.hhs.gov. Please reference CMS # 614195 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDawne Hines\n\nProgram Division Director\n\nDivision of Northeast Imports","2m Associates, Inc.","2m-associates-inc-614195-07202021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F2m-associates-inc-614195-07202021","2026-10-26T08:07:47.610977+00:00","2021-08-03","614195","2022-04-19","Mr. Alpha Bah","2026-08-20T02:43:53.314+00:00","VIA UNITED PARCEL SERVICE","2021-07-20",{"id":215,"raw":216,"subject":220,"body_html":221,"body_text":222,"firm_name":223,"letter_id":224,"created_at":225,"fei_number":19,"letter_url":226,"updated_at":227,"action_type":22,"case_status":23,"posted_date":228,"marcs_cms_no":229,"product_type":26,"closeout_date":19,"issuing_office":59,"recipient_name":230,"body_fetched_at":231,"delivery_method":232,"recipient_title":19,"reference_number":19,"action_taken_date":233,"medical_device_id":19,"response_letter_date":19},21714,[217,218,219,59,220,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-20T04:00:00Z\">08\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsouth-asian-food-inc-728657-08202026\">South Asian Food Inc.\u003C\u002Fa>","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. MohammedS.Kahn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>South Asian Food Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>56-27 56th Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maspeth\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11378\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@safoodinc.com\"> info@safoodinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 20, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS #728657\u003C\u002Fp>\u003Cp>Dear Mr. Mohammed S. Kahn:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your facilities, located at 56-27 56th Drive, Maspeth, NY 11378, \u003Cstrong>(b)(4)\u003C\u002Fstrong> between March 2, through March 9, 2026. During our inspection, the FDA investigator found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123).\u003C\u002Fp>\u003Cp>The specific requirements for imported fish and fishery products are set out in 21 CFR 123.12. As an importer of fish or fishery products, you must operate in accordance with the requirements of Part 123. In accordance with 21 CFR 123.12(d), there must be evidence that all fish and fishery products offered for entry into the United States have been processed under conditions that comply with 21 CFR Part 123. If assurances do not exist that the imported fish or fishery product has been processed under conditions that are equivalent to those required of domestic processors under 21 CFR Part 123, the fish or fishery products will appear to be adulterated under section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4) and will be denied entry (see 21 CFR 123.12(d)) . Because our inspection identified serious violations for 21 CFR Part 123, and assurances do not exist that these imported products have been processed under conditions that comply with 21 CFR Part 123, your imported dried seafood products are adulterated under section 402(a)(4) of the Act (21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the June 2022 4th Edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance (the Hazards Guide) through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483 (FDA-483), Inspectional Observations, listing the deviations found at your firm. After reviewing the inspectional findings, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Seafood HACCP Violations (21 CFR 123)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\u003Cp>1. As a seafood importer, you must have and implement written verification procedures and an affirmative step which ensures that the fish and fishery product(s) you import are processed in accordance with the seafood HACCP regulation, to comply with 21 CFR 123.12(a)(2). Such procedures must at a minimum include product specifications that are designed to ensure the product is not adulterated under section 402 of the Act because it may be injurious to health or have been processed under insanitary conditions, and affirmative steps as specified in 21 CFR 123.12(a)(2)(ii). However, you do not have, nor have you implemented, written verification procedures that include such affirmative steps for vacuum packed ready-to-eat (RTE) Anchovy with Chilli (\u003Cem>Stolephorus indicus\u003C\u002Fem>), vacuum packed RTE Lotia Bombay Duck with Chilli (\u003Cem>Harpadon nehereus\u003C\u002Fem>) and RTE vacuum packed Golden Dried Shrimp with Chilli, Garlic, &amp; Onion (\u003Cem>Metapenaeus ensis\u003C\u002Fem>) manufactured by a \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These products have a process related hazard of \u003Cem>Clostridium Botulinum\u003C\u002Fem>. On March 9, 2026, an Investigator observed the above referenced products in your warehouse, located at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was maintained at an ambient temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>° Fahrenheit. Due to the lack of import verification documentation from the supplier, you could not provide assurance that the hazard of \u003Cem>Clostridium botulinum\u003C\u002Fem> is being controlled at the foreign facility so that these products may be safely stored at ambient temperatures. Furthermore, the label on each of these products includes contradictory storage instructions. Each label includes the statement “Keep In Room Temperature. Keep Frozen**Store at (-18°C).”\u003C\u002Fp>\u003Cp>Your written response dated March 23, 2026, did not include any evidence to demonstrate that you have established affirmative steps to ensure that the above-mentioned RTE vacuum packed fish, or any other seafood your firm imports, are processed in accordance with the seafood HACCP regulations found in 21 CFR Part 123.\u003C\u002Fp>\u003Cp>2. You must monitor sanitation conditions and practices during processing\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> with sufficient frequency to ensure, at a minimum, conformance with those conditions and practices specified in subpart B of 21 CFR part 117 (CGMP regulations) that are both appropriate to the plant and the food being processed and, in relevant part, relate to the exclusion of pests from the food plant (21 CFR 123.11(b)). However, you do not take effective measures to exclude pests from the holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117, Subpart B. Specifically, the following was observed on March 2, 2026:\u003C\u002Fp>\u003Cp>a. A cat was observed roaming between rows of pallets containing food in your warehouse located at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. An open bag of dry cat food, several open cans of cat food, cat litter and a cat litter box with apparent mammal excreta was observed in your warehouse located at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>c. The warehouse doors to each of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> ambient warehouse facilities were kept open with damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> curtains in the doorways. The warehouse doors open to outside of the facilities and lack any other means to prevent egress of pests and rodents. Each warehouse contained varieties of spices, rice, RTE biscuits, toast, and cookies.\u003C\u002Fp>\u003Cp>Your written response dated March 23, 2026 included a “STANDARD OPERATING PROCEDURE (SOP)” entitled “Warehouse Cleaning Procedure”. This procedure does not address excluding pests from your facility. Furthermore, your response does not address how you intend to remove the cats from your food warehouse.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility in connection with your operations. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your facility complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\u003Cp>To comply with 21 CFR 123.10, your HACCP plan must be developed by an individual who has successfully completed training in the application of HACCP principles to fish and fishery product processing that is at least equivalent to that received under standardized curriculum recognized as adequate by the FDA or who is otherwise qualified through job experience to perform these functions. Job experience will qualify an individual to perform these functions if it has provided knowledge at least equivalent to that provided through the standardized curriculum. Your written response dated March 23, 2026, included photographs of your enrollment in a training course titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” offered by \u003Cstrong>(b)(4) \u003C\u002Fstrong>and a “Receipt from \u003Cstrong>(b)(4)\u003C\u002Fstrong>” for “Enrollment in course \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. It is unclear if either of these training courses include training specific to the FDA’s Seafood HACCP regulations found in 21 CFR Part 123.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. We may take further action if you do not promptly correct these violations. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on \"detention without physical examination,\" seize your product(s) and\u002For enjoin your firm from further violating the Act.\u003C\u002Fp>\u003Cp>Please notify FDA in writing within fifteen (15) working days of the receipt of this letter of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete all corrections within fifteen (15) days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply electronically to HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Daniel Johnson, Compliance Officer, at Daniel.Johnson@fda.hhs.gov. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov. Please refer to CMS #728657 on any submissions within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As defined in 21 CFR 123.3(k)(1), processing includes storing with respect to fish and fishery products and your facility engages in storing fish and fishery products.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC DELIVERY\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. MohammedS.Kahn\n\nRecipient Title\n\nCEO\n\nSouth Asian Food Inc.\n\n56-27 56th Dr.\n\nMaspeth, NY 11378\n\nUnited States\n\ninfo@safoodinc.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nAugust 20, 2026\nWARNING LETTER\nRe: CMS #728657\nDear Mr. Mohammed S. Kahn:\nThe United States Food and Drug Administration (FDA) conducted an inspection of your facilities, located at 56-27 56th Drive, Maspeth, NY 11378, (b)(4) between March 2, through March 9, 2026. During our inspection, the FDA investigator found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123).\nThe specific requirements for imported fish and fishery products are set out in 21 CFR 123.12. As an importer of fish or fishery products, you must operate in accordance with the requirements of Part 123. In accordance with 21 CFR 123.12(d), there must be evidence that all fish and fishery products offered for entry into the United States have been processed under conditions that comply with 21 CFR Part 123. If assurances do not exist that the imported fish or fishery product has been processed under conditions that are equivalent to those required of domestic processors under 21 CFR Part 123, the fish or fishery products will appear to be adulterated under section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4) and will be denied entry (see 21 CFR 123.12(d)) . Because our inspection identified serious violations for 21 CFR Part 123, and assurances do not exist that these imported products have been processed under conditions that comply with 21 CFR Part 123, your imported dried seafood products are adulterated under section 402(a)(4) of the Act (21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the June 2022 4th Edition of the Fish and Fisheries Products Hazards & Controls Guidance (the Hazards Guide) through links in FDA’s home page at www.fda.gov.\nAt the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483 (FDA-483), Inspectional Observations, listing the deviations found at your firm. After reviewing the inspectional findings, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\nSeafood HACCP Violations (21 CFR 123)\nYour significant violations are as follows:\n1. As a seafood importer, you must have and implement written verification procedures and an affirmative step which ensures that the fish and fishery product(s) you import are processed in accordance with the seafood HACCP regulation, to comply with 21 CFR 123.12(a)(2). Such procedures must at a minimum include product specifications that are designed to ensure the product is not adulterated under section 402 of the Act because it may be injurious to health or have been processed under insanitary conditions, and affirmative steps as specified in 21 CFR 123.12(a)(2)(ii). However, you do not have, nor have you implemented, written verification procedures that include such affirmative steps for vacuum packed ready-to-eat (RTE) Anchovy with Chilli (Stolephorus indicus), vacuum packed RTE Lotia Bombay Duck with Chilli (Harpadon nehereus) and RTE vacuum packed Golden Dried Shrimp with Chilli, Garlic, & Onion (Metapenaeus ensis) manufactured by a (b)(4) located in (b)(4). These products have a process related hazard of Clostridium Botulinum. On March 9, 2026, an Investigator observed the above referenced products in your warehouse, located at (b)(4), which was maintained at an ambient temperature of (b)(4)° Fahrenheit. Due to the lack of import verification documentation from the supplier, you could not provide assurance that the hazard of Clostridium botulinum is being controlled at the foreign facility so that these products may be safely stored at ambient temperatures. Furthermore, the label on each of these products includes contradictory storage instructions. Each label includes the statement “Keep In Room Temperature. Keep Frozen**Store at (-18°C).”\nYour written response dated March 23, 2026, did not include any evidence to demonstrate that you have established affirmative steps to ensure that the above-mentioned RTE vacuum packed fish, or any other seafood your firm imports, are processed in accordance with the seafood HACCP regulations found in 21 CFR Part 123.\n2. You must monitor sanitation conditions and practices during processing1 with sufficient frequency to ensure, at a minimum, conformance with those conditions and practices specified in subpart B of 21 CFR part 117 (CGMP regulations) that are both appropriate to the plant and the food being processed and, in relevant part, relate to the exclusion of pests from the food plant (21 CFR 123.11(b)). However, you do not take effective measures to exclude pests from the holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117, Subpart B. Specifically, the following was observed on March 2, 2026:\na. A cat was observed roaming between rows of pallets containing food in your warehouse located at (b)(4).\nb. An open bag of dry cat food, several open cans of cat food, cat litter and a cat litter box with apparent mammal excreta was observed in your warehouse located at (b)(4).\nc. The warehouse doors to each of your (b)(4) ambient warehouse facilities were kept open with damaged (b)(4) curtains in the doorways. The warehouse doors open to outside of the facilities and lack any other means to prevent egress of pests and rodents. Each warehouse contained varieties of spices, rice, RTE biscuits, toast, and cookies.\nYour written response dated March 23, 2026 included a “STANDARD OPERATING PROCEDURE (SOP)” entitled “Warehouse Cleaning Procedure”. This procedure does not address excluding pests from your facility. Furthermore, your response does not address how you intend to remove the cats from your food warehouse.\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist at your facility in connection with your operations. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your facility complies with all requirements of federal law, including applicable FDA regulations.\nAdditionally, we offer the following comment:\nTo comply with 21 CFR 123.10, your HACCP plan must be developed by an individual who has successfully completed training in the application of HACCP principles to fish and fishery product processing that is at least equivalent to that received under standardized curriculum recognized as adequate by the FDA or who is otherwise qualified through job experience to perform these functions. Job experience will qualify an individual to perform these functions if it has provided knowledge at least equivalent to that provided through the standardized curriculum. Your written response dated March 23, 2026, included photographs of your enrollment in a training course titled “(b)(4)” offered by (b)(4) and a “Receipt from (b)(4)” for “Enrollment in course (b)(4)”. It is unclear if either of these training courses include training specific to the FDA’s Seafood HACCP regulations found in 21 CFR Part 123.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. We may take further action if you do not promptly correct these violations. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on \"detention without physical examination,\" seize your product(s) and\u002For enjoin your firm from further violating the Act.\nPlease notify FDA in writing within fifteen (15) working days of the receipt of this letter of the specific steps and corrections you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete all corrections within fifteen (15) days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply electronically to HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Daniel Johnson, Compliance Officer, at Daniel.Johnson@fda.hhs.gov. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov. Please refer to CMS #728657 on any submissions within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nDirector\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\n_________________________\n1 As defined in 21 CFR 123.3(k)(1), processing includes storing with respect to fish and fishery products and your facility engages in storing fish and fishery products.","South Asian Food Inc.","south-asian-food-inc-728657-08202026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsouth-asian-food-inc-728657-08202026","2026-11-10T01:02:16.121874+00:00","2026-09-29","728657","Mr. MohammedS.Kahn","2026-10-14T12:35:33.98+00:00","VIA ELECTRONIC DELIVERY","2026-08-20",{"id":235,"raw":236,"subject":240,"body_html":241,"body_text":242,"firm_name":243,"letter_id":244,"created_at":106,"fei_number":19,"letter_url":245,"updated_at":246,"action_type":22,"case_status":23,"posted_date":247,"marcs_cms_no":248,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":249,"body_fetched_at":250,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":251,"medical_device_id":19,"response_letter_date":19},3014,[237,238,239,37,240,13,13,13],"\u003Ctime datetime=\"2021-11-23T14:20:00Z\">11\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-01T04:00:00Z\">10\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmiths-medical-asd-inc-617147-10012021\">Smiths Medical ASD Inc.\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>JehanZeb Noor\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Smiths Medical ASD Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6000 Nathan Lane N.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Minneapolis\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55442\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jehanzeb.noor@smiths-medical.com\"> jehanzeb.noor@smiths-medical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 617147\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 1, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Noor:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Smiths Medical ASD, Inc., located at 6000 Nathan Lane N. Minneapolis, Minnesota, from February 23 – March 30, 2021 with an amended 483 signed May 28, 2021. During the inspection, FDA investigators determined that your firm is a specification developer and manufacturer for a variety of medical devices including blood warmers and infusion pumps. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Parts 803 and 806 - Medical Device Reporting and Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003Cbr>\n\u003Cbr>\nFor example, the information included in Complaint CC-0094982 and Complaint CC-0099632 reasonably suggests that your firm’s Medfusion Syringe Pump malfunctioned (i.e., unexpected battery depletion) while in use. Your firm initiated a recall Z-0610-2020 for the referenced malfunction. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. As such, the referenced complaints meet the definition of a reportable malfunction, as defined in 21 CFR 803.3. There is no information included for the complaints that rules out that the device may not have caused or contributed to the referenced malfunctions. As such, your firm failed to submit an MDR for each of the referenced complaints.\u003C\u002Fp>\n\n\u003Cp>Your firm’s responses dated May 20, 2021, June 25, 2021, June 29, 2021, and July 28, 2021 were reviewed and determined to be inadequate. The responses noted that your firm initiated systemic corrections and corrective actions, such as a root-cause investigation and plan to improve MDR reporting process. However, your firm did not provide documentation or evidence of implementation of its corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>The responses also included a revised procedural document titled “Adverse Event Reporting – United State”, DP-20087, Revision 101, which incorporate a process to identify precedent events. However, after reviewing the document, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>A. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\u003Cbr>\n&nbsp; a. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\n&nbsp; b. Although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for making determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>B. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically:\u003Cbr>\n&nbsp; a. Instructions for how to complete the FDA 3500A form.\u003Cbr>\n&nbsp; b. A process for submitting MDRs electronically in accordance with 21 CFR 803.20(a)(3).\u003Cbr>\n&nbsp; c. How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\u003C\u002Fp>\n\n\u003Cp>C. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>\n&nbsp; a. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>\n&nbsp; b. Information that was evaluated to determine if an event was reportable.\u003Cbr>\n&nbsp; c. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>Furthermore, your firm did not provide documentation or evidence that the corrections and corrective actions, including a retrospective review of precedent events and submission of two referenced malfunction MDRs, have been implemented and completed.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a written report to FDA of any correction or removal of a device initiated to remedy a violation of the Act caused by the device which may present a risk to health, as required by 21 CFR Part 806.10. For example, your firm issued a Customer Information Bulletin dated on December 3, 2015, offering a replacement of the supercapacitor (contained on the main boards) for the Medfusion 3500 and 4000 Infusion Pumps, due to the early failure of the supercapacitor after a supplier change in 2013. This failure led to a “Backup Audible Alarm error” or “Supercap POST (power on self-test) error” which requires that a biomed code be entered before the pump can be returned to use and causes a potential delay of therapy. Your firm did not submit a written report to FDA of the removal, as required by 21 CFR 806.10.\u003C\u002Fp>\n\n\u003Cp>As of October 1, 2021, there is no record of Smith Medical ASD, Inc. submitting a Report of Correction or Removal to FDA.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, including software validation and risk analysis and the results shall be documented in the DHF as required by 21 CFR 820.30(g). Specifically,\u003C\u002Fp>\n\n\u003Cp>A. You have not validated the Medfusion® software version 1.6.1 for use with the firmware bootloader version 1.2; your firm estimated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> units potentially exist in the field with an unvalidated software combination. Your software and firmware are routinely changed in production, yet your firm did not define a design input for downgrading the revision of firmware to match the revision of software on the pump.\u003Cbr>\nB. Your design change CO-10073172 released a “pre-release” of software version 1.7.0 and base bootloader 1.2 for the Medfusion® 4000 that was not validated. You did not have documentation showing these base boards (also known as interconnect boards) were appropriately updated to a final validated version of software prior to release and shipment to customers.\u003Cbr>\nC. Your design change to the power cord retainer for the Medfusion® 4000, did not have an adequate validation or rationale why no formal validation was required for fluid ingress. An evaluation was completed; however, the evaluation did not define any acceptance criteria, nor did it specify key parameters identified in the previous 2013-2014 investigation RTR-007, Revision 100; and ETR-228, Revision 100, such as the salinity of the solution, whether the outlets were grounded and whether the flow rates used in 2019 were comparable to the previous investigations.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish procedures for corrective and preventative action, with documentation of activities and results as required by 21 CFR 820.100. Specifically, your CAPA procedure, \u003Cem>Corrective and Preventive Action (CAPA)\u003C\u002Fem>, \u003Cem>SOP-20046\u003C\u002Fem> has not been adequately established.\u003Cbr>\nA. Your CAPAs did not implement changes in methods or procedures to correct or prevent the identified quality problems, for example:\u003Cbr>\n&nbsp; i. CAPA-000722, opened on October 21, 2020, found design changes to make the pressure doors wider lowered the flow rates and did not guarantee the claimed flow rates in the IFU can always be met. Your firm has received three complaints alleging deaths and seven complaints for serious injury due to this design change since the beginning of 2019. The CAPA was still in investigation phase, with a due date of May 14, 2021.\u003Cbr>\n&nbsp; ii. CAPA 19MBIS069 was opened on April 11, 2019 to address complaint CC-0031585 for an over-infusion event on the Medfusion® 3500 with software version 4.1.5. The CAPA investigation found the software error was also present in software version 5.0.0 and 6.0.0. While Software version 6.0.0 was fixed, it appears no action was taken for Software version 5.0.0.\u003Cbr>\n&nbsp; iii. CAPA 18MOAK003 was opened on July 28, 2017 for out-of-box issues regarding failing the Force Sensor Test. The design controls corrective actions in this CAPA were then transferred to CAPA 19MOAK090, opened on June 20, 2019. During the implementation results phase, the Design Controls corrective action was stated to take place in a separate supplier change document, under Design Change Assessment (DCA) B10004228, Revision 100, Requested on July 23, 2019. These supplier and design changes were still open as of March 30, 2021. The DPRA found 121 complaints for this failure mode from May 01, 2016 – February 28, 2018.\u003Cbr>\nB. CAPAs have not adequately verified or validated the corrective actions to ensure the changes were effective and do not adversely affect the finished device.\u003Cbr>\n&nbsp; i. CAPA 18MOAK030 was opened on October 30, 2017 for Medfusion® pumps that are not recognizing the correct syringe size. The CAPA added a receiving inspection step for the barrel clamp guide and spring, clarified the barrel rod drawing, and added the broken edge dimension for the barrel rod. However, the CAPA did not include a revalidation of the sub-assembly or full assembly, nor are there test results showing these changes were effective and did not adversely affect the product. The verification of effectiveness section of the CAPA only verifies that there were no complaints for the spring slipping over the barrel rod, 6 months after implementation for these changes. CAPA 18MOAK030 resulted in a recall, reported on November 27, 2017 and expanded on April 03, 2018. At least 35 complaints have been received for this failure mode since January 1, 2019.\u003Cbr>\n&nbsp; ii. CAPA-000580 \u002F 20CAPA009 does not have a verification of effectiveness. The implementation phase states that all actions will be addressed by the Quality Plan #B10005892. There was no approved procedure in place to ensure a verification of effectiveness in Quality Plans and your management stated there was no verification of effectiveness for these corrective actions. Three other CAPAs and one CAPA request were also closed to this Quality Plan: 19MMSP067, 19MMSP058, 19MMSP050 and 20CAPA064.\u003Cbr>\nC. Quality data sources are not being analyzed.\u003Cbr>\nYour firm’s procedure “Complaints Signals Review Process,” DP-20099, Revision 100 is your only procedure for quality data analysis. This procedure does not address the review of other sources of quality data, such as Application Support.\u003Cbr>\nD. Your procedure, “Nonconforming Event (NCE),” SOP-20048, Revision 102 has not been adequately implemented.\u003Cbr>\nNCR-000111 was opened on 25-Aug-2020 for an increased number of field complaints and sales team reports from customers experiencing issues with the Level 1 Trauma Tower flow rates and fluid being left in 300 ml blood bags. The risk analysis was marked as “negligible,” despite this failure mode being linked with at least three deaths.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as per 21 CFR 820.198(a). Specifically,\u003Cbr>\nA. Your firm does not maintain records of investigations for complaints that come through application support. Section 6.1.1 of your procedure, Product Complaint Investigation, DVDP5514, Revision 100, requires all product complaint investigations to be documented within Investigation Objects in the complaints management system. However, all complaints originating from your application support helpline only have complaint investigations documented in associated e-mail records, and this does not represent any complaints that are received over the phone.\u003Cbr>\nB. Your procedure, Product Complaint handling, SOP 200077, Revision 100, states the complaint handler will update the Post Investigation Hazard Code after the investigation has been completed. Three of 15 complaints (CC-0044272, CC-0041616 and CC-0043719) reviewed had \"N\u002FA - No Fault Found\" as the \"Post Investigation Hazard Code\" when the returned product was determined to have a known problem with the barrel clamp guide assembly.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain a Design history file for each type of device to demonstrate the design was developed in accordance with the approved design plan and the requirements of 21 CFR 820, as required by 21 CFR 820.30(j). Specifically, your firm’s procedure, Global Post-Market Regulatory Change Impact Assessments, DVDP2500, Revision 100 requires a Letter to File for a change to a Class II U.S. product that is deemed “nonsignificant”. Review of your Design History File for the Medfusion® 4000, found at least 5 Letters to File have not been retained.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your firms’ responses that indicate you have implemented corrective actions; not all your corrective actions have been completed. The effectiveness of the corrections you have taken will be evaluated during your next inspection.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>In addition, we understand you have recently reached out to the Center for Devices and Radiological Health (CDRH) regarding the technological characteristics and intended use of your Medfusion® model 4000 Syringe Infusion Pump device (K111386) cleared on August 29, 2011, which is currently in commercial distribution. CDRH will use the information you have submitted to determine the appropriate regulatory pathway for this device.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer, Demetria Lueneburg at 615-758-7210 or at Demetria.Lueneburg@fda.hhs.gov. Please send your reply electronically to Melissa Michurski, Director of Compliance Branch, at ORADevices2FirmResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nBlake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp; &nbsp;General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJehanZeb Noor\n\nRecipient Title\n\nCEO\n\nSmiths Medical ASD Inc.\n\n6000 Nathan Lane N.\n\nMinneapolis, MN 55442\n\nUnited States\n\njehanzeb.noor@smiths-medical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 617147\n\nOctober 1, 2021\n\nDear Mr. Noor:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Smiths Medical ASD, Inc., located at 6000 Nathan Lane N. Minneapolis, Minnesota, from February 23 – March 30, 2021 with an amended 483 signed May 28, 2021. During the inspection, FDA investigators determined that your firm is a specification developer and manufacturer for a variety of medical devices including blood warmers and infusion pumps. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nOur inspection revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Parts 803 and 806 - Medical Device Reporting and Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n\n1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information included in Complaint CC-0094982 and Complaint CC-0099632 reasonably suggests that your firm’s Medfusion Syringe Pump malfunctioned (i.e., unexpected battery depletion) while in use. Your firm initiated a recall Z-0610-2020 for the referenced malfunction. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. As such, the referenced complaints meet the definition of a reportable malfunction, as defined in 21 CFR 803.3. There is no information included for the complaints that rules out that the device may not have caused or contributed to the referenced malfunctions. As such, your firm failed to submit an MDR for each of the referenced complaints.\n\nYour firm’s responses dated May 20, 2021, June 25, 2021, June 29, 2021, and July 28, 2021 were reviewed and determined to be inadequate. The responses noted that your firm initiated systemic corrections and corrective actions, such as a root-cause investigation and plan to improve MDR reporting process. However, your firm did not provide documentation or evidence of implementation of its corrective actions as they are still ongoing.\n\nThe responses also included a revised procedural document titled “Adverse Event Reporting – United State”, DP-20087, Revision 101, which incorporate a process to identify precedent events. However, after reviewing the document, the following deficiencies were noted:\n\nA. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\n\na. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. Although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for making determinations in a timely manner.\n\nB. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically:\n\na. Instructions for how to complete the FDA 3500A form.\n\nb. A process for submitting MDRs electronically in accordance with 21 CFR 803.20(a)(3).\n\nc. How your firm will submit all information reasonably known to it for each event. Specifically, which sections of the 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow up within your firm.\n\nC. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Information that was evaluated to determine if an event was reportable.\n\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nFurthermore, your firm did not provide documentation or evidence that the corrections and corrective actions, including a retrospective review of precedent events and submission of two referenced malfunction MDRs, have been implemented and completed.\n\n2. Failure to submit a written report to FDA of any correction or removal of a device initiated to remedy a violation of the Act caused by the device which may present a risk to health, as required by 21 CFR Part 806.10. For example, your firm issued a Customer Information Bulletin dated on December 3, 2015, offering a replacement of the supercapacitor (contained on the main boards) for the Medfusion 3500 and 4000 Infusion Pumps, due to the early failure of the supercapacitor after a supplier change in 2013. This failure led to a “Backup Audible Alarm error” or “Supercap POST (power on self-test) error” which requires that a biomed code be entered before the pump can be returned to use and causes a potential delay of therapy. Your firm did not submit a written report to FDA of the removal, as required by 21 CFR 806.10.\n\nAs of October 1, 2021, there is no record of Smith Medical ASD, Inc. submitting a Report of Correction or Removal to FDA.\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, including software validation and risk analysis and the results shall be documented in the DHF as required by 21 CFR 820.30(g). Specifically,\n\nA. You have not validated the Medfusion® software version 1.6.1 for use with the firmware bootloader version 1.2; your firm estimated that (b)(4) units potentially exist in the field with an unvalidated software combination. Your software and firmware are routinely changed in production, yet your firm did not define a design input for downgrading the revision of firmware to match the revision of software on the pump.\n\nB. Your design change CO-10073172 released a “pre-release” of software version 1.7.0 and base bootloader 1.2 for the Medfusion® 4000 that was not validated. You did not have documentation showing these base boards (also known as interconnect boards) were appropriately updated to a final validated version of software prior to release and shipment to customers.\n\nC. Your design change to the power cord retainer for the Medfusion® 4000, did not have an adequate validation or rationale why no formal validation was required for fluid ingress. An evaluation was completed; however, the evaluation did not define any acceptance criteria, nor did it specify key parameters identified in the previous 2013-2014 investigation RTR-007, Revision 100; and ETR-228, Revision 100, such as the salinity of the solution, whether the outlets were grounded and whether the flow rates used in 2019 were comparable to the previous investigations.\n\n2. Failure to establish procedures for corrective and preventative action, with documentation of activities and results as required by 21 CFR 820.100. Specifically, your CAPA procedure, Corrective and Preventive Action (CAPA), SOP-20046 has not been adequately established.\n\nA. Your CAPAs did not implement changes in methods or procedures to correct or prevent the identified quality problems, for example:\n\ni. CAPA-000722, opened on October 21, 2020, found design changes to make the pressure doors wider lowered the flow rates and did not guarantee the claimed flow rates in the IFU can always be met. Your firm has received three complaints alleging deaths and seven complaints for serious injury due to this design change since the beginning of 2019. The CAPA was still in investigation phase, with a due date of May 14, 2021.\n\nii. CAPA 19MBIS069 was opened on April 11, 2019 to address complaint CC-0031585 for an over-infusion event on the Medfusion® 3500 with software version 4.1.5. The CAPA investigation found the software error was also present in software version 5.0.0 and 6.0.0. While Software version 6.0.0 was fixed, it appears no action was taken for Software version 5.0.0.\n\niii. CAPA 18MOAK003 was opened on July 28, 2017 for out-of-box issues regarding failing the Force Sensor Test. The design controls corrective actions in this CAPA were then transferred to CAPA 19MOAK090, opened on June 20, 2019. During the implementation results phase, the Design Controls corrective action was stated to take place in a separate supplier change document, under Design Change Assessment (DCA) B10004228, Revision 100, Requested on July 23, 2019. These supplier and design changes were still open as of March 30, 2021. The DPRA found 121 complaints for this failure mode from May 01, 2016 – February 28, 2018.\n\nB. CAPAs have not adequately verified or validated the corrective actions to ensure the changes were effective and do not adversely affect the finished device.\n\ni. CAPA 18MOAK030 was opened on October 30, 2017 for Medfusion® pumps that are not recognizing the correct syringe size. The CAPA added a receiving inspection step for the barrel clamp guide and spring, clarified the barrel rod drawing, and added the broken edge dimension for the barrel rod. However, the CAPA did not include a revalidation of the sub-assembly or full assembly, nor are there test results showing these changes were effective and did not adversely affect the product. The verification of effectiveness section of the CAPA only verifies that there were no complaints for the spring slipping over the barrel rod, 6 months after implementation for these changes. CAPA 18MOAK030 resulted in a recall, reported on November 27, 2017 and expanded on April 03, 2018. At least 35 complaints have been received for this failure mode since January 1, 2019.\n\nii. CAPA-000580 \u002F 20CAPA009 does not have a verification of effectiveness. The implementation phase states that all actions will be addressed by the Quality Plan #B10005892. There was no approved procedure in place to ensure a verification of effectiveness in Quality Plans and your management stated there was no verification of effectiveness for these corrective actions. Three other CAPAs and one CAPA request were also closed to this Quality Plan: 19MMSP067, 19MMSP058, 19MMSP050 and 20CAPA064.\n\nC. Quality data sources are not being analyzed.\n\nYour firm’s procedure “Complaints Signals Review Process,” DP-20099, Revision 100 is your only procedure for quality data analysis. This procedure does not address the review of other sources of quality data, such as Application Support.\n\nD. Your procedure, “Nonconforming Event (NCE),” SOP-20048, Revision 102 has not been adequately implemented.\n\nNCR-000111 was opened on 25-Aug-2020 for an increased number of field complaints and sales team reports from customers experiencing issues with the Level 1 Trauma Tower flow rates and fluid being left in 300 ml blood bags. The risk analysis was marked as “negligible,” despite this failure mode being linked with at least three deaths.\n\n3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as per 21 CFR 820.198(a). Specifically,\n\nA. Your firm does not maintain records of investigations for complaints that come through application support. Section 6.1.1 of your procedure, Product Complaint Investigation, DVDP5514, Revision 100, requires all product complaint investigations to be documented within Investigation Objects in the complaints management system. However, all complaints originating from your application support helpline only have complaint investigations documented in associated e-mail records, and this does not represent any complaints that are received over the phone.\n\nB. Your procedure, Product Complaint handling, SOP 200077, Revision 100, states the complaint handler will update the Post Investigation Hazard Code after the investigation has been completed. Three of 15 complaints (CC-0044272, CC-0041616 and CC-0043719) reviewed had \"N\u002FA - No Fault Found\" as the \"Post Investigation Hazard Code\" when the returned product was determined to have a known problem with the barrel clamp guide assembly.\n\n4. Failure to establish and maintain a Design history file for each type of device to demonstrate the design was developed in accordance with the approved design plan and the requirements of 21 CFR 820, as required by 21 CFR 820.30(j). Specifically, your firm’s procedure, Global Post-Market Regulatory Change Impact Assessments, DVDP2500, Revision 100 requires a Letter to File for a change to a Class II U.S. product that is deemed “nonsignificant”. Review of your Design History File for the Medfusion® 4000, found at least 5 Letters to File have not been retained.\n\nWe acknowledge your firms’ responses that indicate you have implemented corrective actions; not all your corrective actions have been completed. The effectiveness of the corrections you have taken will be evaluated during your next inspection.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nIn addition, we understand you have recently reached out to the Center for Devices and Radiological Health (CDRH) regarding the technological characteristics and intended use of your Medfusion® model 4000 Syringe Infusion Pump device (K111386) cleared on August 29, 2011, which is currently in commercial distribution. CDRH will use the information you have submitted to determine the appropriate regulatory pathway for this device.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer, Demetria Lueneburg at 615-758-7210 or at Demetria.Lueneburg@fda.hhs.gov. Please send your reply electronically to Melissa Michurski, Director of Compliance Branch, at ORADevices2FirmResponse@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 2 Central\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nDirector\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Smiths Medical ASD Inc.","smiths-medical-asd-inc-617147-10012021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmiths-medical-asd-inc-617147-10012021","2026-10-26T08:09:59.452055+00:00","2021-11-23","617147","JehanZeb Noor","2026-08-20T02:25:48.083+00:00","2021-10-01",{"id":253,"raw":254,"subject":12,"body_html":259,"body_text":260,"firm_name":261,"letter_id":262,"created_at":106,"fei_number":19,"letter_url":263,"updated_at":264,"action_type":22,"case_status":23,"posted_date":265,"marcs_cms_no":266,"product_type":26,"closeout_date":19,"issuing_office":258,"recipient_name":267,"body_fetched_at":268,"delivery_method":269,"recipient_title":19,"reference_number":19,"action_taken_date":270,"medical_device_id":19,"response_letter_date":19},3357,[255,256,257,258,12,13,13,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-29T04:00:00Z\">04\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwismettac-asian-foods-inc-611877-04292021\">Wismettac Asian Foods, Inc.\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Hiroshi Matsuo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Manager of Food Safety Department\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Wismettac Asian Foods, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13409 Orden Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Santa Fe Springs\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90670-6336\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nApril 29, 2021\u003C\u002Fp>\n\n\u003Cp>Re: CMS #611877\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hiroshi Matsuo:\u003C\u002Fp>\n\n\u003Cp>On September 28-30, October 2, 5-6, 9 and 13, 2020, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically. We also conducted inspections on March 6, 2020 and August 30, 2017. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation under 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The most recent FSVP inspection was initiated as part of a \u003Cem>Salmonella\u003C\u002Fem> Stanley multi-state outbreak investigation. During the investigation, epidemiologic and traceback analyses of records identified Shirakiku brand Black Fungus (Kikurage), also known as wood ear mushroom, distributed by your firm as the likely suspect of the outbreak. Information uncovered during our inspection regarding the facilities who conduct processing of your Black Fungus (Kikurage) identified your supplier as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, the California Department of Public Health (CDPH) collected and analyzed samples of unopened packages of your Black Fungus (Kikurage), confirming them to contain \u003Cem>Salmonella\u003C\u002Fem> Stanley. FDA analysis of whole-genome sequencing (WGS) of the isolates from the CDPH samples determined the isolates matched the outbreak strain and likely came from the same source. We acknowledge you initiated a voluntary recall of your Black Fungus (Kikurage).\u003C\u002Fp>\n\n\u003Cp>During the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your Black Fungus (Kikurage) manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; your Shiitake mushroom sliced, manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and the imported products on “List of foods with no FSVP – Wismettac Asian Foods Inc. 10-12-2020.”. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations, which indicates you have not complied with the FSVP regulation.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your emailed response dated November 3, 2020 which included a cover letter addressing the observations on the FDA 483a, and several supporting documents related to your FSVPs, including product and environmental swab sample results from the drying and packing facility for your Black Fungus (Kikurage), the “List of foods with no FSVP - Wismettac Asian Foods Inc. 10-12-2020” with added notations, an updated HACCP plan from the packing facility for your Shitake mushrooms, a copy of your supplier approval program, and an updated supplier approval assessment sheet. We address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not meet the requirements to evaluate your foreign supplier’s performance in accordance with 21 CFR 1.505 for the products you import. Specifically, for your foreign supplier of Black Fungus (Kikurage), \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not evaluate your foreign supplier’s performance and the risk posed by the food (as required by 21 CFR 1.505(a)) or document your approval of your foreign supplier on the basis of the evaluation (as required by 21 CFR 1.505(b)).\u003C\u002Fp>\n\n\u003Cp>During our inspection you provided a Supplier Approval Assessment, dated February 27, 2018, for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, this entity is not the foreign supplier of Black Fungus (Kikurage). Foreign supplier means, for an article of food, the establishment that manufactures\u002Fprocesses the food, raises the animal, or grows the food that is exported to the United States without further manufacturing\u002Fprocessing by another establishment, except for further manufacturing\u002Fprocessing that consists solely of the addition of labeling or any similar activity of a de minimis nature (21 CFR 1.500).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> does not meet the definition of foreign supplier because \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not manufacture\u002Fprocess or grow the food.\u003C\u002Fp>\n\n\u003Cp>For the actual foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, we acknowledge that you provided a Food Safety HACCP Plan dated July 24, 2020, including a hazard analysis and a Supplier Approval Questionnaire, dated September 28, 2020. However, you did not provide records showing that you conducted the evaluation required by 21 CFR 1.505(a) or the approval based on the evaluation required by 21 CFR 1.505(b). In your response to the FDA 483a, you stated you no longer purchase mushroom products from this foreign supplier, and you are not able to conduct a supplier assessment until they complete corrective actions including a root cause analysis, in response to the \u003Cem>Salmonella&nbsp;\u003C\u002Fem>outbreak. You further stated your Shanghai office is working with the supplier and you list steps the supplier is taking to minimize contamination. You provided environmental and product sample analysis from the supplier. You indicated if your supplier is not able to take corrective actions, you will consider changing suppliers or will “switch the product from dried fungus product to fully cooked dried fungus (Ready-to-Eat product)”. While we appreciate the steps you have taken, the fact remains you imported Black Fungus (Kikurage), which were found to be the source of an outbreak of foodborne illness, without conducting the required evaluation of your foreign supplier’s performance and the risk posed by the food prior to importation.\u003C\u002Fp>\n\n\u003Cp>Because your response indicates your ongoing evaluation of this supplier of your Black Fungus (Kikurage), we would like to clarify that we consider your Black Fungus (Kikurage) a ready-to-eat (RTE) food in accordance with 21 CFR 117.3. It is reasonably foreseeable that the food will be eaten without further processing that would significantly minimize biological hazards. Additionally, in light of the \u003Cem>Salmonella\u003C\u002Fem> findings in samples of your Black Fungus (Kikurage), \u003Cem>Salmonella\u003C\u002Fem> would be a known or reasonably foreseeable hazard that may be present in the food and that you should address in your FSVP.\u003C\u002Fp>\n\n\u003Cp>2. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the following products on the “List of foods with no FSVP – Wismettac Asian Foods Inc. 10-12-2020:”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Eggplant, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Seaweed, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Chestnut, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Agar Agar (Gelatin) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Rice flours, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Flavored or Party crackers, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Rice grain snack, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Citrus, mixed jam jelly preserves, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response to the 483a stated that these foods will be the subject of forthcoming FSVPs. For this latter category, you stated that you planned to develop the FSVPs by November 30th. However, you did not provide documentation that would otherwise allow us to verify your corrections. If you have completed corrections, you may submit documentation of such in response to this letter. Otherwise, we will verify your corrections during our next inspection.\u003C\u002Fp>\n\n\u003Cp>3. You must conduct a hazard analysis to determine whether there are any hazards requiring a control (21 CFR 1.504(a)). A hazard means any biological, chemical, or physical agent that is reasonably likely to cause illness or injury (21 CFR 1.500). A hazard requiring a control means a known or reasonably foreseeable hazard for which a person knowledgeable about the safe manufacturing, processing, packing, or holding of food would, based on the outcome of a hazard analysis (which includes an assessment of the probability that the hazard will occur in the absence of controls or measures and the severity of the illness or injury if the hazard were to occur), establish one or more controls or measures to significantly minimize or prevent the hazard in a food and components to manage those controls or measures (such as monitoring, corrections or corrective actions, verification, and records) as appropriate to the food, the facility, and the nature of the control or measure and its role in the facility’s food safety system (21 CFR 1.500). However, during our inspection which concluded October 13, 2020, you provided your hazard analysis for Shiitake mushroom from your foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which did not identify biological hazards, or pathogens, as hazards requiring a control. Your evaluation of the hazard analysis (on form “Supplier Approval Assessment Sheet”) states, “This product is not Ready to Eat food. Biological hazard is controlled by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” At the \u003Cstrong>(b)(4)\u003C\u002Fstrong> acceptance processing step, your hazard analysis listed pathogenic bacteria, mold, and parasites as potential biological hazards and states the \u003Cstrong>(b)(4)\u003C\u002Fstrong> may bring “\u003Cstrong>(b)(4)\u003C\u002Fstrong> bacteria or pollution in the storage and transportation due to insects, animals, and environmental pathogens.” It has been demonstrated that pathogens, including \u003Cem>Salmonella\u003C\u002Fem>, can survive and persist for extended periods of time in low moisture foods. Further studies demonstrate that microorganisms can survive on dried mushrooms. However, the hazard analysis determines that these are not significant hazards. Although your hazard analysis identifies biological hazards on raw materials, it does not identify them as hazards requiring a control at any step during production.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that in your response to the FDA 483a, you submitted a revised HACCP Plan, including a revised hazard analysis, from your foreign supplier for your Shiitake mushroom from manufacturer \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not document your review and assessment of the revised hazard analysis. We acknowledge that you also stated that you stopped importing Shitake mushrooms from \u003Cstrong>(b)(4)\u003C\u002Fstrong> pending your review of the revised HACCP plan and a report of an audit conducted by \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 10\u002F26\u002F2020. However, the fact remains that you imported the product without complying with FSVP requirements.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct the above violations. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of food that you import for which you do not have an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation, including placing the food from your identified foreign suppliers on detention without physical examination (DWPE) when you import the products. In addition, Black Fungus (Kikurage) is currently subject to DWPE per import alert 99-19 and 99-43. You can find DWPE information relating to FSVP in Import Alert #99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we also have the following comments: In your response to the FDA 483a observation regarding your hazard analysis for Shitake mushrooms, submitted November 3, 2020, you stated you stopped importing your Shitake mushroom manufactured by \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>pending your review of the revised HACCP plan and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> report of an audit they conducted on 10\u002F26\u002F2020. To the extent that these steps are intended to comply with the requirements for corrective actions under 21 CFR 1.508, we note that the requirements for corrective actions are that importers must take appropriate corrective actions if they determine that a foreign supplier of a food they import does not produce the food in compliance with the relevant food safety requirements (21 CFR 1.508(a)). This determination could be based on a review of consumer, customer, or other complaints related to food safety, the verification activities conducted under §1.506 or §1.511(c), a reevaluation of the risks posed by the food and the foreign supplier's performance conducted under §1.505(c) or (d), or any other relevant information you obtain (21 CFR 1.508(a)). The appropriate corrective actions will depend on the circumstances but could include discontinuing use of the foreign supplier until the cause or causes of noncompliance, adulteration, or misbranding have been adequately addressed (21 CFR 1.508(a)). You must document any such corrective actions taken in accordance with section 1.508 (21 CFR 1.508(a)).\u003C\u002Fp>\n\n\u003Cp>In addition, we note that you must establish and follow written procedures to ensure that you import foods only from foreign suppliers you have approved, and you must document your use of these procedures (21 CFR 1.506(a)(1)). Although your response to the 483a stated that you have written procedures to ensure you import foods only from approved foreign suppliers and you provided a copy of these procedures (“Attachment-7 WAF-M-010 Supplier Approval Program 05-18-2020”), we note that you are still required to follow and document your use of these procedures.\u003C\u002Fp>\n\n\u003Cp>Further, we note that under 21 CFR 1.506(d)(2), when a hazard in a food will be controlled by the foreign supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals, you must conduct or obtain documentation of an onsite audit of the foreign supplier before initially importing the food and at least annually thereafter, unless you make an adequate written determination that, instead of such initial and annual onsite auditing, other supplier verification activities and\u002For less frequent onsite auditing are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with the relevant food safety standards. You provided a copy of your updated Supplier Approval Assessment Sheet which indicates in the Verification Procedures section the frequency of your verification activities as every \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is also indicated in your Supplier Approval Program under Verification Frequency. Please note hat under 21 CFR 1.506(d)(2), it is necessary to document the basis for conducting verification activities at a less-than-annual frequency for the hazards for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, or that you have complied with FDA regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via phone at (562) 256-9235 or via email at debbie.giang@fda.hhs.gov. Please reference CMS #611877 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lawton W. Lum\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nHiroshi Matsuo\n\nRecipient Title\n\nSenior Manager of Food Safety Department\n\nWismettac Asian Foods, Inc.\n\n13409 Orden Dr.\n\nSanta Fe Springs, CA 90670-6336\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nApril 29, 2021\n\nRe: CMS #611877\n\nDear Mr. Hiroshi Matsuo:\n\nOn September 28-30, October 2, 5-6, 9 and 13, 2020, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically. We also conducted inspections on March 6, 2020 and August 30, 2017. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation under 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nThe most recent FSVP inspection was initiated as part of a Salmonella Stanley multi-state outbreak investigation. During the investigation, epidemiologic and traceback analyses of records identified Shirakiku brand Black Fungus (Kikurage), also known as wood ear mushroom, distributed by your firm as the likely suspect of the outbreak. Information uncovered during our inspection regarding the facilities who conduct processing of your Black Fungus (Kikurage) identified your supplier as (b)(4). Additionally, the California Department of Public Health (CDPH) collected and analyzed samples of unopened packages of your Black Fungus (Kikurage), confirming them to contain Salmonella Stanley. FDA analysis of whole-genome sequencing (WGS) of the isolates from the CDPH samples determined the isolates matched the outbreak strain and likely came from the same source. We acknowledge you initiated a voluntary recall of your Black Fungus (Kikurage).\n\nDuring the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your Black Fungus (Kikurage) manufactured by (b)(4); your Shiitake mushroom sliced, manufactured by (b)(4); and the imported products on “List of foods with no FSVP – Wismettac Asian Foods Inc. 10-12-2020.”. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations, which indicates you have not complied with the FSVP regulation.\n\nWe acknowledge receipt of your emailed response dated November 3, 2020 which included a cover letter addressing the observations on the FDA 483a, and several supporting documents related to your FSVPs, including product and environmental swab sample results from the drying and packing facility for your Black Fungus (Kikurage), the “List of foods with no FSVP - Wismettac Asian Foods Inc. 10-12-2020” with added notations, an updated HACCP plan from the packing facility for your Shitake mushrooms, a copy of your supplier approval program, and an updated supplier approval assessment sheet. We address your response below.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not meet the requirements to evaluate your foreign supplier’s performance in accordance with 21 CFR 1.505 for the products you import. Specifically, for your foreign supplier of Black Fungus (Kikurage), (b)(4), you did not evaluate your foreign supplier’s performance and the risk posed by the food (as required by 21 CFR 1.505(a)) or document your approval of your foreign supplier on the basis of the evaluation (as required by 21 CFR 1.505(b)).\n\nDuring our inspection you provided a Supplier Approval Assessment, dated February 27, 2018, for (b)(4). However, this entity is not the foreign supplier of Black Fungus (Kikurage). Foreign supplier means, for an article of food, the establishment that manufactures\u002Fprocesses the food, raises the animal, or grows the food that is exported to the United States without further manufacturing\u002Fprocessing by another establishment, except for further manufacturing\u002Fprocessing that consists solely of the addition of labeling or any similar activity of a de minimis nature (21 CFR 1.500).\n\n(b)(4) does not meet the definition of foreign supplier because (b)(4) did not manufacture\u002Fprocess or grow the food.\n\nFor the actual foreign supplier, (b)(4), we acknowledge that you provided a Food Safety HACCP Plan dated July 24, 2020, including a hazard analysis and a Supplier Approval Questionnaire, dated September 28, 2020. However, you did not provide records showing that you conducted the evaluation required by 21 CFR 1.505(a) or the approval based on the evaluation required by 21 CFR 1.505(b). In your response to the FDA 483a, you stated you no longer purchase mushroom products from this foreign supplier, and you are not able to conduct a supplier assessment until they complete corrective actions including a root cause analysis, in response to the Salmonella outbreak. You further stated your Shanghai office is working with the supplier and you list steps the supplier is taking to minimize contamination. You provided environmental and product sample analysis from the supplier. You indicated if your supplier is not able to take corrective actions, you will consider changing suppliers or will “switch the product from dried fungus product to fully cooked dried fungus (Ready-to-Eat product)”. While we appreciate the steps you have taken, the fact remains you imported Black Fungus (Kikurage), which were found to be the source of an outbreak of foodborne illness, without conducting the required evaluation of your foreign supplier’s performance and the risk posed by the food prior to importation.\n\nBecause your response indicates your ongoing evaluation of this supplier of your Black Fungus (Kikurage), we would like to clarify that we consider your Black Fungus (Kikurage) a ready-to-eat (RTE) food in accordance with 21 CFR 117.3. It is reasonably foreseeable that the food will be eaten without further processing that would significantly minimize biological hazards. Additionally, in light of the Salmonella findings in samples of your Black Fungus (Kikurage), Salmonella would be a known or reasonably foreseeable hazard that may be present in the food and that you should address in your FSVP.\n\n2. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the following products on the “List of foods with no FSVP – Wismettac Asian Foods Inc. 10-12-2020:”\n\nEggplant, imported from (b)(4)\n\nSeaweed, imported from (b)(4)\n\nChestnut, imported from (b)(4)\n\nAgar Agar (Gelatin) imported from (b)(4)\n\nRice flours, imported from (b)(4)\n\nFlavored or Party crackers, imported from (b)(4)\n\nRice grain snack, imported from (b)(4)\n\nCitrus, mixed jam jelly preserves, imported from (b)(4)\n\nYour response to the 483a stated that these foods will be the subject of forthcoming FSVPs. For this latter category, you stated that you planned to develop the FSVPs by November 30th. However, you did not provide documentation that would otherwise allow us to verify your corrections. If you have completed corrections, you may submit documentation of such in response to this letter. Otherwise, we will verify your corrections during our next inspection.\n\n3. You must conduct a hazard analysis to determine whether there are any hazards requiring a control (21 CFR 1.504(a)). A hazard means any biological, chemical, or physical agent that is reasonably likely to cause illness or injury (21 CFR 1.500). A hazard requiring a control means a known or reasonably foreseeable hazard for which a person knowledgeable about the safe manufacturing, processing, packing, or holding of food would, based on the outcome of a hazard analysis (which includes an assessment of the probability that the hazard will occur in the absence of controls or measures and the severity of the illness or injury if the hazard were to occur), establish one or more controls or measures to significantly minimize or prevent the hazard in a food and components to manage those controls or measures (such as monitoring, corrections or corrective actions, verification, and records) as appropriate to the food, the facility, and the nature of the control or measure and its role in the facility’s food safety system (21 CFR 1.500). However, during our inspection which concluded October 13, 2020, you provided your hazard analysis for Shiitake mushroom from your foreign supplier, (b)(4), which did not identify biological hazards, or pathogens, as hazards requiring a control. Your evaluation of the hazard analysis (on form “Supplier Approval Assessment Sheet”) states, “This product is not Ready to Eat food. Biological hazard is controlled by (b)(4).” At the (b)(4) acceptance processing step, your hazard analysis listed pathogenic bacteria, mold, and parasites as potential biological hazards and states the (b)(4) may bring “(b)(4) bacteria or pollution in the storage and transportation due to insects, animals, and environmental pathogens.” It has been demonstrated that pathogens, including Salmonella, can survive and persist for extended periods of time in low moisture foods. Further studies demonstrate that microorganisms can survive on dried mushrooms. However, the hazard analysis determines that these are not significant hazards. Although your hazard analysis identifies biological hazards on raw materials, it does not identify them as hazards requiring a control at any step during production.\n\nWe acknowledge that in your response to the FDA 483a, you submitted a revised HACCP Plan, including a revised hazard analysis, from your foreign supplier for your Shiitake mushroom from manufacturer (b)(4). However, you did not document your review and assessment of the revised hazard analysis. We acknowledge that you also stated that you stopped importing Shitake mushrooms from (b)(4) pending your review of the revised HACCP plan and a report of an audit conducted by (b)(4) on 10\u002F26\u002F2020. However, the fact remains that you imported the product without complying with FSVP requirements.\n\nThis letter is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct the above violations. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of food that you import for which you do not have an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation, including placing the food from your identified foreign suppliers on detention without physical examination (DWPE) when you import the products. In addition, Black Fungus (Kikurage) is currently subject to DWPE per import alert 99-19 and 99-43. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nIn addition to the above violations, we also have the following comments: In your response to the FDA 483a observation regarding your hazard analysis for Shitake mushrooms, submitted November 3, 2020, you stated you stopped importing your Shitake mushroom manufactured by (b)(4) pending your review of the revised HACCP plan and the (b)(4) report of an audit they conducted on 10\u002F26\u002F2020. To the extent that these steps are intended to comply with the requirements for corrective actions under 21 CFR 1.508, we note that the requirements for corrective actions are that importers must take appropriate corrective actions if they determine that a foreign supplier of a food they import does not produce the food in compliance with the relevant food safety requirements (21 CFR 1.508(a)). This determination could be based on a review of consumer, customer, or other complaints related to food safety, the verification activities conducted under §1.506 or §1.511(c), a reevaluation of the risks posed by the food and the foreign supplier's performance conducted under §1.505(c) or (d), or any other relevant information you obtain (21 CFR 1.508(a)). The appropriate corrective actions will depend on the circumstances but could include discontinuing use of the foreign supplier until the cause or causes of noncompliance, adulteration, or misbranding have been adequately addressed (21 CFR 1.508(a)). You must document any such corrective actions taken in accordance with section 1.508 (21 CFR 1.508(a)).\n\nIn addition, we note that you must establish and follow written procedures to ensure that you import foods only from foreign suppliers you have approved, and you must document your use of these procedures (21 CFR 1.506(a)(1)). Although your response to the 483a stated that you have written procedures to ensure you import foods only from approved foreign suppliers and you provided a copy of these procedures (“Attachment-7 WAF-M-010 Supplier Approval Program 05-18-2020”), we note that you are still required to follow and document your use of these procedures.\n\nFurther, we note that under 21 CFR 1.506(d)(2), when a hazard in a food will be controlled by the foreign supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals, you must conduct or obtain documentation of an onsite audit of the foreign supplier before initially importing the food and at least annually thereafter, unless you make an adequate written determination that, instead of such initial and annual onsite auditing, other supplier verification activities and\u002For less frequent onsite auditing are appropriate to provide adequate assurances that the foreign supplier is producing the food in accordance with the relevant food safety standards. You provided a copy of your updated Supplier Approval Assessment Sheet which indicates in the Verification Procedures section the frequency of your verification activities as every (b)(4). This is also indicated in your Supplier Approval Program under Verification Frequency. Please note hat under 21 CFR 1.506(d)(2), it is necessary to document the basis for conducting verification activities at a less-than-annual frequency for the hazards for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals.\n\nPlease notify FDA in writing, within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, or that you have complied with FDA regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via phone at (562) 256-9235 or via email at debbie.giang@fda.hhs.gov. Please reference CMS #611877 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nLawton W. Lum\n\nActing Program Division Director\n\nDivision of West Coast Imports","Wismettac Asian Foods, Inc.","wismettac-asian-foods-inc-611877-04292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwismettac-asian-foods-inc-611877-04292021","2026-10-26T08:10:32.822789+00:00","2021-05-18","611877","Hiroshi Matsuo","2026-08-20T03:08:27.069+00:00","United Parcel Service","2021-04-29",{"id":272,"raw":273,"subject":278,"body_html":279,"body_text":280,"firm_name":281,"letter_id":282,"created_at":283,"fei_number":19,"letter_url":284,"updated_at":285,"action_type":22,"case_status":23,"posted_date":286,"marcs_cms_no":287,"product_type":69,"closeout_date":19,"issuing_office":288,"recipient_name":289,"body_fetched_at":290,"delivery_method":291,"recipient_title":19,"reference_number":19,"action_taken_date":292,"medical_device_id":19,"response_letter_date":19},2142,[274,275,276,277,278,13,13,13],"\u003Ctime datetime=\"2023-04-04T13:20:00Z\">04\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-22T05:00:00Z\">11\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspire-pharmaceuticals-inc-630328-11222022\">Aspire Pharmaceuticals, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East II ","CGMP\u002FManufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Madhav Pai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aspire Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>41 Veronica Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Somerset\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08873-6800\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #630328\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Pai:\u003Cbr>\n\u003Cbr>\nThis is to advise you that the U.S. Food and Drug Administration (FDA) conducted a joint inspection of your dietary supplement and drug manufacturing facility, located at 37 &amp; 41 Veronica Avenue, Somerset, NJ 08873-6800 on November 29 through 30, 2021; December 1 through 3, 6 through 9, 13 through 14, 17, 2021; and February 1 and 3, 2022. Based on our inspection and our. review of labeling collected during the inspection, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You may find the Act and the FDA's regulations through links on FDA's home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>We received e-mail correspondences from you dated March 14, 2022, April 11, 2022, May 11, 2022, July 11, 2022, and August 11 , 2022, written in response to the Form FDA 483, lnspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement cGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, our investigators found significant violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act (21 U.S.C. § 342(g)(1)] because the dietary supplements have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the cGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to ensure that the tests or examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your finished product testing uses \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to verify if finished product specifications for strength have been met for your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Mini Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Formula Softgels - lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Finished product testing using \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" is not an appropriate, scientifically valid method to verify finished product specifications.\u003C\u002Fp>\n\n\u003Cp>i. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for ingredients including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nii. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Mini Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for each of the ingredients in the product. In addition, during the inspection, you stated that no testing for the strength of any ingredient has been conducted for this product.\u003Cbr>\niii. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for the ingredients&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> extract and \u003Cstrong>(b)(4)\u003C\u002Fstrong> extract. Your specifications for this product, dated May 20, 2021, removed a test for the strength of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, a maker in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> extract. The previous version of your specifications, dated November 6, 2020, included a test for \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>to determine the amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong> using your method, \"MSIH-201 ,\" instead of \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\" During the inspection, you indicated the change to \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" was at the request of the customer, as documented in your change control document dated May 18, 2021. You could not provide a basis for why removing this test and replacing it with \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" would ensure the product met finished product specifications.\u003Cbr>\niv. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for the ingredients&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nv. For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Formula Softgel product: You use \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" as a method to determine whether specifications are met for the ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong> (standardized to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Extract, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Paste, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Extract, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Oil, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (from \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract, \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract (standardized to \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract (standardized to \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>b. You use FTIR for identity testing for some of the ingredients in your dietary supplement products. Your procedure, RMA-279, \"Testing Procedure for Identification by IR in Raw Material\" requires comparison of the sample spectrum to a \"Reference Standard\u002FReference Sample or Monograph Spectrum.\" During the inspection, you informed our investigators that your firm uses a purchased reference standard if there is one commercially available. For many of the ingredients, you use a reference sample because there is no reference standard available. A reference sample is a previous lot of the material from the vendor or a sample provided from the vendor to be used as reference material. However, your laboratory does not require verification of the previous lot or that the provided material is appropriate for use as a standard. Identity testing using FTIR to compare the sample spectrum to an unverified reference sample is not an appropriate, scientifically valid method to verify that specifications are met. For example:\u003C\u002Fp>\n\n\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>: You used FTIR for identity testing of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;is received as a pre-blend of \u003Cstrong>(b)(4)\u003C\u002Fstrong> different ingredients. During the inspection, you stated that FTIR cannot determine if each of the ingredients is present in the product. Identity testing must be able to confirm the identity of each ingredient in the finished product.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> was ultimately used in the manufacturing of the finished dietary supplement \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgel lot&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\nii. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract: You used FTIR for identity testing of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> was ultimately used in the manufacturing of the finished dietary supplement \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgel lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\niii. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract: You used FTIR for identity testing of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Extract lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> was ultimately used in the manufacturing of the finished dietary supplement \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>c. You use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Test Method to test your dietary supplement products for compliance with microbial specifications. This system includes testing for:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Total aerobic plate count, procedure MICROSTP-001\u003C\u002Fli>\n\t\u003Cli>Yeast and mold, procedure MICROSTP-002\u003C\u002Fli>\n\t\u003Cli>Salmonella, procedure MICROSTP-003\u003C\u002Fli>\n\t\u003Cli>Staphylococcus aureus, procedure MICROSTP-004\u003C\u002Fli>\n\t\u003Cli>Escherichia coli, procedure MICROSTP-005\u003C\u002Fli>\n\t\u003Cli>Enterobacteriaceae, procedure MICROSTP-006\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, you are not conducting suitability testing to demonstrate whether these methods are appropriate for testing all of your products. According to your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Technical Report, dated April 8, 2019, you conducted suitability testing for ten products, but not for all products. The report also determined that two of the ten products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, required modified preparation steps for neutralization, or else the test may not provide a valid result.\u003C\u002Fp>\n\n\u003Cp>The ingredients and amount of ingredients unique to individual dietary supplement products may interfere with the ability of microbial tests to provide a reliable result. Without suitability testing to demonstrate that a product does not interfere with the test, the method may not be determined to be an appropriate, scientifically valid method to verify that specifications are met.\u003C\u002Fp>\n\n\u003Cp>Your response dated April 11, 2022 states you will provide new documents and procedures, including Finished Product Dossiers for all the products identified during the inspection and Finished Product Specification and Report Forms. However, we are unable to evaluate the adequacy of your corrective actions because your submission did not include documentation that shows that you are implementing such corrections. For example, you provided only draft examples of your Finished Product Dossiers and Finished Product Specification and Report Forms for some of your dietary supplement products.\u003C\u002Fp>\n\n\u003Cp>In addition, your response suggested exempting ingredients that do not have verification methods from finished product testing, however, you did not provide the required documentation for such exemptions. Note that, to exempt one or more product specifications from verification requirements under 21 CFR 111.75(d), you must document why any component and in-process testing, examination, or monitoring, and any other information, will ensure that such exempted product specification is met without verification through periodic testing of the finished batch, and your quality control personnel must review and approve the documentation that you provide.\u003C\u002Fp>\n\n\u003Cp>2. Your firm's quality control personnel failed to conduct a material review and make a disposition decision when the established specification was not met, as required by 21 CFR 111.113(a)(1).\u003C\u002Fp>\n\n\u003Cp>Specifically, out of specification results were received for the following components and finished products:\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk softgels, \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Suspension raw material lot&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. For these components and finished products, your quality control unit failed to follow your procedure, \"MICRO009: Laboratory Investigation of \"Out of Specification\" Results for Microbiological Testing,\" which outlines the appropriate steps when a microbial specification is not met during testing. Your procedure states, if laboratory testing results fail to meet the specification, \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" and, \"The&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (Attachment Ill).\" You did not follow your procedure to conduct and document a laboratory investigation using Attachment Ill of your procedure; rather, you retested the samples until a passing result was obtained, and then reported the passing result without conducting an investigation for the initial failing results. No material review or disposition decision was performed by your firm in these examples where the dietary supplements or components failed to meet established specifications.\u003C\u002Fp>\n\n\u003Cp>Your response dated April 11, 2022 states, \"Investigations and Corrective Actions are completed. All microbiological testing is currently being sent out while improvements to the micro lab facility and procedures can be carried out to address the apparent contamination issues in the micro lab. (Status: Completed on time).\" We are unable to evaluate the adequacy of your response because you did not provide documentation to support that you have made the proposed corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, your product \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is a misbranded dietary supplement within the meaning of section 403 of the Act [21 U.S.C. § 343] because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>Your \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" product is misbranded within the meaning of section 403(q)(1)(A) of the Act (21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, the product's label declares serving size as 2. The directions state to take two (2) softgels daily divided between morning and evening, with food, or as recommended by a healthcare practitioner. Serving size should be one based on one softgel per eating occasion.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comments:\u003C\u002Fp>\n\n\u003Cp>1. During the inspection, we observed that your quality control operations did not include reviewing and approving the results of required tests as required by 21 CFR 111.110(c). For example, your laboratory Data Reviewer did not review the electronic audit trail for your analytical testing. According to your response letter, dated April 11, 2022; training was provided to include guidelines for audit trail review and are being followed. You also provided an example of what the training consisted of; however, you did not include the names of the personnel who were retained. FDA will assess this observation during the next inspection in order to determine the effectiveness of the training on personnel.\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Softgels Supplement Facts label declares \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" but only lists one ingredient, that being \u003Cstrong>(b)(4)\u003C\u002Fstrong> fruit. We note a proprietary blend refers to more than one ingredient. (21 CFR 101.36(c)].\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Human Drugs CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This section summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501 (a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response, dated March 11, 2022, and subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fp>\n\n\u003Cp>Your quality control (QC) analysts routinely recorded raw data, such as sample weights, into unofficial notebooks during release testing. Our inspection found an analyst maintained two separate notebooks recording different sample weights for the same assay test. Your analyst admitted to altering the sample weights in the approved notebook so that calculations based on those results would meet your release specifications. At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Aspire Daytime Mucus and Sinus soft gel bulk product failed to meet your firm's internal assay specification for the active ingredients. Your quality unit released these batches based on a review of inaccurate laboratory data.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you conducted an investigation, retested the \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches that were released based on falsified data, and concluded that all \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches met your firm's acceptance criteria after retesting.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your quality unit failed to conduct a comprehensive retrospective investigation to determine the extent of breaches of data integrity found during the inspection. It also lacks a root cause investigation into the original assay results failing to meet your release specification when the actual sample weights documented in the unofficial composition notebook were used for the calculation. You failed to provide scientific justification to invalidate the original unexpected results and only report the favorable results.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fp>\n\n\u003Cp>You failed to establish sufficient specifications and analytical testing procedures for critical quality attributes for the drugs that you manufacture. You lacked specifications and failed to test for the 4-aminophenol impurity in acetaminophen-containing drug products.\u003C\u002Fp>\n\n\u003Cp>For example, at least three acetaminophen-containing solid oral dosage form drug products lacked the specification and testing procedure for 4-aminophenol content.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that your drug products do not have a specific USP monograph, and therefore there was not a method for testing for impurities. You also committed to developing, validating, and implementing an analytical method to detect and quantify impurities by September 2022.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Regardless of whether a drug product has a USP monograph, you are responsible for ensuring you have scientifically sound specifications and test methods used to determine drug quality and purity prior to release. The 4-aminophenol impurity is a known impurity of acetaminophen and should be controlled and established as a condition of release of acetaminophen-containing drug products. FDA is also concerned that you plan to continue manufacturing and releasing the same drug products without testing for the 4-aminophenol impurity prior to implementing an analytical testing method. for this impurity. You have not implemented interim controls to ensure product quality and to mitigate the risk to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each batch of your drug products before a batch disposition decision, and the associated procedures, including but not limited to 4-aminophenol content for all acetaminophen containing drug products.\u003C\u002Fli>\n\t\u003Cli>An assessment to ensure complete and appropriate specifications are established for batch release and stability studies for all drug products manufactured by your firm.\u003C\u002Fli>\n\t\u003Cli>Your detailed plan for retrospective testing of all drug product batches that were insufficiently tested and remain within expiry. Determine whether each batch conforms to all appropriate specifications, including but not limited to 4-aminophenol impurity content.\u003C\u002Fli>\n\t\u003Cli>A risk assessment on marketed finished drug product batches containing acetaminophen that were not tested for the 4-aminophenol impurity.\u003C\u002Fli>\n\t\u003Cli>Interim controls established prior to completing the development, validation, and implementation of the test method to detect the 4-aminophenol impurity.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\n\n\u003Cp>During this ·inspection, FDA investigators observed that your firm performed multiple single \"trial\" injections of test samples on high performance liquid chromatography (HPLC) systems without any scientific justification.\u003C\u002Fp>\n\n\u003Cp>Your response stated that your firm's standard operating procedures (SOPs) for liquid chromatographic analysis and gas chromatographic analysis allow \"trial\" injections of the standard solution only to verify the resolution of HPLC and gas chromatography (GC) systems, and the \"trial\" injections must be a part of the sample set sequence. Your investigation report PE-22-0005 confirmed that \"trial\" injections were performed using test samples instead of standards.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. The inspection documented that your HPLC audit trail records showed that these \"trial\" injections were not part of the sample set sequence, which is contrary to the statement in your firm's response to the Form FDA 483 observations. In addition, these standalone sample \"trial\" injections were made before your official reinjections of the content uniformity samples in a sample set sequence, which is contrary to the statement in your retrospective investigation PE-22-0005.\u003C\u002Fp>\n\n\u003Cp>The injection of trial samples is not acceptable, in part, because all data from analysis of product samples must be retained and reviewed (21 CFR 211 .22, 211.165, 211.192, and 211.194). Therefore, FDA considers it a violative practice to perform a trial injection. FDA also considers it a violative practice to use an actual sample in test, preparation, or equilibration runs as a means of disguising testing into compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Reinjecting to obtain favorable results\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate documentation of all calculations and rationale for additional laboratory testing when unexpected content uniformity results for acetaminophen in batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> were obtained during a process validation study for Aspire Mucus and Pain Relief soft gel drug product. Your analyst noticed differences in the peak shapes, reinjected the samples the next day, and used favorable reinjection results to invalidate the original results. Your response indicated that the laboratory manager was informed of the unexpected test results and authorized the reinjection of the samples. However, neither the inspection nor your firm's response included evidence to support that statement.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicated that a retrospective investigation PE-22-0005 was initiated for the unexpected content uniformity results for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> in Aspire Mucus and Pain Relief soft gel process validation. Your investigation, initiated four months after the event, concluded that the initial results were invalidated because the analyst forgot to add the check standard.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your above conclusion is not supported by the chromatography data available. For example, there were two sample sets run on October 11, 2021 : the first set (without the check standard) was aborted in the middle of the run; and the second set (with the check standard) was completed and generated higher peak area counts for the two content uniformity samples. Your firm's conclusion contradicts the analyst's notebook (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) comments which attributed the higher results to the different peak shapes compared to the rest of the samples analyzed in the same sample set.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to investigate above limit results for purified water\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Our review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system audit trail report noted multiple results for total microbial testing of your purified water system were above limit. No investigation was performed. You also failed to follow your SOP MICRO009 and SOP QA025 which require an out of specification (OOS) investigation to be initiated when obtaining out of limit microbial test and purified water results, respectively. Purified water is used as one of the components in your OTC drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that your in-house testing was for information only and you sent the purified water samples to an outside testing laboratory for microbial release testing during the period of January 21, 2021, to July 9, 2021. You also stated that you suspended all internal microbiological laboratory operations until personnel and resources are in place to ensure compliance with all regulatory requirements.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Samples to your external laboratory were sent only after you obtained the in-house out of limit results.\u003C\u002Fli>\n\t\u003Cli>You lack evidence to support that a protocol was in place for the testing of your samples later claimed to be for information only.\u003C\u002Fli>\n\t\u003Cli>You failed to address the in-house test failures from September to November 2021.\u003C\u002Fli>\n\t\u003Cli>Your retrospective investigation was performed in March 2022, approximately one year after the first out of limit result was obtained.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm remains responsible for investigating all out of limit test results in a timely manner.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; &nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, - complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequately scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA's guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a consultant highly qualified in data integrity assessment to assist in your remediation. In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>1. comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003C\u002Fp>\n\n\u003Cp>a) A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\nb) Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\nc) An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility's operations in which you discovered data integrity lapses.\u003Cbr>\nd) A comprehensive retrospective evaluation of the nature of the (testing\u002Fmanufacturing\u002Fother] data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>2. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>3. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\u003C\u002Fp>\n\n\u003Cp>a) A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\nb) A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\nc) Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\nd) Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company's data.\u003Cbr>\ne) A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Compliance Officer Melissa B. Libby at U.S. Food &amp; Drug Administration, 10 Waterview Blvd., 3rd Floor, Parsippany, NJ 07054. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Melissa Libby by telephone at (973) 331-4997 or by email at melissa.libby@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Randy F. Pack\u003Cbr>\nDistrict Director\u002FProgram Division Director\u003Cbr>\nBaltimore District Office\u003Cbr>\nHuman &amp; Animal Food East, Division 2\u003Cbr>\nOffice of Regulatory Affairs\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nDr. Madhav Pai\n\nRecipient Title\n\nPresident & CEO\n\nAspire Pharmaceuticals, Inc.\n\n41 Veronica Avenue\n\nSomerset, NJ 08873-6800\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nWARNING LETTER\n\nCMS #630328\n\nNovember 22, 2022\n\nDear Dr. Pai:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) conducted a joint inspection of your dietary supplement and drug manufacturing facility, located at 37 & 41 Veronica Avenue, Somerset, NJ 08873-6800 on November 29 through 30, 2021; December 1 through 3, 6 through 9, 13 through 14, 17, 2021; and February 1 and 3, 2022. Based on our inspection and our. review of labeling collected during the inspection, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You may find the Act and the FDA's regulations through links on FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nWe received e-mail correspondences from you dated March 14, 2022, April 11, 2022, May 11, 2022, July 11, 2022, and August 11 , 2022, written in response to the Form FDA 483, lnspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\n\nDietary Supplement cGMP Violations\n\nDuring the inspection, our investigators found significant violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (cGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act (21 U.S.C. § 342(g)(1)] because the dietary supplements have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\n\nYour significant violations of the cGMP requirements are as follows:\n\n1. You failed to ensure that the tests or examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1). Specifically:\n\na. Your finished product testing uses \"(b)(4)\" as a method to verify if finished product specifications for strength have been met for your (b)(4) Softgels - lot (b)(4), (b)(4) Mini Softgels - lot (b)(4), (b)(4) Softgels - lot (b)(4), (b)(4) Softgels - lot (b)(4), and (b)(4) Formula Softgels - lot (b)(4). Finished product testing using \"(b)(4)\" is not an appropriate, scientifically valid method to verify finished product specifications.\n\ni. For your (b)(4) Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for ingredients including, but not limited to, (b)(4).\n\nii. For your (b)(4) Mini Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for each of the ingredients in the product. In addition, during the inspection, you stated that no testing for the strength of any ingredient has been conducted for this product.\n\niii. For your (b)(4) Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for the ingredients (b)(4) extract and (b)(4) extract. Your specifications for this product, dated May 20, 2021, removed a test for the strength of (b)(4), a maker in the (b)(4) extract. The previous version of your specifications, dated November 6, 2020, included a test for (b)(4) to determine the amount of (b)(4) using your method, \"MSIH-201 ,\" instead of \"(b)(4).\" During the inspection, you indicated the change to \"(b)(4)\" was at the request of the customer, as documented in your change control document dated May 18, 2021. You could not provide a basis for why removing this test and replacing it with \"(b)(4)\" would ensure the product met finished product specifications.\n\niv. For your (b)(4) Softgels product: You use \"(b)(4)\" as a method to determine whether specifications are met for the ingredients (b)(4).\n\nv. For your (b)(4) Formula Softgel product: You use \"(b)(4)\" as a method to determine whether specifications are met for the ingredients (b)(4) (standardized to (b)(4)), (b)(4) Extract, (b)(4) Paste, (b)(4) Extract, (b)(4) Oil, (b)(4) (from (b)(4)), (b)(4) Extract, (b)(4), (b)(4) Extract (standardized to (b)(4)), and (b)(4) Extract (standardized to (b)(4)).\n\nb. You use FTIR for identity testing for some of the ingredients in your dietary supplement products. Your procedure, RMA-279, \"Testing Procedure for Identification by IR in Raw Material\" requires comparison of the sample spectrum to a \"Reference Standard\u002FReference Sample or Monograph Spectrum.\" During the inspection, you informed our investigators that your firm uses a purchased reference standard if there is one commercially available. For many of the ingredients, you use a reference sample because there is no reference standard available. A reference sample is a previous lot of the material from the vendor or a sample provided from the vendor to be used as reference material. However, your laboratory does not require verification of the previous lot or that the provided material is appropriate for use as a standard. Identity testing using FTIR to compare the sample spectrum to an unverified reference sample is not an appropriate, scientifically valid method to verify that specifications are met. For example:\n\ni. (b)(4): You used FTIR for identity testing of (b)(4) lot (b)(4). During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. In addition, (b)(4) is received as a pre-blend of (b)(4) different ingredients. During the inspection, you stated that FTIR cannot determine if each of the ingredients is present in the product. Identity testing must be able to confirm the identity of each ingredient in the finished product. (b)(4) lot (b)(4) was ultimately used in the manufacturing of the finished dietary supplement (b)(4) Softgel lot (b)(4).\n\nii. (b)(4) Extract: You used FTIR for identity testing of (b)(4) Extract lot (b)(4). During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. (b)(4) lot (b)(4) was ultimately used in the manufacturing of the finished dietary supplement (b)(4) Softgel lot (b)(4).\n\niii. (b)(4) Extract: You used FTIR for identity testing of (b)(4) Extract lot (b)(4). During the inspection, you stated this was a previously received lot and there was no work done to qualify the previously received lot as a reference standard. (b)(4) Extract lot (b)(4) was ultimately used in the manufacturing of the finished dietary supplement (b)(4) lot (b)(4).\n\nc. You use the (b)(4) Test Method to test your dietary supplement products for compliance with microbial specifications. This system includes testing for:\n\nTotal aerobic plate count, procedure MICROSTP-001\n\nYeast and mold, procedure MICROSTP-002\n\nSalmonella, procedure MICROSTP-003\n\nStaphylococcus aureus, procedure MICROSTP-004\n\nEscherichia coli, procedure MICROSTP-005\n\nEnterobacteriaceae, procedure MICROSTP-006\n\nHowever, you are not conducting suitability testing to demonstrate whether these methods are appropriate for testing all of your products. According to your (b)(4) Technical Report, dated April 8, 2019, you conducted suitability testing for ten products, but not for all products. The report also determined that two of the ten products, (b)(4), required modified preparation steps for neutralization, or else the test may not provide a valid result.\n\nThe ingredients and amount of ingredients unique to individual dietary supplement products may interfere with the ability of microbial tests to provide a reliable result. Without suitability testing to demonstrate that a product does not interfere with the test, the method may not be determined to be an appropriate, scientifically valid method to verify that specifications are met.\n\nYour response dated April 11, 2022 states you will provide new documents and procedures, including Finished Product Dossiers for all the products identified during the inspection and Finished Product Specification and Report Forms. However, we are unable to evaluate the adequacy of your corrective actions because your submission did not include documentation that shows that you are implementing such corrections. For example, you provided only draft examples of your Finished Product Dossiers and Finished Product Specification and Report Forms for some of your dietary supplement products.\n\nIn addition, your response suggested exempting ingredients that do not have verification methods from finished product testing, however, you did not provide the required documentation for such exemptions. Note that, to exempt one or more product specifications from verification requirements under 21 CFR 111.75(d), you must document why any component and in-process testing, examination, or monitoring, and any other information, will ensure that such exempted product specification is met without verification through periodic testing of the finished batch, and your quality control personnel must review and approve the documentation that you provide.\n\n2. Your firm's quality control personnel failed to conduct a material review and make a disposition decision when the established specification was not met, as required by 21 CFR 111.113(a)(1).\n\nSpecifically, out of specification results were received for the following components and finished products:(b)(4) lot (b)(4), (b)(4) lot (b)(4), (b)(4) lot (b)(4) bulk softgels, (b)(4) raw material lot (b)(4), (b)(4) raw material lot (b)(4), and (b)(4) Suspension raw material lot (b)(4). For these components and finished products, your quality control unit failed to follow your procedure, \"MICRO009: Laboratory Investigation of \"Out of Specification\" Results for Microbiological Testing,\" which outlines the appropriate steps when a microbial specification is not met during testing. Your procedure states, if laboratory testing results fail to meet the specification, \"(b)(4)\" and, \"The (b)(4) (Attachment Ill).\" You did not follow your procedure to conduct and document a laboratory investigation using Attachment Ill of your procedure; rather, you retested the samples until a passing result was obtained, and then reported the passing result without conducting an investigation for the initial failing results. No material review or disposition decision was performed by your firm in these examples where the dietary supplements or components failed to meet established specifications.\n\nYour response dated April 11, 2022 states, \"Investigations and Corrective Actions are completed. All microbiological testing is currently being sent out while improvements to the micro lab facility and procedures can be carried out to address the apparent contamination issues in the micro lab. (Status: Completed on time).\" We are unable to evaluate the adequacy of your response because you did not provide documentation to support that you have made the proposed corrective actions.\n\nMisbranded Dietary Supplements\n\nIn addition, your product (b)(4), is a misbranded dietary supplement within the meaning of section 403 of the Act [21 U.S.C. § 343] because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\nYour \"(b)(4)\" product is misbranded within the meaning of section 403(q)(1)(A) of the Act (21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, the product's label declares serving size as 2. The directions state to take two (2) softgels daily divided between morning and evening, with food, or as recommended by a healthcare practitioner. Serving size should be one based on one softgel per eating occasion.\n\nWe also offer the following comments:\n\n1. During the inspection, we observed that your quality control operations did not include reviewing and approving the results of required tests as required by 21 CFR 111.110(c). For example, your laboratory Data Reviewer did not review the electronic audit trail for your analytical testing. According to your response letter, dated April 11, 2022; training was provided to include guidelines for audit trail review and are being followed. You also provided an example of what the training consisted of; however, you did not include the names of the personnel who were retained. FDA will assess this observation during the next inspection in order to determine the effectiveness of the training on personnel.\n\n2. Your (b)(4) Softgels Supplement Facts label declares \"(b)(4)\" but only lists one ingredient, that being (b)(4) fruit. We note a proprietary blend refers to more than one ingredient. (21 CFR 101.36(c)].\n\nHuman Drugs CGMP Violations\n\nThis section summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501 (a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe acknowledge receipt of your response, dated March 11, 2022, and subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nYour quality control (QC) analysts routinely recorded raw data, such as sample weights, into unofficial notebooks during release testing. Our inspection found an analyst maintained two separate notebooks recording different sample weights for the same assay test. Your analyst admitted to altering the sample weights in the approved notebook so that calculations based on those results would meet your release specifications. At least (b)(4) batches of Aspire Daytime Mucus and Sinus soft gel bulk product failed to meet your firm's internal assay specification for the active ingredients. Your quality unit released these batches based on a review of inaccurate laboratory data.\n\nIn your response, you stated that you conducted an investigation, retested the (b)(4) batches that were released based on falsified data, and concluded that all (b)(4) batches met your firm's acceptance criteria after retesting.\n\nYour response is inadequate because your quality unit failed to conduct a comprehensive retrospective investigation to determine the extent of breaches of data integrity found during the inspection. It also lacks a root cause investigation into the original assay results failing to meet your release specification when the actual sample weights documented in the unofficial composition notebook were used for the calculation. You failed to provide scientific justification to invalidate the original unexpected results and only report the favorable results.\n\nIn response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYou failed to establish sufficient specifications and analytical testing procedures for critical quality attributes for the drugs that you manufacture. You lacked specifications and failed to test for the 4-aminophenol impurity in acetaminophen-containing drug products.\n\nFor example, at least three acetaminophen-containing solid oral dosage form drug products lacked the specification and testing procedure for 4-aminophenol content.\n\nIn your response, you stated that your drug products do not have a specific USP monograph, and therefore there was not a method for testing for impurities. You also committed to developing, validating, and implementing an analytical method to detect and quantify impurities by September 2022.\n\nYour response is inadequate. Regardless of whether a drug product has a USP monograph, you are responsible for ensuring you have scientifically sound specifications and test methods used to determine drug quality and purity prior to release. The 4-aminophenol impurity is a known impurity of acetaminophen and should be controlled and established as a condition of release of acetaminophen-containing drug products. FDA is also concerned that you plan to continue manufacturing and releasing the same drug products without testing for the 4-aminophenol impurity prior to implementing an analytical testing method. for this impurity. You have not implemented interim controls to ensure product quality and to mitigate the risk to patients.\n\nIn response to this letter, provide:\n\nA list of chemical and microbial test methods and specifications used to analyze each batch of your drug products before a batch disposition decision, and the associated procedures, including but not limited to 4-aminophenol content for all acetaminophen containing drug products.\n\nAn assessment to ensure complete and appropriate specifications are established for batch release and stability studies for all drug products manufactured by your firm.\n\nYour detailed plan for retrospective testing of all drug product batches that were insufficiently tested and remain within expiry. Determine whether each batch conforms to all appropriate specifications, including but not limited to 4-aminophenol impurity content.\n\nA risk assessment on marketed finished drug product batches containing acetaminophen that were not tested for the 4-aminophenol impurity.\n\nInterim controls established prior to completing the development, validation, and implementation of the test method to detect the 4-aminophenol impurity.\n\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nDuring this ·inspection, FDA investigators observed that your firm performed multiple single \"trial\" injections of test samples on high performance liquid chromatography (HPLC) systems without any scientific justification.\n\nYour response stated that your firm's standard operating procedures (SOPs) for liquid chromatographic analysis and gas chromatographic analysis allow \"trial\" injections of the standard solution only to verify the resolution of HPLC and gas chromatography (GC) systems, and the \"trial\" injections must be a part of the sample set sequence. Your investigation report PE-22-0005 confirmed that \"trial\" injections were performed using test samples instead of standards.\n\nYour response is inadequate. The inspection documented that your HPLC audit trail records showed that these \"trial\" injections were not part of the sample set sequence, which is contrary to the statement in your firm's response to the Form FDA 483 observations. In addition, these standalone sample \"trial\" injections were made before your official reinjections of the content uniformity samples in a sample set sequence, which is contrary to the statement in your retrospective investigation PE-22-0005.\n\nThe injection of trial samples is not acceptable, in part, because all data from analysis of product samples must be retained and reviewed (21 CFR 211 .22, 211.165, 211.192, and 211.194). Therefore, FDA considers it a violative practice to perform a trial injection. FDA also considers it a violative practice to use an actual sample in test, preparation, or equilibration runs as a means of disguising testing into compliance.\n\nReinjecting to obtain favorable results\n\nYour firm lacked adequate documentation of all calculations and rationale for additional laboratory testing when unexpected content uniformity results for acetaminophen in batches (b)(4) were obtained during a process validation study for Aspire Mucus and Pain Relief soft gel drug product. Your analyst noticed differences in the peak shapes, reinjected the samples the next day, and used favorable reinjection results to invalidate the original results. Your response indicated that the laboratory manager was informed of the unexpected test results and authorized the reinjection of the samples. However, neither the inspection nor your firm's response included evidence to support that statement.\n\nIn your response, you indicated that a retrospective investigation PE-22-0005 was initiated for the unexpected content uniformity results for batch (b)(4) and (b)(4) in Aspire Mucus and Pain Relief soft gel process validation. Your investigation, initiated four months after the event, concluded that the initial results were invalidated because the analyst forgot to add the check standard.\n\nYour response is inadequate. Your above conclusion is not supported by the chromatography data available. For example, there were two sample sets run on October 11, 2021 : the first set (without the check standard) was aborted in the middle of the run; and the second set (with the check standard) was completed and generated higher peak area counts for the two content uniformity samples. Your firm's conclusion contradicts the analyst's notebook ((b)(4)) comments which attributed the higher results to the different peak shapes compared to the rest of the samples analyzed in the same sample set.\n\nFailure to investigate above limit results for purified water\n\nOur review of your (b)(4) system audit trail report noted multiple results for total microbial testing of your purified water system were above limit. No investigation was performed. You also failed to follow your SOP MICRO009 and SOP QA025 which require an out of specification (OOS) investigation to be initiated when obtaining out of limit microbial test and purified water results, respectively. Purified water is used as one of the components in your OTC drug products.\n\nIn your response, you stated that your in-house testing was for information only and you sent the purified water samples to an outside testing laboratory for microbial release testing during the period of January 21, 2021, to July 9, 2021. You also stated that you suspended all internal microbiological laboratory operations until personnel and resources are in place to ensure compliance with all regulatory requirements.\n\nYour response is inadequate:\n\nSamples to your external laboratory were sent only after you obtained the in-house out of limit results.\n\nYou lack evidence to support that a protocol was in place for the testing of your samples later claimed to be for information only.\n\nYou failed to address the in-house test failures from September to November 2021.\n\nYour retrospective investigation was performed in March 2022, approximately one year after the first out of limit result was obtained.\n\nYour firm remains responsible for investigating all out of limit test results in a timely manner.\n\nIn response to this letter, provide:\n\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, - complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA's guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain a consultant highly qualified in data integrity assessment to assist in your remediation. In response to this letter, provide the following:\n\n1. comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\na) A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\nb) Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\nc) An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility's operations in which you discovered data integrity lapses.\n\nd) A comprehensive retrospective evaluation of the nature of the (testing\u002Fmanufacturing\u002Fother] data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n2. A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n3. A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\n\na) A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\nb) A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\nc) Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding batches to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\nd) Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company's data.\n\ne) A status report for any of the above activities already underway or completed.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Compliance Officer Melissa B. Libby at U.S. Food & Drug Administration, 10 Waterview Blvd., 3rd Floor, Parsippany, NJ 07054. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have questions regarding this letter, please contact Melissa Libby by telephone at (973) 331-4997 or by email at melissa.libby@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRandy F. Pack\n\nDistrict Director\u002FProgram Division Director\n\nBaltimore District Office\n\nHuman & Animal Food East, Division 2\n\nOffice of Regulatory Affairs\n\nU.S. Food and Drug Administration","Aspire Pharmaceuticals, Inc.","aspire-pharmaceuticals-inc-630328-11222022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspire-pharmaceuticals-inc-630328-11222022","2026-10-26T08:07:58.561486+00:00","2023-04-04","630328","Division of Human and Animal Food Operations East II","Dr. Madhav Pai","2026-08-20T01:10:12.698+00:00","VIA UPS","2022-11-22",{"id":294,"raw":295,"subject":100,"body_html":299,"body_text":300,"firm_name":301,"letter_id":302,"created_at":283,"fei_number":19,"letter_url":303,"updated_at":304,"action_type":22,"case_status":23,"posted_date":305,"marcs_cms_no":306,"product_type":112,"closeout_date":19,"issuing_office":99,"recipient_name":307,"body_fetched_at":308,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":305,"medical_device_id":19,"response_letter_date":19},2490,[296,297,298,99,100,13,13,13],"\u003Ctime datetime=\"2022-08-24T19:00:00Z\">08\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-24T04:00:00Z\">08\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fka-vapes-llc-dba-kickin-ash-636133-08242022\">KA Vapes, LLC d\u002Fb\u002Fa Kickin’ Ash\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kristi Kendall\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>KA Vapes, LLC d\u002Fb\u002Fa Kickin’ Ash\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11220 South Memorial Parkway, Suite H\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huntsville\u003C\u002Fspan>, \u003Cspan>AL\u003C\u002Fspan> \u003Cspan>35803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@kickinash.biz\"> contact@kickinash.biz\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 24, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Kendall:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that KA Vapes, LLC d\u002Fb\u002Fa Kickin’ Ash manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, this product is required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Kickin’ Ash Friendzone 12mg\u002F30ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200621, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nKristi Kendall\n\nRecipient Title\n\nOwner\n\nKA Vapes, LLC d\u002Fb\u002Fa Kickin’ Ash\n\n11220 South Memorial Parkway, Suite H\n\nHuntsville, AL 35803\n\nUnited States\n\ncontact@kickinash.biz\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 24, 2022\n\nWARNING LETTER\n\nDear Ms. Kendall:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that KA Vapes, LLC d\u002Fb\u002Fa Kickin’ Ash manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, this product is required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Kickin’ Ash Friendzone 12mg\u002F30ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200621, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","KA Vapes, LLC d\u002Fb\u002Fa Kickin’ Ash","ka-vapes-llc-dba-kickin-ash-636133-08242022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fka-vapes-llc-dba-kickin-ash-636133-08242022","2026-10-26T08:09:07.309301+00:00","2022-08-24","636133","Kristi Kendall","2026-08-20T01:38:05.923+00:00",{"id":310,"raw":311,"subject":315,"body_html":316,"body_text":317,"firm_name":318,"letter_id":319,"created_at":18,"fei_number":19,"letter_url":320,"updated_at":321,"action_type":22,"case_status":23,"posted_date":322,"marcs_cms_no":323,"product_type":134,"closeout_date":19,"issuing_office":123,"recipient_name":324,"body_fetched_at":325,"delivery_method":326,"recipient_title":19,"reference_number":327,"action_taken_date":328,"medical_device_id":19,"response_letter_date":19},1001,[312,313,314,123,315,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-24T05:00:00Z\">02\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-pharmacare-holdings-limited-701671-02242025\">Aspen Pharmacare Holdings Limited\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-46\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Stephen Saad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group Chief Executive  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aspen Pharmacare Holdings Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9 Rydall Vale Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Douglas Saunders Drive, La Lucia Ridge\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Durban\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>KwaZulu-Natal\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>4051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Africa\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:SSaad@aspenpharma\"> SSaad@aspenpharma\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-46\u003C\u002Fp>\u003Cp>February 24, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Saad:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aspen SA Sterile Operations (Pty) Ltd. (an Aspen Pharmacare Holdings Limited subsidiary), FEI 3007490529, at 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020, from September 9 to 17, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 8, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not establish appropriate specifications or test your sterile over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products to monitor impurities at release and throughout expiry. For example:\u003C\u002Fp>\u003Cul>\u003Cli>You did not perform impurity testing prior to release and during stability for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>You did not establish scientifically justified specifications to monitor impurities during stability testing of drug products containing Naphazoline Hydrochloride or Tetrahydrozoline Hydrochloride active pharmaceutical ingredient (API).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that the impurity limits were established based on your customer’s requirements and that no limits were included for release testing. You provide your customer’s health hazard evaluation (HHE) which concluded that the presence of Impurity \u003Cstrong>(b)(4)\u003C\u002Fstrong> at stability levels of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>% of the labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> content would not pose any safety risk for those that use the products according to directions. The Agency disagrees with the HHE assessment and concludes that the presence of impurity levels at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% may pose a risk to patient safety at the recommended dosage. It is your responsibility to ensure that appropriate specifications are established to monitor impurities throughout the expiry period.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack adequate scientific rationale for the current impurity specifications of your drug products. A similar deficiency for the lack of impurity specifications for release and stability testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> API containing products was also identified during the 2016 inspection. However, this deficiency has not been fully addressed to date. Additionally, your risk assessment does not include an evaluation of reserve samples of potentially impacted product batches distributed to the United States.\u003C\u002Fp>\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity prior to release. Insufficient release and stability testing to appropriately detect impurities in your drug products could potentially impact product quality and patient safety.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Degradation study protocols and reports for your drug products, which should include impurities that will be monitored throughout the product life cycle as well as your scientific justification for the acceptance criteria and study design.\u003C\u002Fli>\u003Cli>A list of current and revised specifications for release and stability testing, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Practices\u003C\u002Fem>\u003C\u002Fp>\u003Cp>During the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. These poor practices included, but were not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Operators blocked first air by placing their gloved hands directly over open sterilized bottles without clearing them from the aseptic filling line.\u003C\u002Fli>\u003Cli>Operators used their gloved hands instead of using appropriate sterile tools to remove jammed bottles.\u003C\u002Fli>\u003Cli>Operator movements in the critical areas were not always slow and deliberate.\u003C\u002Fli>\u003Cli>Operators used goggles that had numerous open holes and therefore had exposed skin during line set-up and aseptic processing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In 2022, your firm identified contamination in two media fill batches one on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line and another on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line. You identified the root cause as poor aseptic behavior. These contamination events along with the poor aseptic practices observed during our inspection indicate your aseptic manufacturing operations may lack adequate control. Your firm did not perform a sufficiently comprehensive evaluation of aseptic behavior of operators as part of this recurrent trend.\u003C\u002Fp>\u003Cp>We also note that open door interventions required a large door to be opened. On numerous occasions, the door remained opened for extended periods of time while the line was still in-operation. When opened, the door was exposed to the ISO 7 area, and when being closed, there was a significant risk of the lower quality room air sweeping into the ISO 5 aseptic processing area. Empty sterile containers were located extremely close to the door. In addition, operators did not adequately disinfect the open door. While spraying disinfectant on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, operators failed to consider open sterilized bottles on the line, exposing them to potential contamination.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Smoke Studies and Cleanroom Design\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your smoke studies did not adequately demonstrate unidirectional air flow in the ISO 5 classified areas used for the aseptic filling of ophthalmic drug products on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling lines. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your smoke studies lacked simulation of aseptic line set-up, dynamic operations, and interventions that occur during aseptic manufacturing operations.\u003C\u002Fli>\u003Cli>Generation of smoke was not sufficient to demonstrate unidirectional air flow.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We also note that there were multiple aspects of your cleanroom and aseptic processing line design which represented fundamental contamination risks:\u003C\u002Fp>\u003Cul>\u003Cli>There was no physical barrier between the operator and the open \u003Cstrong>(b)(4)\u003C\u002Fstrong>-sterilized bottles on the conveyor. Your production operator remained inside the ISO 5 aseptic processing area, sitting or standing next to the conveyor line where open, exposed bottles pass.\u003C\u002Fli>\u003Cli>There were extensive manual interactions with the aseptic processing line and its exposed sterile drug product and containers\u002Fclosures.\u003C\u002Fli>\u003Cli>Operators performed multiple manual interventions during filling by \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> not being installed on these \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These interventions may pose inherent risks to your aseptic processes.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The ISO 5 area is critical because sterile product is exposed and therefore vulnerable to contamination. Your aseptic filling process should be designed, and operations executed, to prevent contamination hazards to your sterile product. The flawed design of the filling line and execution of the aseptic operations promote influx of contamination into the critical filling areas.\u003C\u002Fp>\u003Cp>In your response, you indicate that you temporarily suspended manufacturing on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line. You acknowledge that the design of your aseptic filling lines is not optimal and indicate that an independent review of your design and remediation plans for both “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling lines will be performed. You also commit to perform new smoke studies under static and dynamic conditions and evaluate associated risks. You indicate that you have engaged a third-party consultant to assist in improving aseptic practices.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not sufficiently address the lack of oversight of aseptic behavior of operators. Further, you do not adequately investigate poor aseptic practices to determine the impact on sterile drug products manufactured and aseptic processing areas. You also do not clearly specify how you will improve your smoke studies, including what interventions will be included, and how you will address potential deficiencies.\u003C\u002Fp>\u003Cp>For additional guidance on aseptic processing see FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fli>\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and suitability, including ergonomics for each human interaction.\u003Cbr>o Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\u003Cbr>o Reduction or elimination of aseptic manipulations and connections (e.g., replacing post-filtration aseptic connections with sterilize-in-place system)\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Smoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your Production and QU did not review electronic raw data and audit trails to ensure data integrity prior to batch release. Your operators obtained and printed a passing result after multiple production filter integrity tests failed. Your operators did not record or print the failing results. For example:\u003C\u002Fp>\u003Cul>\u003Cli>On August 8, 2024, two operators performed four post-use sterilizing filter integrity tests for \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The four tests included three failing results and the final passing result. Your operators only reported the passing result.\u003C\u002Fli>\u003Cli>On July 25, 2024, two operators performed nine filter integrity tests associated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, bulk batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The nine tests included five failing results, three aborted tests, and the final passing result. Your operators only reported the passing result.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you acknowledge the deficiency and commit to perform a full audit trail review of your production equipment. You also indicate that you are completing the investigations into anomalous filter integrity tests.\u003C\u002Fp>\u003Cp>Your response is inadequate as you do not provide details of the investigation outcome or explain whether effective corrective actions and preventive actions (CAPAs) have been implemented. Further, you do not provide the scope and time period of the retrospective review to ensure all batches potentially affected are part of the assessment.\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003Cbr>o A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>o A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including manufacturing records.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Ensure that appropriate procedures are in place regarding the review of all critical electronic data (e.g., filter integrity testing).\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You did not establish an adequate system for monitoring environmental conditions on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ aseptic filling line. For example:\u003C\u002Fp>\u003Cul>\u003Cli>You did not conduct viable monitoring of the air and surfaces in ISO 5 areas where an operator was continuously present removing fallen bottles.\u003C\u002Fli>\u003Cli>You did not place the non-viable particle monitoring (NVPM) probes in representative ISO 5 areas where the product and primary components were exposed. Our investigators noted the following:\u003Cbr>o The NVPM probe closest to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was located approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> above the level of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o The NVPM probe nearest to the sterile cap \u003Cstrong>(b)(4)\u003C\u002Fstrong> was located approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> above the level of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Your operators routinely placed mobile NVPM devices in locations different from those specified in your procedures to monitor the ISO 5 areas. As such, NVPM data may not accurately represent the critical areas in operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to upgrade your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” aseptic filling line and perform a Quality Risk Assessment for NVPM in Suite \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. While you commit to conducting a Quality Risk Assessment for NVPM to identify, assess, and mitigate all gaps, you have not provided any updates on the status of risk assessment. Vigilant and responsive environmental monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A thorough, independent assessment, and CAPA for your environmental monitoring program. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention, and overall environmental control in your assessment.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>An independent, retrospective evaluation of all ISO 5 NVPM deviations, root causes, and a relevant CAPA plan.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. You are responsible for ensuring consultants you use are qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements and to correct repeat violations. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs for the U.S. market.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert (IA) 66-40 on February 10, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Aspen SA Sterile Operations (Pty) Ltd., 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020 into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. We request you email CDER-OC-OMQ-Communications@fda.hhs.gov, within 5 days of receipt of this letter to schedule a regulatory meeting.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007490529 and ATTN: Anita Narula, Ph.D.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-46\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Stephen Saad\n\nRecipient Title\n\nGroup Chief Executive\n\nAspen Pharmacare Holdings Limited\n\n9 Rydall Vale Park\n\nDouglas Saunders Drive, La Lucia Ridge\n\nDurban\n\nKwaZulu-Natal\n\n4051\n\nSouth Africa\n\nSSaad@aspenpharma\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-46\nFebruary 24, 2025\nDear Mr. Saad:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aspen SA Sterile Operations (Pty) Ltd. (an Aspen Pharmacare Holdings Limited subsidiary), FEI 3007490529, at 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020, from September 9 to 17, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 8, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour firm did not establish appropriate specifications or test your sterile over-the-counter (OTC) (b)(4) drug products to monitor impurities at release and throughout expiry. For example:\nYou did not perform impurity testing prior to release and during stability for (b)(4).\nYou did not establish scientifically justified specifications to monitor impurities during stability testing of drug products containing Naphazoline Hydrochloride or Tetrahydrozoline Hydrochloride active pharmaceutical ingredient (API).\nIn your response, you state that the impurity limits were established based on your customer’s requirements and that no limits were included for release testing. You provide your customer’s health hazard evaluation (HHE) which concluded that the presence of Impurity (b)(4) at stability levels of up to (b)(4)% of the labeled (b)(4) content would not pose any safety risk for those that use the products according to directions. The Agency disagrees with the HHE assessment and concludes that the presence of impurity levels at (b)(4)% may pose a risk to patient safety at the recommended dosage. It is your responsibility to ensure that appropriate specifications are established to monitor impurities throughout the expiry period.\nYour response is inadequate. You lack adequate scientific rationale for the current impurity specifications of your drug products. A similar deficiency for the lack of impurity specifications for release and stability testing for (b)(4) API containing products was also identified during the 2016 inspection. However, this deficiency has not been fully addressed to date. Additionally, your risk assessment does not include an evaluation of reserve samples of potentially impacted product batches distributed to the United States.\nDrug product batches must be tested for identity, strength, quality, and purity prior to release. Insufficient release and stability testing to appropriately detect impurities in your drug products could potentially impact product quality and patient safety.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nDegradation study protocols and reports for your drug products, which should include impurities that will be monitored throughout the product life cycle as well as your scientific justification for the acceptance criteria and study design.\nA list of current and revised specifications for release and stability testing, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nPoor Aseptic Practices\nDuring the inspection of your facility, we observed poor practices and behaviors in ISO 5 areas during the manufacturing of sterile (b)(4) drug products. These poor practices included, but were not limited to:\nOperators blocked first air by placing their gloved hands directly over open sterilized bottles without clearing them from the aseptic filling line.\nOperators used their gloved hands instead of using appropriate sterile tools to remove jammed bottles.\nOperator movements in the critical areas were not always slow and deliberate.\nOperators used goggles that had numerous open holes and therefore had exposed skin during line set-up and aseptic processing.\nIn 2022, your firm identified contamination in two media fill batches one on the “(b)(4)” aseptic filling line and another on the “(b)(4)” aseptic filling line. You identified the root cause as poor aseptic behavior. These contamination events along with the poor aseptic practices observed during our inspection indicate your aseptic manufacturing operations may lack adequate control. Your firm did not perform a sufficiently comprehensive evaluation of aseptic behavior of operators as part of this recurrent trend.\nWe also note that open door interventions required a large door to be opened. On numerous occasions, the door remained opened for extended periods of time while the line was still in-operation. When opened, the door was exposed to the ISO 7 area, and when being closed, there was a significant risk of the lower quality room air sweeping into the ISO 5 aseptic processing area. Empty sterile containers were located extremely close to the door. In addition, operators did not adequately disinfect the open door. While spraying disinfectant on the (b)(4), operators failed to consider open sterilized bottles on the line, exposing them to potential contamination.\nInadequate Smoke Studies and Cleanroom Design\nYour smoke studies did not adequately demonstrate unidirectional air flow in the ISO 5 classified areas used for the aseptic filling of ophthalmic drug products on the “(b)(4)” and “(b)(4)” aseptic filling lines. For example:\nYour smoke studies lacked simulation of aseptic line set-up, dynamic operations, and interventions that occur during aseptic manufacturing operations.\nGeneration of smoke was not sufficient to demonstrate unidirectional air flow.\nWe also note that there were multiple aspects of your cleanroom and aseptic processing line design which represented fundamental contamination risks:\nThere was no physical barrier between the operator and the open (b)(4)-sterilized bottles on the conveyor. Your production operator remained inside the ISO 5 aseptic processing area, sitting or standing next to the conveyor line where open, exposed bottles pass.\nThere were extensive manual interactions with the aseptic processing line and its exposed sterile drug product and containers\u002Fclosures.\nOperators performed multiple manual interventions during filling by (b)(4) or (b)(4) due to (b)(4) not being installed on these (b)(4). These interventions may pose inherent risks to your aseptic processes.\nThe ISO 5 area is critical because sterile product is exposed and therefore vulnerable to contamination. Your aseptic filling process should be designed, and operations executed, to prevent contamination hazards to your sterile product. The flawed design of the filling line and execution of the aseptic operations promote influx of contamination into the critical filling areas.\nIn your response, you indicate that you temporarily suspended manufacturing on the “(b)(4)” aseptic filling line. You acknowledge that the design of your aseptic filling lines is not optimal and indicate that an independent review of your design and remediation plans for both “(b)(4)” and “(b)(4)” aseptic filling lines will be performed. You also commit to perform new smoke studies under static and dynamic conditions and evaluate associated risks. You indicate that you have engaged a third-party consultant to assist in improving aseptic practices.\nYour response is inadequate because it does not sufficiently address the lack of oversight of aseptic behavior of operators. Further, you do not adequately investigate poor aseptic practices to determine the impact on sterile drug products manufactured and aseptic processing areas. You also do not clearly specify how you will improve your smoke studies, including what interventions will be included, and how you will address potential deficiencies.\nFor additional guidance on aseptic processing see FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support operations.\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and suitability, including ergonomics for each human interaction.\no Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\no Reduction or elimination of aseptic manipulations and connections (e.g., replacing post-filtration aseptic connections with sterilize-in-place system)\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nSmoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\n3. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\nYour Production and QU did not review electronic raw data and audit trails to ensure data integrity prior to batch release. Your operators obtained and printed a passing result after multiple production filter integrity tests failed. Your operators did not record or print the failing results. For example:\nOn August 8, 2024, two operators performed four post-use sterilizing filter integrity tests for (b)(4) batch (b)(4). The four tests included three failing results and the final passing result. Your operators only reported the passing result.\nOn July 25, 2024, two operators performed nine filter integrity tests associated with (b)(4), bulk batch (b)(4). The nine tests included five failing results, three aborted tests, and the final passing result. Your operators only reported the passing result.\nIn your response, you acknowledge the deficiency and commit to perform a full audit trail review of your production equipment. You also indicate that you are completing the investigations into anomalous filter integrity tests.\nYour response is inadequate as you do not provide details of the investigation outcome or explain whether effective corrective actions and preventive actions (CAPAs) have been implemented. Further, you do not provide the scope and time period of the retrospective review to ensure all batches potentially affected are part of the assessment.\nSee FDA’s guidance document, Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97005\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\no A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\no A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including manufacturing records.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Ensure that appropriate procedures are in place regarding the review of all critical electronic data (e.g., filter integrity testing).\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\nYou did not establish an adequate system for monitoring environmental conditions on the “(b)(4)’ aseptic filling line. For example:\nYou did not conduct viable monitoring of the air and surfaces in ISO 5 areas where an operator was continuously present removing fallen bottles.\nYou did not place the non-viable particle monitoring (NVPM) probes in representative ISO 5 areas where the product and primary components were exposed. Our investigators noted the following:\no The NVPM probe closest to the (b)(4) was located approximately (b)(4) above the level of the (b)(4).\no The NVPM probe nearest to the sterile cap (b)(4) was located approximately (b)(4) above the level of the (b)(4).\nYour operators routinely placed mobile NVPM devices in locations different from those specified in your procedures to monitor the ISO 5 areas. As such, NVPM data may not accurately represent the critical areas in operation.\nIn your response, you commit to upgrade your “(b)(4)” aseptic filling line and perform a Quality Risk Assessment for NVPM in Suite (b)(4).\nYour response is inadequate. While you commit to conducting a Quality Risk Assessment for NVPM to identify, assess, and mitigate all gaps, you have not provided any updates on the status of risk assessment. Vigilant and responsive environmental monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment. Operations that include highly manually intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to, heightened emphasis on well-timed sampling to appropriately monitor batch manufacturing conditions.\nIn response to this letter, provide:\nA thorough, independent assessment, and CAPA for your environmental monitoring program. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention, and overall environmental control in your assessment.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nAn independent, retrospective evaluation of all ISO 5 NVPM deviations, root causes, and a relevant CAPA plan.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nCGMP Consultant Recommended\nWe acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. You are responsible for ensuring consultants you use are qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements and to correct repeat violations. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all drugs for the U.S. market.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed products offered for import into the United States from your firm on Import Alert (IA) 66-40 on February 10, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Aspen SA Sterile Operations (Pty) Ltd., 8B Gibaud Road, Kortsen, Gqeberha, South Africa 6020 into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. We request you email CDER-OC-OMQ-Communications@fda.hhs.gov, within 5 days of receipt of this letter to schedule a regulatory meeting.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007490529 and ATTN: Anita Narula, Ph.D.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Aspen Pharmacare Holdings Limited","aspen-pharmacare-holdings-limited-701671-02242025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-pharmacare-holdings-limited-701671-02242025","2026-10-26T08:07:58.529819+00:00","2025-03-18","701671","Mr. Stephen Saad","2026-08-19T16:56:02.725+00:00","VIA EMAIL WITH READ RECEIPT","320-25-46","2025-02-24",{"id":330,"raw":331,"subject":335,"body_html":336,"body_text":337,"firm_name":338,"letter_id":339,"created_at":43,"fei_number":19,"letter_url":340,"updated_at":341,"action_type":22,"case_status":23,"posted_date":342,"marcs_cms_no":19,"product_type":343,"closeout_date":19,"issuing_office":123,"recipient_name":344,"body_fetched_at":345,"delivery_method":291,"recipient_title":19,"reference_number":346,"action_taken_date":347,"medical_device_id":19,"response_letter_date":19},115,[332,333,334,123,335,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fasanuma-corporation-721136-sagamihara-factory\">Asanuma Corporation - Sagamihara Factory \u003C\u002Fa>","CGMP\u002FOTC Finished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-84\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Hiroshi Saito\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager Quality Assurance Department  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Asanuma Corporation - Sagamihara Factory \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Chome 14-41\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nishihashimoto, Midori\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sagamihara\u003C\u002Fspan>, \u003Cspan>Kanagawa\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-84\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Saito:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 25, 2025, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Asanuma Corporation - Sagamihara Factory, FEI 3010960168, at 1 Chome 14-41, Nishihashimoto, Midori, Sagamihara, Kanagawa, as well as subsequent correspondence.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product labeled to contain the active drug ingredients \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This drug product is also labeled and formulated to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\u003C\u002Fp>\u003Cp>You have not demonstrated that you appropriately tested incoming talc drug components used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you indicate that you did not perform testing for asbestos in talc, and our review found that you do not conduct identity testing on talc prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>You also failed to provide records indicating that you established the reliability of your supplier’s analyses through appropriate validation of the supplier’s test results. Although 21 CFR 211.84(d)(2) provides for some reliance on a certificate of analysis (COA) from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Identity, assay and impurity test results from testing retains for all lots of talc (drug component) used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate written specifications for identity, purity, strength, and quality. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A gap analysis for specifications for drug components (active and inactive) between your current specifications and test procedures against the United States Pharmacopeia (USP), where applicable. Based on your gap analysis, provide a comprehensive plan for conformance of your drug component specifications and testing to USP standards, where applicable.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current USP talc monograph could be used to meet this requirement for talc; however, specifications for your talc components failed to include testing for identification, assay, and multiple impurities (e.g., limits of \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Notably, you failed to have a specification that includes a test for the absence of asbestos and your current specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong> in talc of \u003Cstrong>(b)(4)\u003C\u002Fstrong> parts per million (ppm) exceeds the USP limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003C\u002Fli>\u003Cli>A complete and final review of representative batches within expiry and their related information before the QU disposition decision\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Specifications Regarding Talc\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Talc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&amp;C Act. FDA reviewed your specifications for talc components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in June 2026.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on January 9, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Asanuma Corporation - Sagamihara Factory, 1 Chome 14-41, Nishihashimoto, Midori, Sagamihara, Kanagawa into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010960168 and ATTN: Nancy Espinal.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cstrong>2\u003C\u002Fstrong> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-84\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Hiroshi Saito\n\nRecipient Title\n\nGeneral Manager Quality Assurance Department\n\nAsanuma Corporation - Sagamihara Factory\n\n1 Chome 14-41\n\nNishihashimoto, Midori\n\nSagamihara, Kanagawa\n\nJapan\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-84\nJune 2, 2026\nDear Mr. Saito:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 25, 2025, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Asanuma Corporation - Sagamihara Factory, FEI 3010960168, at 1 Chome 14-41, Nishihashimoto, Midori, Sagamihara, Kanagawa, as well as subsequent correspondence.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\nYour firm manufactures (b)(4), an OTC (b)(4) drug product labeled to contain the active drug ingredients (b)(4). This drug product is also labeled and formulated to contain the inactive ingredient talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Your (b)(4) drug product, (b)(4), is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation.\nYou have not demonstrated that you appropriately tested incoming talc drug components used in the manufacture of your (b)(4) drug products for identity, purity, strength, and quality. In response to our 704(a)(4) request, you indicate that you did not perform testing for asbestos in talc, and our review found that you do not conduct identity testing on talc prior to use in the manufacture of your drug products.\nYou also failed to provide records indicating that you established the reliability of your supplier’s analyses through appropriate validation of the supplier’s test results. Although 21 CFR 211.84(d)(2) provides for some reliance on a certificate of analysis (COA) from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nIdentity, assay and impurity test results from testing retains for all lots of talc (drug component) used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\nA description of how you will test each component lot for conformity with all appropriate written specifications for identity, purity, strength, and quality. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nThe chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\nA gap analysis for specifications for drug components (active and inactive) between your current specifications and test procedures against the United States Pharmacopeia (USP), where applicable. Based on your gap analysis, provide a comprehensive plan for conformance of your drug component specifications and testing to USP standards, where applicable.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that your test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). The current USP talc monograph could be used to meet this requirement for talc; however, specifications for your talc components failed to include testing for identification, assay, and multiple impurities (e.g., limits of (b)(4)). Notably, you failed to have a specification that includes a test for the absence of asbestos and your current specification for (b)(4) in talc of (b)(4) parts per million (ppm) exceeds the USP limit of (b)(4)ppm. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\nA complete and final review of representative batches within expiry and their related information before the QU disposition decision\nQuality Specifications Regarding Talc\nTalc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&C Act. FDA reviewed your specifications for talc components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in June 2026.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on January 9, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Asanuma Corporation - Sagamihara Factory, 1 Chome 14-41, Nishihashimoto, Midori, Sagamihara, Kanagawa into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010960168 and ATTN: Nancy Espinal.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n__________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F","Asanuma Corporation - Sagamihara Factory","asanuma-corporation-721136-sagamihara-factory","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fasanuma-corporation-721136-sagamihara-factory","2026-10-26T08:07:58.203675+00:00","2026-06-09","Drugs Over-the-Counter Drugs","Mr. Hiroshi Saito","2026-08-19T04:37:22.155+00:00","320-26-84","2026-06-02",{"id":349,"raw":350,"subject":81,"body_html":355,"body_text":356,"firm_name":357,"letter_id":358,"created_at":129,"fei_number":19,"letter_url":359,"updated_at":360,"action_type":22,"case_status":23,"posted_date":361,"marcs_cms_no":362,"product_type":26,"closeout_date":19,"issuing_office":59,"recipient_name":363,"body_fetched_at":364,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":365,"medical_device_id":19,"response_letter_date":19},565,[351,352,353,59,354,13,13,13],"\u003Ctime datetime=\"2025-09-30T04:00:00Z\">09\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-21T04:00:00Z\">08\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnestor-reyes-farm-associates-701874-08212025\">Nestor Reyes Farm &amp; Associates\u003C\u002Fa>","PHS Act\u002FShell Egg Regulation\u002FAdulterated ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nestor E. Reyes del Valle\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nestor Reyes Farm &amp; Associates\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Rd. 956, Km 10.0, Bo. Guzman Arriba\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rio Grande\u003C\u002Fspan> \u003Cspan>00745\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Puerto Rico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 21, 2025\u003C\u002Fp>\u003Cp>CMS #701874\u003C\u002Fp>\u003Cp>Dear Mr. Nestor E. Reyes del Valle:\u003C\u002Fp>\u003Cp>On November 13-15 &amp; 19, 2024, and December 6, 2024, the United States Food and Drug Administration (FDA) conducted an inspection of your shell egg farm and egg processing facility, where your shell eggs are washed and packed, located at Rd. 956, Km 10.0, Bo. Guzman Arriba, Rio Grande, PR 00745. During the inspection of your farm, FDA investigators observed serious violations of the Prevention of Salmonella Enteritidis (SE) in Shell Eggs During Production, Storage, and Transportation regulation (the Shell Egg regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118). At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your farm.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings, we have determined that the shell eggs produced on your farm do not comply with the provisions of 21 CFR Part 118. Failure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the FD&amp;C Act, the PHS Act and the Shell Egg regulation through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>We received your response to the FDA-483 via email on December 20, 2024, which described corrective actions taken or planned by your farm. Based on our review of the inspectional findings and your response, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your farm.\u003C\u002Fp>\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\u003Cp>\u003Cu>Shell Egg Regulation (21 CFR Part 118)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>1. You did not have and implement a written SE Prevention Plan that includes, at a minimum, the SE prevention measures required by 21 CFR 118.4. You did not have a written SE Prevention Plan for the approximate \u003Cstrong>(b)(4)\u003C\u002Fstrong> layers on your farm. Your written response stated that an SE Prevention Plan would be finalized between December 2024 and January 2025. To date, we have not received a written SE Prevention Plan. You are required to have an SE Prevention Plan that includes, at a minimum, the SE prevention measures outlined in 21 CFR 118.4 (a) – (e), which include:\u003C\u002Fp>\u003Cp>a. \u003Cu>Pullets\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, the required SE prevention measures relating to pullets. Under 21 CFR 118.4(a), these measures include procuring pullets that are SE monitored or raising pullets under SE monitored conditions. Under 21 CFR 118.4(a)(1), “SE monitored” means that chicks are procured from SE-monitored breeder flocks that meet the National Poultry Improvement Plan’s (NPIP) standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard. Under 21 CFR 118.4(a)(2), “SE monitored” also means that the pullet environment is tested for SE when pullets are 14-16 weeks of age.\u003C\u002Fp>\u003Cp>Your farm received a primary flock of \u003Cstrong>(b)(4)\u003C\u002Fstrong> chicks on April 30, 2024, followed by a secondary flock of \u003Cstrong>(b)(4)\u003C\u002Fstrong> chicks on May 7, 2024. We acknowledge you provided a NPIP Form for the flock of chicks you procured from your supplier on May 7, 2024, but you did not provide documentation for the chicks received on or around April 30, 2024. Furthermore, you did not conduct the required SE environmental test for both flocks at 14-to-16 weeks of age, as required by 21 CFR 118.4(a)(2)(i).\u003C\u002Fp>\u003Cp>Your written response stated that you will schedule for future flocks to be tested for SE between 14-16 weeks of age by a licensed professional. However, as discussed above, we have not received a written SE Prevention Plan that describes these measures. We also note that your written response stated, as part of your firm’s corrective actions, that FDA swabbed poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong> on November 19, 2024, with subsequent negative results. The layers were approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> weeks of age when FDA conducted this sampling. This does not constitute a corrective action and should not be viewed as suc\u003Ca>h.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>b. \u003Cu>Biosecurity\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, the required SE prevention measures relating to biosecurity, as stated in 21 CFR 118.4(b). That provision requires you to take steps to ensure that there is no introduction or transfer of SE into or among poultry houses. These biosecurity measures must include, at a minimum:\u003C\u002Fp>\u003Cul>\u003Cli>Limiting visitors on the farm and in the poultry houses (21 CFR 118.4(b)(1));\u003C\u002Fli>\u003Cli>Maintaining practices that will protect against cross contamination when equipment is moved among poultry houses (21 CFR 118.4(b)(2));\u003C\u002Fli>\u003Cli>Maintaining practices that will protect against cross contamination when persons move between poultry houses (21 CFR 118.4(b)(3));\u003C\u002Fli>\u003Cli>Preventing stray poultry, wild birds, cats, and other animals from entering poultry houses (21 CFR 118.4(b)(4)); and\u003C\u002Fli>\u003Cli>Not allowing employees to keep birds at home (21 CFR 118.4(b)(5)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>As discussed above, you did not have a written SE Prevention Plan to address these measures. Furthermore, visitors’ access to the facility was not limited and, despite your indication on November 13, 2024, that individuals enter the facility to pick up or distribute eggs every other day, our investigators identified August 20, 2024, as the last date a pickup was registered in your entry log. Additionally, for poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA investigators observed there was no entry door to limit access and the house had damaged or missing netting and gaps within the cement structure. Numerous wild birds located inside the poultry house above layers in cages, in walkways, and eating directly from feed trays. Wild birds were also observed in the manure pits, and along the perimeter of your exposed house. Furthermore, cats and several species of reptiles were also observed in the manure pit and surrounding the poultry house.\u003C\u002Fp>\u003Cp>We acknowledge your written response, in which you state you are now restricting visitor access to the farm through signs, and that you have implemented a visitor log and provided employee training. You also described how you will prevent stray animals from entering the poultry houses by adding physical barriers. You state your poultry houses are under construction, which you expect to be completed by June 2025. However, your written response lacks supporting detail to further assess how you will implement these corrective actions and practices. Additionally, you did not provide an SE Prevention Plan to describe any biosecurity steps.\u003C\u002Fp>\u003Cp>c. \u003Cu>Rodents, Flies, and Other Pest Control\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, the required rodent, fly, and other pest control measures as stated in 21 CFR 118.4(c). As discussed above, you did not have a written SE Prevention Plan to address these measures. Furthermore, you were not monitoring for the presence of rodents and flies by appropriate monitoring methods, as required by 21 CFR 118.4(c)(1) and 21 CFR 118.4(c)(2), nor did you remove debris within a poultry house and vegetation and debris outside the poultry house that may provide harborage for pests, as required by 21 CFR 118.4(c)(3).\u003C\u002Fp>\u003Cp>Specifically, for rodents, you stated you receive monthly services by a subcontractor; however, there were no pest control records available for review. Additionally, FDA investigators observed multiple rodent bait stations for poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were broken and\u002For did not contain bait. For flies, you did not have any monitoring or control measures in place, and FDA investigators also observed flies too numerous to count inside the poultry house that were in direct contact with hens, eggs, and chicken feed. Furthermore, FDA investigators observed harborage for pests in and outside of your poultry house. This included excessive amounts of accumulated trash and debris, stagnant water, piles of broken eggs, and spilled chicken feed. Also, multiple deceased layers were observed inside poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with two of the deceased birds having their heads in direct contact with the egg belt, causing the eggs to get jammed.\u003C\u002Fp>\u003Cp>Your written response acknowledged that rodents were not being monitored appropriately and stated that the rodent monitoring and bait stations have been installed and updated, more rodent bait stations have been added around buildings, professional pest control services have been engaged, and that you have cleaned and removed debris that may attract rodents. Furthermore, your response acknowledged that the presence of flies was not being appropriately monitored and stated that fly monitoring systems have been updated. Additionally, you stated potential pest harborage sites inside and outside the poultry houses have been eliminated. However, your response did not provide an SE Prevention Plan or provide supporting details to assess whether the corrective actions were adequate. Please note that in addition to describing appropriate monitoring methods for rodents and flies, a written SE Prevention Plan must also address the requirement that when monitoring indicates unacceptable rodent or fly activity within a poultry house, you must use appropriate methods to achieve satisfactory rodent\u002Ffly control.\u003C\u002Fp>\u003Cp>d. \u003Cu>Cleaning and Disinfection\u003C\u002Fu>\u003Cbr>A written SE Prevention Plan must include, among other things, cleaning and disinfection procedures for the poultry house, as stated in 21 CFR 118.4(d). You must clean and disinfect the poultry house according to these procedures before new laying hens are added to the house, if you have had an environmental test or an egg test that was positive for SE at any point during the life of a flock that was housed in the poultry house prior to depopulation.\u003C\u002Fp>\u003Cp>As discussed above, you did not have a written SE Prevention Plan. Your written response states that you are developing a written SE Prevention Plan that will include, among other things, cleaning and disinfection protocols. However, as discussed above, you still have not provided a written SE Prevention Plan.\u003C\u002Fp>\u003Cp>e. \u003Cu>Refrigeration\u003C\u002Fu>\u003Cbr>You did not hold eggs at or below 45°F ambient temperature beginning 36 hours after time of lay, nor do you have a written SE Prevention Plan including these refrigeration requirements, as required by 21 CFR 118.4(e). For example:\u003C\u002Fp>\u003Cul>\u003Cli>On November 14, 2024, your two analog thermometers located at the back and entrance of the cooler read \u003Cstrong>(b)(4)\u003C\u002Fstrong>°-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F, while FDA’s calibrated thermometer read 52°-58°F. On November 14, 2024, the same two analog thermometers read between \u003Cstrong>(b)(4)\u003C\u002Fstrong>°-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F, while the FDA calibrated thermometer read 58.8°F.\u003C\u002Fli>\u003Cli>On November 15, 2024, your two thermometers at the entrance of the cooler read \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (digital) \u002F \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (analog), while the FDA calibrated thermometer read 46.5°F.\u003C\u002Fli>\u003Cli>On November 19, 2024, your two thermometers at the entrance of the cooler read \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (digital) \u002F \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (analog), while the FDA calibrated thermometer read 51.9°F\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We acknowledge your written response, in which you state that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You stated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response did not provide an SE Prevention Plan or provide supporting details to assess whether the corrective actions were adequate.\u003C\u002Fp>\u003Cp>2. You have never registered your egg farm with FDA, as required by 21 CFR 118.11(a).\u003C\u002Fp>\u003Cp>Your written response states that you registered your farm with FDA by December 6, 2024; however, we do not have a record of your registration.\u003C\u002Fp>\u003Cp>\u003Cu>Federal Food, Drug, and Cosmetic Act (FD&amp;C Act)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your eggs were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health within the meaning of section 402(a)(4) of the FD&amp;C Act. Specifically, during the inspection, our investigators observed the following insanitary conditions and practices at your farm during the processing of shell eggs:\u003C\u002Fp>\u003Cul>\u003Cli>FDA investigators observed too numerous to count dead flies inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong>-gallon water tank of the egg washer and lying on the surface of the egg washer. Flies were also observed inside the packaging room on top of washed eggs.\u003C\u002Fli>\u003Cli>The conveyor belt connecting poultry house \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the egg washing\u002Fpackaging room was uncovered, outside of any building structure. FDA investigators observed that the eggs held on this conveyor belt are continuously exposed to the environment and to pests and other animals, including flying insects, reptiles, cats, and wild birds, for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours (because collection and packaging operations are conducted every other day\u003Ca>).\u003C\u002Fa>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, you did not follow the disinfectant manufacturer’s instructions in preparing the disinfectant solution for the eggs by using the correct amount of disinfectant within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>-gallon water tanks. You stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> oz. of disinfectant is used for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>-gallon tank of the washing machine, instead of the 22.5 oz. directed by the manufacturer’s instructions of 0.5 oz per gallon.\u003C\u002Fp>\u003Cp>Your written response stated that a monitoring program has been established to inspect conveyor belts and poultry houses daily. Furthermore, you stated your employees were not properly trained on the manufacturer’s instructions for the appropriate level of disinfectant. As your corrective actions, you state you have retrained your employees on the proper preparation of the disinfectant and revised your procedures and displayed them near the egg washer. Furthermore, your written response stated you have cleaned the washer, have implemented a daily cleaning and inspection schedule to ensure consistent hygiene, and introduced a new maintenance log for documenting cleaning and sanitation activities. You have not provided additional supporting details in order for us to fully evaluate these corrective actions.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&amp;C Act, the PHS Act, and the Shell Egg regulation.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Comment\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Records are an important component to ensure your compliance with FDA’s Shell Egg regulation. 21 CFR 118.10 describes the records required for your SE Prevention Plan and other general recordkeeping requirements. We encourage you to review these requirements when working to develop and implement your SE Prevention Plan and environmental testing procedures. Please note that resources are also available on our website at www.fda.gov\u002Feggs that address various aspects of shell egg regulation, including some of the topics addressed in this letter. For example, the December 2011 Guidance for Industry “Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” and the July 2015 Guidance for Industry “Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” provide answers to common questions about the Shell Egg regulation.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply via email to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Lisa Thursam, Compliance Officer, at Lisa.Thursam@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Lisa Thursam, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Lisa Thursam, Compliance Officer, via email at Lisa.Thursam@fda.hhs.gov. Please include CMS reference #701874 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, J.D., M.B.A.\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Nestor E. Reyes del Valle\n\nRecipient Title\n\nPresident\n\nNestor Reyes Farm & Associates\n\nRd. 956, Km 10.0, Bo. Guzman Arriba\n\nRio Grande 00745\n\nPuerto Rico\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nAugust 21, 2025\nCMS #701874\nDear Mr. Nestor E. Reyes del Valle:\nOn November 13-15 & 19, 2024, and December 6, 2024, the United States Food and Drug Administration (FDA) conducted an inspection of your shell egg farm and egg processing facility, where your shell eggs are washed and packed, located at Rd. 956, Km 10.0, Bo. Guzman Arriba, Rio Grande, PR 00745. During the inspection of your farm, FDA investigators observed serious violations of the Prevention of Salmonella Enteritidis (SE) in Shell Eggs During Production, Storage, and Transportation regulation (the Shell Egg regulation), Title 21, Code of Federal Regulations, Part 118 (21 CFR Part 118). At the conclusion of the inspection, FDA investigators issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your farm.\nBased on FDA’s inspectional findings, we have determined that the shell eggs produced on your farm do not comply with the provisions of 21 CFR Part 118. Failure to comply with the provisions of 21 CFR Part 118 causes your shell eggs to be in violation of section 361(a) of the Public Health Service Act (the PHS Act), 42 U.S.C. § 264(a). In addition, these violations render your shell eggs adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. § 342(a)(4), in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the FD&C Act, the PHS Act and the Shell Egg regulation through links on FDA’s home page at www.fda.gov.\nWe received your response to the FDA-483 via email on December 20, 2024, which described corrective actions taken or planned by your farm. Based on our review of the inspectional findings and your response, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your farm.\nYour significant violations are as follows:\nShell Egg Regulation (21 CFR Part 118)\n1. You did not have and implement a written SE Prevention Plan that includes, at a minimum, the SE prevention measures required by 21 CFR 118.4. You did not have a written SE Prevention Plan for the approximate (b)(4) layers on your farm. Your written response stated that an SE Prevention Plan would be finalized between December 2024 and January 2025. To date, we have not received a written SE Prevention Plan. You are required to have an SE Prevention Plan that includes, at a minimum, the SE prevention measures outlined in 21 CFR 118.4 (a) – (e), which include:\na. Pullets\nA written SE Prevention Plan must include, among other things, the required SE prevention measures relating to pullets. Under 21 CFR 118.4(a), these measures include procuring pullets that are SE monitored or raising pullets under SE monitored conditions. Under 21 CFR 118.4(a)(1), “SE monitored” means that chicks are procured from SE-monitored breeder flocks that meet the National Poultry Improvement Plan’s (NPIP) standards for “U.S. S. Enteritidis Clean” status (9 CFR 145.23(d)) or an equivalent standard. Under 21 CFR 118.4(a)(2), “SE monitored” also means that the pullet environment is tested for SE when pullets are 14-16 weeks of age.\nYour farm received a primary flock of (b)(4) chicks on April 30, 2024, followed by a secondary flock of (b)(4) chicks on May 7, 2024. We acknowledge you provided a NPIP Form for the flock of chicks you procured from your supplier on May 7, 2024, but you did not provide documentation for the chicks received on or around April 30, 2024. Furthermore, you did not conduct the required SE environmental test for both flocks at 14-to-16 weeks of age, as required by 21 CFR 118.4(a)(2)(i).\nYour written response stated that you will schedule for future flocks to be tested for SE between 14-16 weeks of age by a licensed professional. However, as discussed above, we have not received a written SE Prevention Plan that describes these measures. We also note that your written response stated, as part of your firm’s corrective actions, that FDA swabbed poultry house (b)(4) on November 19, 2024, with subsequent negative results. The layers were approximately (b)(4) weeks of age when FDA conducted this sampling. This does not constitute a corrective action and should not be viewed as such.\nb. Biosecurity\nA written SE Prevention Plan must include, among other things, the required SE prevention measures relating to biosecurity, as stated in 21 CFR 118.4(b). That provision requires you to take steps to ensure that there is no introduction or transfer of SE into or among poultry houses. These biosecurity measures must include, at a minimum:\nLimiting visitors on the farm and in the poultry houses (21 CFR 118.4(b)(1));\nMaintaining practices that will protect against cross contamination when equipment is moved among poultry houses (21 CFR 118.4(b)(2));\nMaintaining practices that will protect against cross contamination when persons move between poultry houses (21 CFR 118.4(b)(3));\nPreventing stray poultry, wild birds, cats, and other animals from entering poultry houses (21 CFR 118.4(b)(4)); and\nNot allowing employees to keep birds at home (21 CFR 118.4(b)(5)).\nAs discussed above, you did not have a written SE Prevention Plan to address these measures. Furthermore, visitors’ access to the facility was not limited and, despite your indication on November 13, 2024, that individuals enter the facility to pick up or distribute eggs every other day, our investigators identified August 20, 2024, as the last date a pickup was registered in your entry log. Additionally, for poultry house (b)(4), FDA investigators observed there was no entry door to limit access and the house had damaged or missing netting and gaps within the cement structure. Numerous wild birds located inside the poultry house above layers in cages, in walkways, and eating directly from feed trays. Wild birds were also observed in the manure pits, and along the perimeter of your exposed house. Furthermore, cats and several species of reptiles were also observed in the manure pit and surrounding the poultry house.\nWe acknowledge your written response, in which you state you are now restricting visitor access to the farm through signs, and that you have implemented a visitor log and provided employee training. You also described how you will prevent stray animals from entering the poultry houses by adding physical barriers. You state your poultry houses are under construction, which you expect to be completed by June 2025. However, your written response lacks supporting detail to further assess how you will implement these corrective actions and practices. Additionally, you did not provide an SE Prevention Plan to describe any biosecurity steps.\nc. Rodents, Flies, and Other Pest Control\nA written SE Prevention Plan must include, among other things, the required rodent, fly, and other pest control measures as stated in 21 CFR 118.4(c). As discussed above, you did not have a written SE Prevention Plan to address these measures. Furthermore, you were not monitoring for the presence of rodents and flies by appropriate monitoring methods, as required by 21 CFR 118.4(c)(1) and 21 CFR 118.4(c)(2), nor did you remove debris within a poultry house and vegetation and debris outside the poultry house that may provide harborage for pests, as required by 21 CFR 118.4(c)(3).\nSpecifically, for rodents, you stated you receive monthly services by a subcontractor; however, there were no pest control records available for review. Additionally, FDA investigators observed multiple rodent bait stations for poultry house (b)(4) that were broken and\u002For did not contain bait. For flies, you did not have any monitoring or control measures in place, and FDA investigators also observed flies too numerous to count inside the poultry house that were in direct contact with hens, eggs, and chicken feed. Furthermore, FDA investigators observed harborage for pests in and outside of your poultry house. This included excessive amounts of accumulated trash and debris, stagnant water, piles of broken eggs, and spilled chicken feed. Also, multiple deceased layers were observed inside poultry house (b)(4), with two of the deceased birds having their heads in direct contact with the egg belt, causing the eggs to get jammed.\nYour written response acknowledged that rodents were not being monitored appropriately and stated that the rodent monitoring and bait stations have been installed and updated, more rodent bait stations have been added around buildings, professional pest control services have been engaged, and that you have cleaned and removed debris that may attract rodents. Furthermore, your response acknowledged that the presence of flies was not being appropriately monitored and stated that fly monitoring systems have been updated. Additionally, you stated potential pest harborage sites inside and outside the poultry houses have been eliminated. However, your response did not provide an SE Prevention Plan or provide supporting details to assess whether the corrective actions were adequate. Please note that in addition to describing appropriate monitoring methods for rodents and flies, a written SE Prevention Plan must also address the requirement that when monitoring indicates unacceptable rodent or fly activity within a poultry house, you must use appropriate methods to achieve satisfactory rodent\u002Ffly control.\nd. Cleaning and Disinfection\nA written SE Prevention Plan must include, among other things, cleaning and disinfection procedures for the poultry house, as stated in 21 CFR 118.4(d). You must clean and disinfect the poultry house according to these procedures before new laying hens are added to the house, if you have had an environmental test or an egg test that was positive for SE at any point during the life of a flock that was housed in the poultry house prior to depopulation.\nAs discussed above, you did not have a written SE Prevention Plan. Your written response states that you are developing a written SE Prevention Plan that will include, among other things, cleaning and disinfection protocols. However, as discussed above, you still have not provided a written SE Prevention Plan.\ne. Refrigeration\nYou did not hold eggs at or below 45°F ambient temperature beginning 36 hours after time of lay, nor do you have a written SE Prevention Plan including these refrigeration requirements, as required by 21 CFR 118.4(e). For example:\nOn November 14, 2024, your two analog thermometers located at the back and entrance of the cooler read (b)(4)°-(b)(4)°F, while FDA’s calibrated thermometer read 52°-58°F. On November 14, 2024, the same two analog thermometers read between (b)(4)°-(b)(4)°F, while the FDA calibrated thermometer read 58.8°F.\nOn November 15, 2024, your two thermometers at the entrance of the cooler read (b)(4)°F (digital) \u002F (b)(4)°F (analog), while the FDA calibrated thermometer read 46.5°F.\nOn November 19, 2024, your two thermometers at the entrance of the cooler read (b)(4)°F (digital) \u002F (b)(4)°F (analog), while the FDA calibrated thermometer read 51.9°F\nWe acknowledge your written response, in which you state that “(b)(4).” You stated (b)(4). However, your response did not provide an SE Prevention Plan or provide supporting details to assess whether the corrective actions were adequate.\n2. You have never registered your egg farm with FDA, as required by 21 CFR 118.11(a).\nYour written response states that you registered your farm with FDA by December 6, 2024; however, we do not have a record of your registration.\nFederal Food, Drug, and Cosmetic Act (FD&C Act)\nYour eggs were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health within the meaning of section 402(a)(4) of the FD&C Act. Specifically, during the inspection, our investigators observed the following insanitary conditions and practices at your farm during the processing of shell eggs:\nFDA investigators observed too numerous to count dead flies inside the (b)(4)-gallon water tank of the egg washer and lying on the surface of the egg washer. Flies were also observed inside the packaging room on top of washed eggs.\nThe conveyor belt connecting poultry house (b)(4) to the egg washing\u002Fpackaging room was uncovered, outside of any building structure. FDA investigators observed that the eggs held on this conveyor belt are continuously exposed to the environment and to pests and other animals, including flying insects, reptiles, cats, and wild birds, for up to (b)(4) hours (because collection and packaging operations are conducted every other day).\nFurthermore, you did not follow the disinfectant manufacturer’s instructions in preparing the disinfectant solution for the eggs by using the correct amount of disinfectant within the (b)(4)-gallon water tanks. You stated that (b)(4) oz. of disinfectant is used for the (b)(4)-gallon tank of the washing machine, instead of the 22.5 oz. directed by the manufacturer’s instructions of 0.5 oz per gallon.\nYour written response stated that a monitoring program has been established to inspect conveyor belts and poultry houses daily. Furthermore, you stated your employees were not properly trained on the manufacturer’s instructions for the appropriate level of disinfectant. As your corrective actions, you state you have retrained your employees on the proper preparation of the disinfectant and revised your procedures and displayed them near the egg washer. Furthermore, your written response stated you have cleaned the washer, have implemented a daily cleaning and inspection schedule to ensure consistent hygiene, and introduced a new maintenance log for documenting cleaning and sanitation activities. You have not provided additional supporting details in order for us to fully evaluate these corrective actions.\nThis letter is not intended to be an all-inclusive statement of the violations that may exist at your farm or in connection with your shell eggs. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your shell egg production practices are conducted in compliance with federal law, including the FD&C Act, the PHS Act, and the Shell Egg regulation.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, injunction, or the initiation of administrative enforcement procedures under 21 CFR 118.12(a).\nAdditional Comment\nRecords are an important component to ensure your compliance with FDA’s Shell Egg regulation. 21 CFR 118.10 describes the records required for your SE Prevention Plan and other general recordkeeping requirements. We encourage you to review these requirements when working to develop and implement your SE Prevention Plan and environmental testing procedures. Please note that resources are also available on our website at www.fda.gov\u002Feggs that address various aspects of shell egg regulation, including some of the topics addressed in this letter. For example, the December 2011 Guidance for Industry “Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” and the July 2015 Guidance for Industry “Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation” provide answers to common questions about the Shell Egg regulation.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that you have complied with pertinent laws and regulations, include your reasoning and any supporting information for our consideration.\nPlease send your reply via email to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Lisa Thursam, Compliance Officer, at Lisa.Thursam@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Lisa Thursam, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Lisa Thursam, Compliance Officer, via email at Lisa.Thursam@fda.hhs.gov. Please include CMS reference #701874 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, J.D., M.B.A.\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\nFood and Drug Administration","Nestor Reyes Farm & Associates","nestor-reyes-farm-associates-701874-08212025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnestor-reyes-farm-associates-701874-08212025","2026-10-26T08:09:31.916283+00:00","2025-09-30","701874","Mr. Nestor E. Reyes del Valle","2026-08-19T16:16:25.355+00:00","2025-08-21",{"id":367,"raw":368,"subject":375,"body_html":376,"body_text":377,"firm_name":378,"letter_id":379,"created_at":380,"fei_number":19,"letter_url":381,"updated_at":382,"action_type":22,"case_status":109,"posted_date":383,"marcs_cms_no":384,"product_type":134,"closeout_date":385,"issuing_office":372,"recipient_name":386,"body_fetched_at":387,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":388,"medical_device_id":19,"response_letter_date":19},1939,[369,370,371,372,373,13,374,13],"\u003Ctime datetime=\"2023-08-15T13:20:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-04T04:00:00Z\">08\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fastrazeneca-pharmaceuticals-lp-664789-08042023\">AstraZeneca Pharmaceuticals LP\u003C\u002Fa>","The Office of Prescription Drug Promotion (OPDP)","False &amp; Misleading Claims\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fastrazeneca-pharmaceuticals-lp-664789-05292024\">\u003Ctime datetime=\"2024-05-31T04:00:00Z\">05\u002F31\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pascal Soriot\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Director and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AstraZeneca Pharmaceuticals LP\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1800 Concord Pike\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wilmington\u003C\u002Fspan>, \u003Cspan>DE\u003C\u002Fspan> \u003Cspan>19850\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>The Office of Prescription Drug Promotion (OPDP)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>RE: NDA 212122\u003C\u002Fstrong>\u003Cbr>\nBREZTRI AEROSPHERE™ (budesonide, glycopyrrolate, and formoterol fumarate) inhalation aerosol, for oral inhalation use MA 385\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Pascal Soriot:\u003C\u002Fp>\n\n\u003Cp>The Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed a promotional communication, a professional sales aid (US-68433), for BREZTRI AEROSPHERE™ (budesonide, glycopyrrolate, and formoterol fumarate) inhalation aerosol, for oral inhalation use (Breztri) submitted by AstraZeneca under cover of Form FDA 2253. The sales aid makes false or misleading claims and\u002For representations about the efficacy of Breztri. Thus, the sales aid misbrands Breztri within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), and makes its distribution violative. 21 U.S.C. 352(a); 331(a). Cf. 21 CFR 202.1(e)(5). These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the overall benefits a patient may expect as a result of Breztri treatment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Breztri.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> According to the FDA-approved Prescribing Information (PI):\u003C\u002Fp>\n\n\u003Cp>BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Limitations of Use:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma.\u003C\u002Fp>\n\n\u003Cp>Breztri is contraindicated in patients who have demonstrated hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate, or any of the excipients. The PI for Breztri includes the following Warnings and Precautions: serious asthma-related events—hospitalizations, intubations, and death; deterioration of disease and acute episodes; avoid excessive use of Breztri and avoid use with other long-acting beta2-agonists; oropharyngeal candidiasis; pneumonia; immunosuppression and risk of infections; transferring patients from systemic corticosteroid therapy; hypercorticism and adrenal suppression; drug interactions with strong cytochrome P450 3A4 inhibitors; paradoxical bronchospasm; hypersensitivity reactions including anaphylaxis; cardiovascular effects; reduction in bone mineral density; glaucoma and cataracts, worsening of narrow-angle glaucoma; worsening of urinary retention; coexisting conditions; and hypokalemia and hyperglycemia. The most common adverse reactions reported with use of Breztri are upper respiratory tract infection, pneumonia, back pain, oral candidiasis, influenza, muscle spasm, urinary tract infection, cough, sinusitis, and diarrhea.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>False or Misleading Claims about Efficacy\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to efficacy. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\u003C\u002Fp>\n\n\u003Cp>The sales aid includes the prominent headline claim (emphasis original), “\u003Cstrong>DIFFERENCE OBSERVED IN TIME TO ALL-CAUSE MORTALITY (OVER 52 WEEKS)\u003C\u002Fstrong>,” in conjunction with a graph titled, “\u003Cstrong>SECONDARY ENDPOINT STUDY 1: Time to all-cause mortality in the ITT\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>population\u003C\u002Fstrong>,” and the following claims (emphasis original):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>An observed relative difference with BREZTRI vs LAMA\u002FLABA was shown in data published in 2020\u002F2021, including in the \u003Cem>New England Journal of Medicine\u003C\u002Fem>\u003C\u002Fstrong>”\u003C\u002Fli>\n\t\u003Cli>“\u003Cstrong>49% Observed relative difference with BREZTRI vs LAMA\u002FLABA\u003C\u002Fstrong>”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These claims and presentation, in the context of a promotional communication describing the safety and efficacy of Breztri, are misleading because they suggest that Breztri treatment has been shown to have a positive impact on all-cause mortality (ACM) and reduce the risk of death in COPD patients. These suggestions are not supported by the cited references\u003Csup>\u003Cem>\u003Cstrong>2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that analyzed data from the Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) trial. The ETHOS trial was designed with ACM as one of multiple secondary endpoints, and due to the failure of the study to show statistically significant results on endpoints higher in the analysis hierarchy, the trial does not allow for any conclusions to be drawn from the ACM data. In addition, as the ETHOS study design required removing patients from inhaled corticosteroids (ICS) prior to entering a treatment arm, abrupt withdrawal of ICS may have been a confounding factor when analyzing any positive effect on ACM. Due to the statistical testing hierarchy failure and to the fact that abrupt withdrawal of ICS may have been a confounding factor, no conclusions about the effect of Breztri on ACM can be drawn from the ETHOS trial. We note the statement below the graph, “These results are observational in nature, and any comparisons between treatment arms should be interpreted with caution.” However, this does not mitigate the misleading impression. To date, no drug has been shown to improve ACM in COPD.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The results of the ETHOS trial do not exclude the possibility that the benefits in ACM claimed above may be attributable to chance or to the withdrawal of ICS and not due to Breztri. These claims and presentation are concerning from a public health perspective because they overstate the efficacy of the drug and misleadingly suggest that Breztri will have a positive impact on ACM and reduce the risk of death in COPD patients.\u003C\u002Fp>\n\n\u003Cp>The sales aid also includes the following claims (bolded emphasis original, underlined emphasis added):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“In a 52-week study where patients had a history of exacerbations within the last year, \u003Cstrong>BREZTRI was the ONLY triple therapy vs ICS\u002FLABA to show a significant reduction in severe exacerbations\u003C\u002Fstrong>”\u003C\u002Fli>\n\t\u003Cli>“\u003Cstrong>20% EXACERBATION REDUCTION VS ICS\u002FLABA\u003C\u002Fstrong>[;] rate ratio: 0.80[;] \u003Cem>P=0.02\u003C\u002Fem>”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The presentation of these claims with the associated p-value creates a misleading impression regarding the benefit of the drug by suggesting that Breztri will have a statistically significant reduction in severe exacerbations. This suggestion is not supported by the ETHOS trial data analyzed in the cited reference\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> because the reduction in severe exacerbations was not statistically significant for patients treated with Breztri relative to comparator groups. A pvalue is generally understood to indicate statistical significance if it is less than 0.05. Therefore, the inclusion of a p-value of 0.02 in conjunction with the above presentation creates the impression that the reduction in severe exacerbations was statistically significant. However, for the Breztri to inhaled corticosteroid\u002Flong-acting beta agonist (ICS\u002FLABA) comparison (i.e., “20% REDUCTION VS ICS\u002FLABA”), the result was not statistically significant due to the p-value being greater than the significance threshold (critical value) established in the testing strategy. In the ETHOS trial\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> testing strategy the raw p-value of each hypothesis test was compared to the corresponding critical value to determine whether the test was statistically significant. As the p-value for the Breztri to ICS\u002FLABA comparison (p=0.02) was greater than the critical value (0.008) for that hypothesis test, the result, per the threshold set by the testing strategy, is not statistically significant. Therefore, the presentation of these claims (i.e., with a p-value of 0.02) creates the misleading impression that Breztri provides a \u003Cem>statistically significant\u003C\u002Fem> reduction in severe exacerbations compared to ICS\u002FLABA by 20% when this has not been demonstrated. We acknowledge the footnote, “*Based on predefined Type-1 error control plan” is included following these claims and related presentations. However, this does not mitigate the misleading impression. The presentation is concerning from a public health perspective because it overstates the efficacy of the drug and misleadingly represents that Breztri significantly reduces severe exacerbations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For the reasons discussed above, the detail aid misbrands Breztri within the meaning of the FD&amp;C Act and makes its distribution violative. 21 U.S.C. 352(a); 331(a). Cf. 21 CFR 202.1(e)(5).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that AstraZeneca cease any violations of the FD&amp;C Act. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Breztri that contain representations such as those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Breztri.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\n\n\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Breztri; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\n\n\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\n\n\u003Cp>Please direct your response to the undersigned at the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 385 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Additionally, the response submission should be coded as an Amendment to eCTD Sequence 0454 under NDA 212122. Questions related to the submission of your response letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nTwyla Mosey, Pharm.D.\u003Cbr>\nDirector\u003Cbr>\nDivision of Advertising &amp; Promotion Review 2\u003Cbr>\nOffice of Prescription Drug Promotion\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nMATTHEW J FALTER on behalf of TWYLA N MOSEY\u003Cbr>\n08\u002F04\u002F2023 10:20:52 AM\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communications cited in this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\u002Fglycopyrrolate\u002Fformoterol for COPD: a randomized, double-blind, multi-center, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553-564.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very severe COPD. N Engl J Med. 2020;383(1):35-48.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Through the issuance of this letter, FDA does not intend to convey any views on whether data that did show that Breztri improved ACM in COPD would support a change to the FDA-approved labeling for Breztri.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See FN3.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> The ETHOS trial used a combination of hierarchical and Hochberg test procedures to control the overall Type I error among different endpoints and different doses.\u003C\u002Fp>\n\n\u003Ch3>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F171157\u002Fdownload?attachment\">PROMOTIONAL MATERIAL\u003C\u002Fa>\u003C\u002Fh3>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nPascal Soriot\n\nRecipient Title\n\nExecutive Director and Chief Executive Officer\n\nAstraZeneca Pharmaceuticals LP\n\n1800 Concord Pike\n\nWilmington, DE 19850\n\nUnited States\n\nIssuing Office:\n\nThe Office of Prescription Drug Promotion (OPDP)\n\nUnited States\n\nRE: NDA 212122\n\nBREZTRI AEROSPHERE™ (budesonide, glycopyrrolate, and formoterol fumarate) inhalation aerosol, for oral inhalation use MA 385\n\nWARNING LETTER\n\nDear Pascal Soriot:\n\nThe Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed a promotional communication, a professional sales aid (US-68433), for BREZTRI AEROSPHERE™ (budesonide, glycopyrrolate, and formoterol fumarate) inhalation aerosol, for oral inhalation use (Breztri) submitted by AstraZeneca under cover of Form FDA 2253. The sales aid makes false or misleading claims and\u002For representations about the efficacy of Breztri. Thus, the sales aid misbrands Breztri within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and makes its distribution violative. 21 U.S.C. 352(a); 331(a). Cf. 21 CFR 202.1(e)(5). These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the overall benefits a patient may expect as a result of Breztri treatment.\n\nBackground\n\nBelow are the indication and summary of the most serious and most common risks associated with the use of Breztri.1 According to the FDA-approved Prescribing Information (PI):\n\nBREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).\n\nLimitations of Use:\n\nBREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma.\n\nBreztri is contraindicated in patients who have demonstrated hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate, or any of the excipients. The PI for Breztri includes the following Warnings and Precautions: serious asthma-related events—hospitalizations, intubations, and death; deterioration of disease and acute episodes; avoid excessive use of Breztri and avoid use with other long-acting beta2-agonists; oropharyngeal candidiasis; pneumonia; immunosuppression and risk of infections; transferring patients from systemic corticosteroid therapy; hypercorticism and adrenal suppression; drug interactions with strong cytochrome P450 3A4 inhibitors; paradoxical bronchospasm; hypersensitivity reactions including anaphylaxis; cardiovascular effects; reduction in bone mineral density; glaucoma and cataracts, worsening of narrow-angle glaucoma; worsening of urinary retention; coexisting conditions; and hypokalemia and hyperglycemia. The most common adverse reactions reported with use of Breztri are upper respiratory tract infection, pneumonia, back pain, oral candidiasis, influenza, muscle spasm, urinary tract infection, cough, sinusitis, and diarrhea.\n\nFalse or Misleading Claims about Efficacy\n\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to efficacy. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\n\nThe sales aid includes the prominent headline claim (emphasis original), “DIFFERENCE OBSERVED IN TIME TO ALL-CAUSE MORTALITY (OVER 52 WEEKS),” in conjunction with a graph titled, “SECONDARY ENDPOINT STUDY 1: Time to all-cause mortality in the ITT\n\npopulation,” and the following claims (emphasis original):\n\n“An observed relative difference with BREZTRI vs LAMA\u002FLABA was shown in data published in 2020\u002F2021, including in the New England Journal of Medicine”\n\n“49% Observed relative difference with BREZTRI vs LAMA\u002FLABA”\n\nThese claims and presentation, in the context of a promotional communication describing the safety and efficacy of Breztri, are misleading because they suggest that Breztri treatment has been shown to have a positive impact on all-cause mortality (ACM) and reduce the risk of death in COPD patients. These suggestions are not supported by the cited references2,3 that analyzed data from the Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) trial. The ETHOS trial was designed with ACM as one of multiple secondary endpoints, and due to the failure of the study to show statistically significant results on endpoints higher in the analysis hierarchy, the trial does not allow for any conclusions to be drawn from the ACM data. In addition, as the ETHOS study design required removing patients from inhaled corticosteroids (ICS) prior to entering a treatment arm, abrupt withdrawal of ICS may have been a confounding factor when analyzing any positive effect on ACM. Due to the statistical testing hierarchy failure and to the fact that abrupt withdrawal of ICS may have been a confounding factor, no conclusions about the effect of Breztri on ACM can be drawn from the ETHOS trial. We note the statement below the graph, “These results are observational in nature, and any comparisons between treatment arms should be interpreted with caution.” However, this does not mitigate the misleading impression. To date, no drug has been shown to improve ACM in COPD.4 The results of the ETHOS trial do not exclude the possibility that the benefits in ACM claimed above may be attributable to chance or to the withdrawal of ICS and not due to Breztri. These claims and presentation are concerning from a public health perspective because they overstate the efficacy of the drug and misleadingly suggest that Breztri will have a positive impact on ACM and reduce the risk of death in COPD patients.\n\nThe sales aid also includes the following claims (bolded emphasis original, underlined emphasis added):\n\n“In a 52-week study where patients had a history of exacerbations within the last year, BREZTRI was the ONLY triple therapy vs ICS\u002FLABA to show a significant reduction in severe exacerbations”\n\n“20% EXACERBATION REDUCTION VS ICS\u002FLABA[;] rate ratio: 0.80[;] P=0.02”\n\nThe presentation of these claims with the associated p-value creates a misleading impression regarding the benefit of the drug by suggesting that Breztri will have a statistically significant reduction in severe exacerbations. This suggestion is not supported by the ETHOS trial data analyzed in the cited reference5 because the reduction in severe exacerbations was not statistically significant for patients treated with Breztri relative to comparator groups. A pvalue is generally understood to indicate statistical significance if it is less than 0.05. Therefore, the inclusion of a p-value of 0.02 in conjunction with the above presentation creates the impression that the reduction in severe exacerbations was statistically significant. However, for the Breztri to inhaled corticosteroid\u002Flong-acting beta agonist (ICS\u002FLABA) comparison (i.e., “20% REDUCTION VS ICS\u002FLABA”), the result was not statistically significant due to the p-value being greater than the significance threshold (critical value) established in the testing strategy. In the ETHOS trial6 testing strategy the raw p-value of each hypothesis test was compared to the corresponding critical value to determine whether the test was statistically significant. As the p-value for the Breztri to ICS\u002FLABA comparison (p=0.02) was greater than the critical value (0.008) for that hypothesis test, the result, per the threshold set by the testing strategy, is not statistically significant. Therefore, the presentation of these claims (i.e., with a p-value of 0.02) creates the misleading impression that Breztri provides a statistically significant reduction in severe exacerbations compared to ICS\u002FLABA by 20% when this has not been demonstrated. We acknowledge the footnote, “*Based on predefined Type-1 error control plan” is included following these claims and related presentations. However, this does not mitigate the misleading impression. The presentation is concerning from a public health perspective because it overstates the efficacy of the drug and misleadingly represents that Breztri significantly reduces severe exacerbations.\n\nConclusion and Requested Action\n\nFor the reasons discussed above, the detail aid misbrands Breztri within the meaning of the FD&C Act and makes its distribution violative. 21 U.S.C. 352(a); 331(a). Cf. 21 CFR 202.1(e)(5).\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that AstraZeneca cease any violations of the FD&C Act. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Breztri that contain representations such as those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Breztri.\n\nFailure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\n\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Breztri; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\n\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\n\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 385 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Additionally, the response submission should be coded as an Amendment to eCTD Sequence 0454 under NDA 212122. Questions related to the submission of your response letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.\n\nSincerely,\n\n{See appended electronic signature page}\n\nTwyla Mosey, Pharm.D.\n\nDirector\n\nDivision of Advertising & Promotion Review 2\n\nOffice of Prescription Drug Promotion\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nMATTHEW J FALTER on behalf of TWYLA N MOSEY\n\n08\u002F04\u002F2023 10:20:52 AM\n\n_____________________\n\n1 This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communications cited in this letter.\n\n2 Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\u002Fglycopyrrolate\u002Fformoterol for COPD: a randomized, double-blind, multi-center, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553-564.\n\n3 Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very severe COPD. N Engl J Med. 2020;383(1):35-48.\n\n4 Through the issuance of this letter, FDA does not intend to convey any views on whether data that did show that Breztri improved ACM in COPD would support a change to the FDA-approved labeling for Breztri.\n\n5 See FN3.\n\n6 The ETHOS trial used a combination of hierarchical and Hochberg test procedures to control the overall Type I error among different endpoints and different doses.\n\nPROMOTIONAL MATERIAL","AstraZeneca Pharmaceuticals LP","astrazeneca-pharmaceuticals-lp-664789-08042023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fastrazeneca-pharmaceuticals-lp-664789-08042023","2026-10-26T08:07:58.631772+00:00","2023-08-15","664789","2024-05-31","Pascal Soriot","2026-08-20T00:47:24.033+00:00","2023-08-04",{"id":390,"raw":391,"subject":395,"body_html":396,"body_text":397,"firm_name":398,"letter_id":399,"created_at":129,"fei_number":19,"letter_url":400,"updated_at":401,"action_type":22,"case_status":23,"posted_date":402,"marcs_cms_no":403,"product_type":134,"closeout_date":19,"issuing_office":123,"recipient_name":404,"body_fetched_at":405,"delivery_method":291,"recipient_title":19,"reference_number":406,"action_taken_date":407,"medical_device_id":19,"response_letter_date":19},989,[392,393,394,123,395,13,13,13],"\u003Ctime datetime=\"2025-03-25T04:00:00Z\">03\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-05T05:00:00Z\">03\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-biopharma-labs-private-limited-698665-03052025\">Aspen Biopharma Labs Private Limited\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-50\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. K. Sateesh Reddy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aspen Biopharma Labs Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot 10, Phase - II; Lalgadi Malakpet Village, Rangareddy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hyderabad\u003C\u002Fspan> \u003Cspan>500078\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Telangana\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-50\u003C\u002Fp>\u003Cp>March 5, 2025\u003Cbr>\u003Cbr>Dear Mr. Reddy:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, at Aspen Biopharma Labs Private Limited, FEI 3012796281, at Plot 10, Phase – II; Lalgadi Malakpet Village, Rangareddy, Hyderabad, Telangana, 500078, India, from September 16 to September 21, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to design and construct buildings and facilities used in the manufacture of your API in a manner to minimize potential contamination, facilitate appropriate cleaning, maintenance, and operations.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You produce higher-risk APIs in an inadequate facility including one that lacks appropriate separation for high pharmacological activity or toxic materials including \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs. During the inspection, our investigator observed your facility was in a state of disrepair, with manufacturing areas open to the outdoor environment with inadequate protection of materials. Our investigator also observed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs were manufactured in a common area.\u003C\u002Fp>\u003Cp>For example, your firm stated that “all the operations are conducted under one roof in \u003Cstrong>(b)(4) \u003C\u002Fstrong>Block Annex without proper segregation” and that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Block Annex manufacturing facility is in the process of demolish.” Of note, FDA collected batch indicating you produced drugs during this time period.\u003C\u002Fp>\u003Cp>In your response you indicate that your facility is undergoing renovations. Your response is inadequate because you did not provide sufficient details of how your facility design will prevent contamination of drug substances from the open environment, as well as cross-contamination of non-toxic drug substance from highly toxic components.\u003C\u002Fp>\u003Cp>It is expected that buildings used in the manufacture of APIs are designed and constructed to minimize potential contamination.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes and failure to adequately validate written procedures for the cleaning and maintenance of equipment.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Process Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to appropriately validate your processes and adequately qualify the equipment used to manufacture your drugs. Specifically, you have not completed process validation for commercial size lots of your APIs. For example, you rely on studies conducted on development lot sizes for \u003Cstrong>(b)(4)\u003C\u002Fstrong> API intermediates manufactured utilizing different equipment than that used for commercial production.\u003C\u002Fp>\u003Cp>In your response, you state that you compared commercial lots to the smaller development validation lots, found no significant variations, and will perform commercial size process validations. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a manufacturing process must be designed appropriately to assure the quality of raw material inputs, in-process materials, and finished APIs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process performance qualification (PPQ) studies incorporating the use of appropriately qualified equipment and validated test methods are necessary prior to commercial distribution. Thereafter, ongoing vigilant oversight of process performance and drug quality is necessary to ensure you maintain a stable manufacturing operation throughout the drug lifecycle. Failure to implement adequate analytical method validation practices can result in insufficient understanding of process variables or failure to detect a drift in capability, which increases the risk of drug quality defects. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You lacked cleaning validation studies that demonstrate your cleaning procedures are adequate. For example, you previously identified the need to implement a cleaning validation based on your internal deviation report, yet our investigator observed that you lack cleaning validation.\u003C\u002Fp>\u003Cp>In addition, our investigators observed manufacturing equipment labeled “Cleaned” that contained liquid with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> floating substance or residue on product-contact surfaces.\u003C\u002Fp>\u003Cp>In your response you indicate that you plan to perform cleaning validation for your drugs and perform hold time studies. Your response is inadequate because you did not provide supportive documentation or your interim plans for drug production while you complete corrective and preventive actions.\u003C\u002Fp>\u003Cp>Inadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety. Cleaning procedures should consider solubility, cleaning difficulty, and residue limits, while reproducible and effective for the removal or obliteration of previous lot identification and protection of clean equipment from contamination prior to use. Furthermore, the use of dedicated production areas should be considered for higher-risk material of an infectious nature or high pharmacological activity or toxicity (e.g., certain steroids or \u003Cstrong>(b)(4) \u003C\u002Fstrong>agents) where cleaning and inactivation alone are not sufficient controls.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the drug lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-lot and inter-lot variation to ensure a continuing state of control. This should include the process for selecting API lots to achieve the \u003Cstrong>(b)(4)\u003C\u002Fstrong> API blend.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed API. Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>An assessment of each API process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make them difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003Cbr>In addition, describe the steps that must be taken in your change management system before the introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of your updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drugs may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drugs and equipment; and all other needed remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to have originals or copies of records readily available and promptly retrievable during the retention period.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure adequate document control over paper and electronic records. For example, you provided a written statement on firm letterhead admitting to backdating a QC lab document and you signed a declaration confirming commercial drugs shipped to the US were not supported by appropriate original data.\u003C\u002Fp>\u003Cp>In your response, you acknowledge a lack of original data and that you will improve your document management system. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide a management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to design a documented, on-going stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s stability program is inadequate. For example, your firm does not have adequate data to support the retest date for drugs shipped to the United States.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the deficiencies of your stability program and propose corrective actions including addition of stability indicating analysis. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>Without an adequate stability program, you cannot ensure that your APIs meet established specifications and all pre-determined quality criteria throughout the APIs’ assigned shelf-life.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability-indicating methods.\u003Cbr>o Stability studies for each drug in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative lots of each drug is added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On January 14, 2025, FDA held a teleconference with you recommending you consider removing any lots of drugs currently in distribution from the U.S. market. On January 16, 2025, you agreed to voluntary recall of all drugs in current distribution in United States.\u003C\u002Fp>\u003Cp>We acknowledge that you initiated a voluntary nationwide recall on February 7, 2025, of all products distributed in the United States.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Status\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge that you deregistered your facility on January 6, 2025, however, it is unclear whether you intend to cease production of drugs for the U.S. market. In response to this letter, clarify whether you intend to cease manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional API CGMP Guidance\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether APIs are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations we identified, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed drugs offered for import into the U.S. from your firm on Import Alert 66-40 on January 15, 2025.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012796281 and ATTN: Reba Gates.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-50\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. K. Sateesh Reddy\n\nRecipient Title\n\nCEO\n\nAspen Biopharma Labs Private Limited\n\nPlot 10, Phase - II; Lalgadi Malakpet Village, Rangareddy\n\nHyderabad 500078\n\nTelangana\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-50\nMarch 5, 2025\n\nDear Mr. Reddy:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, at Aspen Biopharma Labs Private Limited, FEI 3012796281, at Plot 10, Phase – II; Lalgadi Malakpet Village, Rangareddy, Hyderabad, Telangana, 500078, India, from September 16 to September 21, 2024.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence\nDuring our inspection, our investigators observed deviations including, but not limited to, the following.\n1. Failure to design and construct buildings and facilities used in the manufacture of your API in a manner to minimize potential contamination, facilitate appropriate cleaning, maintenance, and operations.\nYou produce higher-risk APIs in an inadequate facility including one that lacks appropriate separation for high pharmacological activity or toxic materials including (b)(4) drugs. During the inspection, our investigator observed your facility was in a state of disrepair, with manufacturing areas open to the outdoor environment with inadequate protection of materials. Our investigator also observed that (b)(4) drugs were manufactured in a common area.\nFor example, your firm stated that “all the operations are conducted under one roof in (b)(4) Block Annex without proper segregation” and that “(b)(4) Block Annex manufacturing facility is in the process of demolish.” Of note, FDA collected batch indicating you produced drugs during this time period.\nIn your response you indicate that your facility is undergoing renovations. Your response is inadequate because you did not provide sufficient details of how your facility design will prevent contamination of drug substances from the open environment, as well as cross-contamination of non-toxic drug substance from highly toxic components.\nIt is expected that buildings used in the manufacture of APIs are designed and constructed to minimize potential contamination.\nIn response to this letter provide:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n2. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes and failure to adequately validate written procedures for the cleaning and maintenance of equipment.\nProcess Validation\nYou failed to appropriately validate your processes and adequately qualify the equipment used to manufacture your drugs. Specifically, you have not completed process validation for commercial size lots of your APIs. For example, you rely on studies conducted on development lot sizes for (b)(4) API intermediates manufactured utilizing different equipment than that used for commercial production.\nIn your response, you state that you compared commercial lots to the smaller development validation lots, found no significant variations, and will perform commercial size process validations. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant (b)(4) of a manufacturing process must be designed appropriately to assure the quality of raw material inputs, in-process materials, and finished APIs. Process qualification studies determine whether an initial state of control has been established.\nSuccessful process performance qualification (PPQ) studies incorporating the use of appropriately qualified equipment and validated test methods are necessary prior to commercial distribution. Thereafter, ongoing vigilant oversight of process performance and drug quality is necessary to ensure you maintain a stable manufacturing operation throughout the drug lifecycle. Failure to implement adequate analytical method validation practices can result in insufficient understanding of process variables or failure to detect a drift in capability, which increases the risk of drug quality defects. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nCleaning Validation\nYou lacked cleaning validation studies that demonstrate your cleaning procedures are adequate. For example, you previously identified the need to implement a cleaning validation based on your internal deviation report, yet our investigator observed that you lack cleaning validation.\nIn addition, our investigators observed manufacturing equipment labeled “Cleaned” that contained liquid with a (b)(4) floating substance or residue on product-contact surfaces.\nIn your response you indicate that you plan to perform cleaning validation for your drugs and perform hold time studies. Your response is inadequate because you did not provide supportive documentation or your interim plans for drug production while you complete corrective and preventive actions.\nInadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety. Cleaning procedures should consider solubility, cleaning difficulty, and residue limits, while reproducible and effective for the removal or obliteration of previous lot identification and protection of clean equipment from contamination prior to use. Furthermore, the use of dedicated production areas should be considered for higher-risk material of an infectious nature or high pharmacological activity or toxicity (e.g., certain steroids or (b)(4) agents) where cleaning and inactivation alone are not sufficient controls.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the drug lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-lot and inter-lot variation to ensure a continuing state of control. This should include the process for selecting API lots to achieve the (b)(4) API blend.\nA timeline for performing appropriate PPQ for each of your marketed API. Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\nAn assessment of each API process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make them difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before the introduction of new manufacturing equipment or a new product.\nA summary of your updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drugs may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drugs and equipment; and all other needed remediations.\n3. Failure to have originals or copies of records readily available and promptly retrievable during the retention period.\nYou failed to ensure adequate document control over paper and electronic records. For example, you provided a written statement on firm letterhead admitting to backdating a QC lab document and you signed a declaration confirming commercial drugs shipped to the US were not supported by appropriate original data.\nIn your response, you acknowledge a lack of original data and that you will improve your document management system. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide a management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n4. Failure to design a documented, on-going stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\nYour firm’s stability program is inadequate. For example, your firm does not have adequate data to support the retest date for drugs shipped to the United States.\nIn your response, you acknowledge the deficiencies of your stability program and propose corrective actions including addition of stability indicating analysis. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\nWithout an adequate stability program, you cannot ensure that your APIs meet established specifications and all pre-determined quality criteria throughout the APIs’ assigned shelf-life.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability-indicating methods.\no Stability studies for each drug in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative lots of each drug is added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\nDrug Recall\nOn January 14, 2025, FDA held a teleconference with you recommending you consider removing any lots of drugs currently in distribution from the U.S. market. On January 16, 2025, you agreed to voluntary recall of all drugs in current distribution in United States.\nWe acknowledge that you initiated a voluntary nationwide recall on February 7, 2025, of all products distributed in the United States.\nDrug Production Status\nWe acknowledge that you deregistered your facility on January 6, 2025, however, it is unclear whether you intend to cease production of drugs for the U.S. market. In response to this letter, clarify whether you intend to cease manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\nAdditional API CGMP Guidance\nFDA considers the expectations outlined in ICH Q7 when determining whether APIs are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the deviations we identified, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed drugs offered for import into the U.S. from your firm on Import Alert 66-40 on January 15, 2025.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012796281 and ATTN: Reba Gates.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Aspen Biopharma Labs Private Limited","aspen-biopharma-labs-private-limited-698665-03052025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-biopharma-labs-private-limited-698665-03052025","2026-10-26T08:07:58.483518+00:00","2025-03-25","698665","Mr. K. Sateesh Reddy","2026-08-19T16:54:47.671+00:00","320-25-50","2025-03-05",34,{"510k":410,"classification":411,"enforcement":412,"event":413,"event_backfill":414,"pma":415,"warning_letter":416},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]